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Preface 
 
I was admitted to PhD as a supernumerary student. In the last three years I received 
three research grants on two different topics. In the first year of my PhD I dealt with 
the synthesis of model compounds for the study of Hydrogen Atom Transfer (HAT) 
mechanisms in energy-related processes, whose results are at a preliminary stage and 
are not reported in this thesis. The project was not founded for the second and the 
third PhD years, so I changed my PhD project in “Synthesis of novel cancer selective 
theranostic nano devices”. The project herein reported is thus relative to my second 
and third PhD years. It was funded by Istituto Toscana Tumori (ITT) and it was carried 
out in collaboration with Luisa Bracci’s research group from Department of Medical 
Biotechnologies at the University of Siena.   
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Abbreviations  
Compounds numbering restart for each chapter; each compound number is preceded 
by the number of the chapter in which it is reported (e.g. compound 2.3 indicate 
compound number 3 of chapter 2). All numbers relative to the same compound, when 
it appears in different chapters, are reported in the experimental section. 
DCM Dichloromethane 
DMF Dimethylformamide 
ET2O Diethyl ether 
DMAP 4-dimethylaminopyridine 
DIAD Diisopropylazodicarboxylate 
MeOH Methanol 
THF Tetrahydrofuran 
DMTrCl 4-4’-dimethoxytrityl chloride 
DCC N,N’-dicyclohexylcarbodiimide 
EtOH Ethanol 
AcOEt Ethyl acetate 
EP Petroleum ether 
NMR Nuclear magnetic resonance 
IR Infrared 
DIC N,N-diisopropylcarbodiimide 
PTX Paclitaxel  
TOAB tetraoctylamonium bromide 
DIPEA N,N-diisopropyl-N-ethyl amine 
TEA Tiethylamine 
DMSO Dimethylsulfoxide 
ESI Electrospray ionization 
TEM Transmission Electron Microscopy 
QDs Quantum Dots 
AuNPs gold nanoparticles 
AuNPs-C5 penthantiol-capped gold nanoparticles 
PCC pyridinium chlorochromate 
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1. Introduction 
1.1 Introduction to chemotherapy 
 
Chemotherapy (often abbreviated to chemo) is the treatment of cancer with one or 
more cytotoxic antineoplastic drugs. The term “chemotherapy” has been coined by 
Paul Ehrlich in the early 1900s to describe a therapeutic approach which implies the use 
of chemicals to treat infectious diseases.
1
 Although now the term “chemotherapy” is 
currently referred, in its common use, to cancer therapy, it originally indicated the use 
of drugs to cure diseases which were not caused by an endogenous organ dysfunction, 
rather induced by allogenous pathogens such as viruses, bacteria, parasites and so on. 
Cancerous cells, although deriving from sane human cells, are thus considered in the 
same manner as allogenous pathogens are: a strange sort of “enemy” cells which can 
be defeated by means of chemical agents, just like a bacterial infection can be 
eradicated by penicillin. Ehrlich was also the first to envisage a selective therapy aimed 
at eradicating pathogen-caused diseases; a therapy which could take advantage of the 
many differences existing between a human cell and the cell of the pathogen. He 
imagined a therapy armed with chemicals (which he called “magic bullets”) that could 
specifically interfere with biochemical pathways exclusive to the infective micro-
organism. 
For instance, arsphenamine, marketed under the name of Salvarsan, was introduced at 
the beginning of the 1910s as the first effective treatment for syphilis. This 
organoarsenic compound steamed form Ehrlich’s theory, that by screening many 
compounds, a drug could be discovered with antimicrobial activity without killing the 
human. Thus, it is nowadays considered the first modern chemotherapeutic agent. For 
sure, penicillin, inhibiting DD-transpeptidase, an enzyme which is involved in the 
synthesis of peptidoglican cell walls, not expressed by human cells, can be the perfect 
example of a “magic bullet”, hitting a bacteria-specific target and avoiding mechanism-
of-action related toxicity (Figure 1.1). 
 
 
Figure 1.1 - Destruction of the peptidoglican cell wall operated by penicillin 
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Unfortunately, cancer cells, although distorted by a wild mutation process, are human 
cells and share the majority of biochemical pathways with the latter; as a consequence, 
a cytotoxic therapy aimed at killing the totality of cancer cells obviously implies a 
dramatic mechanism-of-action related toxicity. Although chemotherapy still remains 
one of the most controversial therapeutic approaches to cancer, research has the duty 
to persevere in its improvement, as it is one of the few approaches which can be 
adopted in the treatment of metastatic cancer. While surgical interventions are by far 
the most successful procedures in early cancer cure protocols (although ineffective in 
the treatment of advanced cancer), chemotherapy (in particular classic chemotherapy, 
as discussed above) attains satisfactory results in terms of survival and remissions 
number only in a restricted number of tumors (e.g. chronic myeloid leukemia) and it 
can often even worsen the clinical situation of the patient. 
 
1.2 Classic versus targeted chemotherapeutics 
 
The beginnings of the modern era of chemotherapy can be traced directly to the 
discovery of nitrogen mustard as an effective treatment for cancer.
2
 In 1942, Goodman 
and Gilman, at Yale University, treated a patient with non-Hodgkin’s lymphoma with 
nitrogen mustard, observing a remission, even if only temporary, of the tumorous 
masses.
3
 Later on, in the earliest phases of the development of cancer chemotherapy, 
emphasis was on cell duplication rate, which constitutes a first discriminating factor 
between cancer cells and healthy cells. As a matter of fact, cancer cells proliferate 
several times faster than their “normal cell” homologues as a result of growth-
promoting genes activation (oncogenes, such as ras genes) and mutation of growth-
suppressing genes (oncosuppressors, such as p53). Thus, in the second post war period, 
every research effort was addressed to the development of drugs which could interfere 
with cells duplication, such as DNA alkylating agents, mitosis inhibitors, antimetabolites 
and every kind of toxin which could disrupt cellular cycle biochemical pathways, in 
order to kill high-rate duplication cells in which those processes were statistically more 
frequent.  
Classic Chemotherapeutics: These first chemotherapeutic agents (commonly referred to 
as classic chemotherapeutics) show high toxicity and thus several side effects, below 
indicated: 
i) Firstly, they act killing cells that divide rapidly, exerting their cytotoxic 
effect also on healthy cells with a high duplication rate in physiological 
conditions, such as epithelial, giving rise to a series of often intolerable 
side effects. In particular, hematopoietic precursors, gastrointestinal 
epithelial cells and hair follicles are hit, resulting in the typical side effects 
of chemotherapy: myelosuppression (decreased production of blood 
cells), mucositis (inflammation of the lining of the digestive tract) and 
alopecia (hair loss). These side effects lead many already compromised 
patients to give up therapy, as the latter are often more dangerous than 
the disease itself. It is, in fact, very difficult to find a compromise between 
 5 
 
benefits and therapy-associated risk. Among others, frequent, heavy side 
effects are emesis and neuropathic pain, which necessarily require 
dedicated treatment, thus broadening the already wide number of drugs 
simultaneously administered to the patient, the risk of dangerous 
pharmacokinetic and pharmacodynamic interactions critically increases. 
Regarding neuropathic pain, for instance, platinum-based cancer 
chemotherapies induce a neurotoxicity characterized by a dose-
dependent painful sensory neuropathy, presenting with symptoms in 
distal extremities that forced the patient to suspend the treatment in a 
early stage of the therapeutic protocol. 
ii) Secondly, the most threatening risk associated to the use of classic 
chemotherapeutic agents is the possibility of the development of 
secondary cancers, provoked by drug-induced DNA damage. This occurs 
most frequently in patients treated with alkylating agents and recently the 
carcinogenicity of platinum complexes such as cisplatin has been 
anticipated by several studies.
4
 
iii) Finally, classic cytotoxic agents have often unfavorable pharmacokinetic 
features which end up in a significant decrease of absorbed drug quantity, 
not to mention the high biodiversity of CYP 450 and other metabolic 
enzymes by which many chemotherapeutics are processed in vivo and 
which would require a personalized therapeutic protocol. Therefore, to 
reach minimum effective dose in blood stream, the administered drug 
dose has to be augmented, leading to a significant increase of the rise of 
the previously said side effects, which can be fatal in certain cases. 
Targeted chemotherapeutics: In the case of targeted chemotherapy, instead, similar 
toxicological problems have not been observed thanks to the intrinsic specificity of 
these drugs mechanism of action. These drugs are indeed designed to attack only 
tumor-specific targets. During the last decades of the 20
th
 century, consistent research 
efforts were made in order to develop targeted drugs that block the growth and spread 
of cancer by interfering with specific molecules involved in tumor growth and 
progression. Even though many breakthroughs have undoubtedly been made in this 
field and although many new, tumor-selective molecules have been successfully 
developed and tested, it has often been observed that these new drugs, though safer 
and more tolerable, can lose efficacy in a relatively short period of time due to the 
arising of specific resistance.
5
 The most famous representative of this drug class is 
certainly Imatinib©, the lead compound in the tumor kinase inhibitor family. Imatinib© 
has been designed to inhibit BCR-ABL, a kimeric protein deriving only from Ph+ 
(Philadelphia gene-positive) cells, which are mutated cells common in chronic myeloid 
leukemia and other kind of rare tumors. Such kinase inhibition is fatal to cancer cells, 
while healthy cells are not affected. Nevertheless, such therapeutic approach has a 
significant limit. Because of their extraordinary duplication rate, tumor cells are 
subjected to develop mutation with a much higher frequency than healthy cells. 
Targeted drugs such as Imatinib© only exert their cytotoxic activity by means of a 
single, specific mechanism (such as the inhibition of a particular enzyme) and the 
continuative administration of such treatments can lead, in a relatively short period, to 
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the selection of a resistant generation of cancer cells. Cancer cells acquire this kind of 
specific resistance, for instance, by alteration of the active site of the target enzyme. 
Given their absolutely no specific mechanism of action, the activity of classic 
chemotherapeutic agents is not diminished in the least by this kind of mutation, but 
targeted chemotherapeutics result completely inactive once specific resistance has 
risen. 
Nonetheless, both classic and target chemotherapy are limited by another kind of 
tumor cell resistance, namely multi-drug resistance (MDR). If specific resistance to a 
certain cytotoxic molecule is attained by tumor cells by modification of the molecule’s 
target, multi-drug resistance is a condition enabling the tumor cells to resist distinct 
drugs or chemicals of a wide variety. Cancer cells explicate multi-drug resistance 
through various mechanisms, such as enzymatic deactivation of the anti-cancer drug, 
decreased cell wall permeability to cytotoxic drugs, altered active sites also in less 
specific enzymatic targets, increased mutation rate as a stress response, efflux 
mechanisms to remove drugs, e.g. glycoprotein P overexpression. 
For all of these reasons, it is evidently necessary to maximize drug dose in proximity of 
the target, in order to increase the efficacy of the treatment and to minimize 
chemotherapy side effects. Therefore, the selective targeting of tumor cells is the goal 
of modern cancer therapy, aimed at overcoming this non-specific toxicity. This 
ambitious aim may be achieved by means of a targeted drug delivery system-involving 
therapy. Instead of focusing on a targeted pharmacodynamic activity, which may 
increase the probability of the development of specific resistance to targeted drugs, 
emphasis should be put on both selective pharmacodynamic and pharmacokinetic 
activity. This novel kind of therapeutic approach is very promising, for it may overcome 
the classical limits of chemotherapy, as reported in section 1.3. 
 
1.3 Targeted drug delivery systems: the new frontier of chemotherapy 
 
A targeted-drug delivery system strategy is aimed at conveying a bioactive molecule to 
its action site as specifically as possible, thus maximizing the in situ drug quantity 
without increasing administration dose and minimizing the side effects. The main target 
of all sophisticated drug delivery systems is to deploy medications intact to specifically 
targeted parts of the body through a medium that can control the therapy’s 
administration (a process which is also known as drug vectorization) by means of either 
a physiological or chemical trigger. As a matter of fact, instead of exploiting tumor-
specific pharmacodynamics targets, such as enzymes, in targeted drug delivery the 
specificity of action is ensured by interaction between the therapeutic agent and a 
tumor-specific pharmacokinetic target so that the distribution of the drug in vivo 
regards only the cancerous lesion. A similar pharmacokinetic target may be 
represented, for instance, by a receptor which is overexpressed by the tumor cell. The 
interaction with the specific target is not cytotoxic in itself, but the bond between the 
targeted drug delivery system and the receptor is exploited as a Trojan horse in order 
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to allow a highly focused distribution of the drug into the tumor cell. Drug delivery is 
often approached via a drug's chemical formulation, but it may also involve medical 
devices or drug-device combination products. The most common approach in the 
development of targeted drug delivery systems consists in conjugating the 
chemotherapeutic agent, which constitutes the cytotoxic portion of the system, to a 
carrier of various natures.  
The carrier is the portion of the system which is expected to target the tumor cell, 
establishing a preferential interaction with the latter. Although the carrier may have an 
intrinsic cytotoxic activity (as shown in studies on metallic nanoparticles carriers),
6
 it 
usually only works as a vehicle delivering the drug into the cancerous cell. It is thus 
evident that targeted drug delivery systems present numerous advantages. In detail: 
i) Specific delivery of cytotoxic agents to tumor overexpressed receptors and 
subsequently a more selective killing of cancer cells. Moreover, the sparing of 
normal tissues from the harmful side effects of systemic therapy, allows 
lowering the administered dose in cure protocols. Such a decrease of the initial 
administered drug dose brings a series of major benefits, as a lowering in the 
incidence of chemotherapy side effects, not to mention the fact that this 
would postpone the necessity of dose escalation indicated whenever intrinsic 
resistance of some tumors to chemotherapeutic agents rises;  
ii) Recycling of those classic, very cytotoxic chemotherapeutic agents which have 
been eliminated from cure protocols because of their critical toxicological 
profile. In fact, minimizing drug tissue distribution, dangerous but efficacious 
cytotoxins may be used (or re-used) in therapy and this could represent a 
certain benefit both from the therapeutic and the economical point of view.  
iii) Very versatile entity which offers many modifiable sites on which the 
researcher can operate to improve the technological performance of the 
delivery system and the chemical stability of the conjugated pharmaceutical 
agent. A suitably modified carrier, in fact, may not function only as a mere 
drug vehicle, but (as in the case of liposomes, for instance) it could constitute a 
shield for a highly instable drug, protecting it e.g. from chemical or enzymatic 
hydrolysis in vivo or from degradation and aging during its shelf life. 
It is for all these reasons that a rising interest on targeted drug delivery systems has 
been growing during the last three decades and nowadays, given the recent, impressive 
breakthroughs of nanomedicine, the possibilities offered by drug vectorization seem to 
be endless. This is also due to the very broad range of carriers which have been 
developed since the 1980s. In general, three main generations of vectors can be 
identified: 
1) First generation carriers: these first vectors are constituted by organic polymer 
microcapsules or microspheres, which are injected intra arterially in the proximity of 
solid, primary tumors. Besides conveying the drugs directly to the tumor tissue, they 
also have a chemoembolization effect, which consists in causing a vascular disruption 
and the starving of the tumor, which undergoes ischemic necrosis.
 
The obstruction in 
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tumor-lining blood vessels also prevents the drug from distributing in the systemic 
blood flow. This therapeutic strategy is not being applied in a very great number of 
cases; however, trans-arterial chemoembolization (TACE) has become standard 
treatment in selected patients affected by hepatocellular carcinoma.
7
 
2) Second generation carriers: carriers such as liposomes
8
 and nanoparticles
9
 belong to 
this generation of vectors. They normally have colloidal dimensions (<1 µm) and are 
characterized by better intracellular permeation compared to first generation carriers. 
Liposomes are artificially-prepared vesicles composed of a lipid bilayer in which a drug 
may be encapsulated. Their surface offers many modifiable sites that can be 
functionalized with tumor receptor ligands (e.g. peptides, glycopeptides or even 
antibodies) to enhance the selectivity of its distribution. Besides working as specific 
carriers, they can protect the drug from in vivo degradation and slow drug metabolism 
and elimination down. For what concerns nanoparticles, a detailed analysis will be 
presented in the section 6. 
3) Third generation carriers: antibodies,
10
 especially monoclonal human or humanized 
antibodies (mAbs) against tumor antigens, are the most famous representatives of this 
generation of vectors, as they are undoubtedly the mainly used carriers of conjugated 
moieties for targeted tumor therapy or diagnosis. 
In the1970s, the B-cell cancer myeloma was known, and it was understood that these 
cancerous B-cells all produce a single type of antigen. This was used to study the 
structure of antibodies, but it was not possible to produce identical antibodies specific 
to a given antigen. The process of producing monoclonal antibodies was invented by 
Georges Köhler and César Milstein in 1975.
11
 Many antibodies-based pharmaceutical 
specialties have recently been approved by FDA, such as Herceptin (1998) for breast 
cancer, Erbitux (2004) and Avastin (2004) for metastatic colorectal cancer, with a 
subsequent revolution in chemotherapy. One possible treatment for cancer involves 
monoclonal antibodies that bind only to cancer cells specific antigens and induce 
immunological response on the target cancer cell (naked antibodies). Although 
unmodified mAbs may show some therapeutic potency, their effect tend to be various 
and ultimately not curative when not used in combination with classical chemotherapy. 
These antibodies would need to be administered to patients in massive doses to be 
effective, thus leading to serious side effects. As a result, mAbs have been armed with 
drugs, toxins, cytokines or radionuclides opening the door to the clinical use of targeted 
tumor therapy (Figure 1.2). 
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Figure 1.2 - Monoclonal antibodies for cancer. ADEPT, antibody directed enzyme 
prodrug therapy; ADCC, antibody dependent cell-mediated cytotoxicity; CDC, 
complement dependent cytotoxicity; mAb, monoclonal antibody; scFv, single-chain Fv 
fragment. 
Antibodies-based drug delivery systems employ several mechanisms to damage cancer 
cells: 
i) Making the cancer cells more visible to the immune system. The antibody 
marks the cancer cells as physiological B-cell produced antibodies normally 
mark pathogen cells during infections; as sometimes cancer cells are not 
recognized as enemies by the immune system, the antibody-mediated marking 
induces an immunological response addressed to the cancer cells; 
ii) Blocking growth signals. Certain cancer cells overexpress growth factor 
receptors, whose interaction with their ligand makes them grow faster than 
healthy cells. Antibodies can also have an intrinsic antitumor activity, by 
binding to growth factor receptors. This synergistic combination of specific 
vectorization of pharmaceuticals to the cancer cell and selective cytotoxic 
activity, particularly increases the potency of this pharmaceutical specialties; 
iii) Delivering radiation to cancer cells. By combining a radioactive particle with a 
monoclonal antibody, radiation can be delivered directly to the cancer cell; 
iv) Delivering powerful drugs into cancer cells. Powerful anti-cancer drugs or 
toxins can be attached to monoclonal antibodies. Drugs remain inactive until 
they penetrate the target cells, lowering the chance of harming other cells. 
 
This kind of drug delivery systems has raised great expectations among oncologists, so 
that many new antibodies-based targeted therapies have been approved by U.S. Food 
and Drug Administration (FDA) since 2010. Nonetheless, the use of immunoglobulins as 
targeting moieties has some drawbacks, such as the high costs of production, the 
difficulty in obtaining specific antibodies for every tumor type and, finally, toxicological 
issues. In fact, although antibodies can be disguised as human to evade the immune 
response, these delivery systems are xenobiotic substances and are soon recognized as 
such. This means there is only a short time when antibody therapy can be used before 
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it becomes ineffective, not to mention the fact that the xenobiotic moiety may trigger 
an abnormal immunologic response, which could give rise to severe side effects. More 
fundamentally, the number of tumor cells in patients with terminal disease overwhelms 
the therapy. Some cells express too little antigen to be targeted and cells in a large 
mass may escape attention altogether. Antibody therapy is most likely to be useful in 
the context of minimal, but disseminated disease; in fact just the situation that often 
occurs after conventional chemo-radiotherapy. Moreover, antibodies conjugates are 
characterized by suboptimal pharmacokinetics and biodistribution, as well as non-
specific uptake by the liver and reticuloendothelial system (RES), which may result in a 
systemic diffusion of the drug, losing the targeting effect.
12
 To overcome the limits of 
antibody-based therapeutic approach, another strategy has been recently developed, 
in which the targeting moiety of the drug delivery conjugate is a peptide (as discussed 
in section 1.4). 
 
1.4 Drug-peptide conjugates as an evolution of antibodies-based drug delivery 
systems: the case of Neurotensin 
 
The discovery that receptors for different endogenous regulatory peptides are 
overexpressed in several primary and metastatic human tumors led to their use as 
tumor antigens; this opened the door to peptide-based therapeutic and diagnostic 
approaches in oncology.
13
 These receptors can be used as molecular targets by which 
radiolabeled peptides can localize cancers in vivo, a strategy which can be exploited 
both for therapeutic and diagnostic purposes. As tumor targeting agents, peptides have 
several advantages over antibodies,
14
 including: 
i) Better organ or tumor penetration and more efficient cellular 
internalization, because the antibody molecules are relatively large and 
might not reach the tumor easily; 
ii) Greater stability (long storage at room temperature); 
iii) Lower manufacturing costs (recombinant production takes approximately 
twice as much, in terms of time and costs than chemical synthesis) and 
more reproducible production performances; 
iv) Batch-to-batch production parameters, due to the advances in solid-phase 
peptide synthesis; 
v) Fewer and less expensive regulatory requirements (chemical synthesis 
versus recombinant production) and easier and quicker authority 
approval. 
Peptides can serve as carriers for the local delivery of cytotoxic agents to the tumors, as 
demonstrated by the successful clinical use of radiolabeled somatostatin analog for the 
detection and treatment of some somatostatin receptor-positive tumors.
15
 Thus, in 
recent years a series of cytotoxic peptide hormone conjugates were developed. 
Moreover, an increasing number of tumors may be addressed by ‘peptide-bullet’ 
strategy: peptides can be conjugated with cytotoxic moieties or radionuclides and, 
provided that the receptor-ligand complex is internalized on binding, the functional 
moiety can be specifically delivered into the tumor cell.
16
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An excellent candidate for a drug-peptide conjugate therapy is, among many others, 
neurotensin, a regulatory peptide whose receptors are over-expressed by many types 
of tumors and on which our work has been focused. 
 
Neurotensin 
 
Neurotensin (NT) was first isolated in 1973 from extracts of bovine hypothalamus 
based on its ability to cause a visible vasodilatation in the exposed cutaneous regions of 
anesthetized rats.
17
 NT is a 13-amino acids regulatory peptide, sharing significant 
similarity in its C-terminal portion of amino acids with several other neuropeptides 
(Figure 1.3). This region is responsible for the biological activity as neurotransmitter 
while the N-terminal portion has a modulator function.  
 
 
a. 
 
b. 
Figure 1.3 - a. Neurotensin (NT), b. QLYENKPRRPYIL, schematic representation. 
 
NT is distributed in discrete regions of the CNS of mammals, where this peptide likely 
plays an important role as a neurotransmitter or neuromodulator in neuronal signaling. 
It has also been shown to be present in the hypothalamus of a variety of species 
including rat, mouse, rabbit and man. In 1988, the rat NT gene was isolated and 
sequenced, finding out that the amino acids 8-13 of NT are essential for biologic 
activity.
18
  
As many other neuropeptides, neurotensin works as both a neurotransmitter in the 
central nervous system (CNS) and as a local hormone in the peripheral tissues. In 
mammals, NT is widely distributed throughout the CNS (with highest levels in the 
hypothalamus, amygdala and nucleus accumbens) and digestive tract (enteroendocrine 
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cells of the small intestine), where it acts as a growth factor on a variety of normal or 
cancer cells.
19
  
Neurotensin has various physiological functions; firstly it works as a vasodilation and 
hypotension inducer. In fact, it has been observed that central administration of 
neurotensin produces a marked dose-related decrease in body temperature of mice 
and rats at an ambient temperature of 25 °C. Other effects observed after central 
administration of neurotensin are decreases in locomotion and sedation. The effect is 
observed in both rats and mice, but only after central administration, neurotensin is, in 
fact, inactive after peripheral administration. This suggests that the tridecapeptide is 
not able to cross the blood-brain barrier in sufficient quantities to exert direct brain 
effects and also that the central nervous system locus of action of this compound lies 
within the confines of the blood-brain barrier. Thus, although neurotensin has been 
reported to induce several endocrine (increases in plasma concentrations of 
gonadotropins, ACTH, growth hormone, prolactin, corticosteroids, and glucagon) and 
hemodynamic (hypotension, vasodilatation, and cyanosis) changes after i.v. 
administration, it appears that the brain effects of this peptide are not mediated by 
such peripheral processes. Major peripheral functions of neurotensin include the 
stimulation of pancreatic exocrine secretion, inhibition of gastric acid secretion, and 
inhibition of gastroduodenal motility. Fat ingestion induces a dose-related increase in 
neurotensin plasma concentrations, whereas glucose and amino acids produce only 
minor or no effect.
20 
The actions of NT are mediated by the stimulation of several specific receptors, called 
NTR. Three specific membrane receptors have been described so far. NTR1 shows a 
high affinity for NT, whereas NTR2 exhibits a low affinity (Figure 1.4).  
 
 
Figure 1.4 - Overview of agonist-bound NTR1
21 
NTR1 and NTR2 belong to the family of G protein-coupled receptors (GPCRs). NTR3, 
also named Sortilin (Sort1) is an entirely new type of neuropeptide receptor with a 
single transmembrane domain and it has been recently described as having an 
important role in pancreatic ductal adenocarcinoma cell migration. As previously 
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reported, NT receptors are overexpressed by certain tumor type. Reubi et al. found 
receptors expressed on many tumor cells, such as meningioma, pancreatic, prostatic, 
lung and colon carcinomas, in particular the high affinity NTR1.
 
Over 75% of all ductal 
pancreatic carcinomas were reported to overexpress neurotensin receptors, whereas 
normal pancreas tissue, pancreatitis, and endocrine pancreas do not. Neurotensin 
receptors are observed more often in differentiated than in poorly differentiated 
tumors: indeed, as many as 83% of the differentiated adenocarcinomas are receptor 
positive; in particular, tumors with tubular differentiation are more often positive than 
solid tumors. Recently, it has been observed by Gui et al.
22
 that NTR1 is commonly 
expressed in breast carcinomas; what is most interesting is that this overexpression is 
independent of ER/PR/Her2 profile, so a neurotensin based adjuvant therapy may be a 
breakthrough in the cure of “triple negative” breast carcinomas who cannot be treated 
with Herceptin and derivatives. Further and up-to-date elucidations about possible 
interactions between neurotensin and receptors or other membrane proteins are 
reported in below sections. 
For all these reasons, neurotensin is considered an excellent lead compound for the 
design of a drug delivery system targeting moiety and, in particular, it seems to be the 
best possible candidate for peptide based therapy of exocrine pancreatic carcinomas, 
due to the high incidence and density of neurotensin receptors in these tumors, and of 
the whole gastrointestinal tract cancers in general. Unfortunately, the bottleneck for 
development of peptides as drugs has always been their extremely short half-life, due 
to physiological degradation by peptidases and proteases. High affinity ligands are also 
necessary, since unlike antibodies, monomeric peptides do not have the advantage of 
multimeric binding. To overcome this problem, various neurotensin analogues have 
been synthesized, including linear peptides, cyclic peptides, and non-peptide molecules 
(inserting D-amino acids, or pseudo amino acids),
 38
 but chemical modification of the 
native peptide may radically modify receptor affinity and specificity. 
Prof. Luisa Bracci’s group at the University of Siena, previously reported that synthesis 
in branched form increased the bio-stability of certain peptides, including neurotensin, 
obtaining promising results in vitro and in vivo both for diagnostic and therapeutic 
purposes.
23
 The synthesis of bioactive peptides in Multiple Antigen Peptide (MAP) 
dendrimeric form turns out to be useful, leading to acquired resistance to protease and 
peptidase activity (Figure 1.5).  
 
Figure 1.5 - Schematic MAP representation. 
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The greater in vivo stability to proteolytic enzymes of MAPs (Multiple Antigenic 
Peptides) compared to monomeric peptides is due to the greater complexity of their 
structure. The MAP system utilizes a peptidyl core of three or seven radially branched 
lysine residues, on to which the antigen sequences of interest (in this case a peptide) 
can be built using standard solid-phase chemistry (Figure 1.6). 
 
Lys
Lys
Lys
PEPTIDE
PEPTIDE
PEPTIDE
PEPTIDE
Functional Unit
 
Figure 1.6 - Peptide tetramer with three-lysine branched core 
Thanks to this lysine core, the MAP can bear four or eight copies of the peptide epitope 
(resulting in high molar ratio), depending on the inner core that generally accounts for 
less than 10% of total molecular weight. Moreover, the MAP system does not require a 
carrier protein for conjugation.  
MAPs can be more efficient than monomeric peptides in diagnostic applications and 
also have the possibility to be conjugated to various Functional Units such as 
fluorophores, photosensitizes, cytotoxic groups or chelators for radioisotopes. As said 
before, the in-vitro and in vivo efficiency of dendrimeric peptides like MAPs is generally 
ascribed to their multimeric nature, which enables polyvalent interactions. 
In order to demonstrate the longer half-life of MAPs derivate, Professor Luisa Bracci‘s 
research group (also thanks to AIRC funding) compared the stability of monomeric and 
tetrabranched neurotensin. Bioactivity of monomeric and MAP peptides was checked 
by testing the inhibition of nM [
3
H]neurotensin-specific binding to membranes 
prepared from the human colon adenocarcinoma cell line HT 29.
24
 Experiments were 
performed in the presence of protease inhibitors. MAP NT efficiently inhibited nM 
[
3
H]neurotensin-specific binding, and its IC50 value was analogous to that of monomeric 
NT. The resistance to protease activity in human plasma and serum was tested for the 
two peptides. Monomeric and tetrabranched peptides were incubated with human 
plasma or serum for 2 or 24 h, and the mixture was analyzed by HPLC and mass 
spectrometry to follow the presence of uncleaved monomeric and MAP peptides. As a 
general rule, peptides that are cleaved in plasma in 2h are also cleaved in serum at the 
same time. Those resistant in serum after 24h are also resistant in plasma. It was found 
that the MAP form was more resistant than the monomeric form (Table 1.1).  
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Table 1.1 - The absence (-) or presence (+) of peptide after the incubation times refers 
to the unproteolyzed peptide sequence as detected by HPLC and MS. 
Moreover, in order to test the possible influence of peptide length, number of peptide 
copies, and steric hindrance on branched peptide stability to peptidases, the 
monomeric, two branched and tetra-branched forms of NT were synthesized and their 
stability, after incubation with human plasma and serum was compared. Prof. Bracci’s 
research group found that the tetra-branched form of neurotensin was stable in both 
human plasma and serum for 24h, whereas the di-branched for 5h and the monomeric 
analogue was degraded in roughly 5h (Table 1.2).
16 
 
Peptide Plasma 
(2h) 
Plasma 
(5h) 
Plasma 
(24) 
Serum 
(2h) 
Serum 
(5h) 
Serum  
(24h) 
Monomeric NT + - - + - - 
Dibranched NT + + - + + - 
Tetrabranched NT + + + + + + 
 
Table 1.2 - Stability of the three peptides in plasma and serum. 
As a result, steric hindrance may limit the access of such peptides to the cleavage site 
of proteolytic enzymes, increasing the peptide half-life, with obvious advantages for 
their use as drugs. The possibility to form supramolecular aggregates is another feature 
of branched peptides probably accounting for their increased stability. Tetrabranched 
peptides may arrange their four arms in parallel structures stabilized by intramolecular 
H-bonding of the backbone. This structure would resemble that of self-assembling β-
sheet peptides. Prof. Bracci’s results indicate that synthesis in dendrimeric form may be 
a general method to increase in vivo stability of bioactive peptides and so a step 
forward on the direction of the finding of new specifically targeted cytotoxic drugs. 
Peptide Plasma (2h) Plasma (24h) Serum (2h) Serum (24h) 
NT + - + - 
MAP-NT + + + + 
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1.5 Towards the synthesis of a MAP-NT based drug delivery system 
 
MAP-NT does not present binding sites for bioactive molecules; therefore, in order to 
functionalize the dendrimer with the drug moiety, the synthesis of a non-peptidic linker 
able to bind the therapeutic moiety to the lysine core has been necessary. The C-
terminal lysine side chain was functionalized with the chemotherapeutic agents spaced 
by an amino-terminal PEG (polyethylenglycol) moiety, chosen in consideration of 
synthetic and biological issues. Spacing is necessary, as the hindrance of the branched 
peptide might impair the access of the activated chemotherapeutic and therefore give 
poor reaction yields. Moreover the drug moiety, if closely linked to the branched 
peptide, might impair receptor recognition and, for slow realizing compounds, the 
closeness of branched peptide might compromise drug-target interaction inside the 
cell. A special care in choosing the suitable linker to insert between the functional unit 
and the tetrabranched peptide was taken, considering that in the case of cytotoxic 
molecules the link has to be broken preferably upon internalization into the tumor cell. 
In this sense the complex should be considered as a ‘pro-drug’, defined as a precursor 
of a drug that has to undergo chemical conversion by metabolic processes before 
becoming an active pharmacological agent. The final structure is then a lysine-core NT 
tetramer functionalized with an amino-terminal linker, which could constitute the 
binding sites for the therapeutic unit (Figure 1.7).  
 
 
Figure 1.7 - Schematic representation of the amino-terminal linker functionalized MAP-
NT. 
As reported in previous works,
24
 suitable derivatives of some of the most used 
chemotherapeutics, such as methotrexate or 5-Fluorouridin or Gemcitabine, were 
synthesized so that they could be linked to the amino-terminal MAP-NT moiety (Figure 
1.8). 
 
 17 
 
 
Figure 1.8 - Conjugation procedure. 
These drugs have been coupled with aliphatic α-ω diacids. Such carboxylate-decorated 
drugs can be then coupled through an amidic bond with the amino-terminal MAP-NT 
moiety. The advantage of this final coupling is that the drug derivatives can be treated 
as an amino-acid and linked to the peptide exploiting the same procedure used for 
building up the primary sequence of MAP-NT on solid phase. It was decided to use 
ester linkage as covalent bonds suitable for safety delivering the drug inside the cell 
where the releasing of the anticancer agent occurs by hydrolysis (also mediated by 
ubiquitous esterases).  
As for the achievement of the targeted drug delivery system, Bracci’s group in Siena has 
set up a general method allowing conjugation by standard solid-phase peptide 
synthesis (Figure 10). Unfortunately this strategy couldn’t be applied to all the 
chemically modified anticancer drug prepared. Indeed, in the last step peptide-
functional unit conjugates are cleaved from the resin by treatment with concentrated 
trifluoroacetic acid (TFA). The drastic acid condition of the cleavage could, in some 
cases, partially or completely demolish the drugs integrity leading to an irreversible 
damage of the conjugate. Some antimetabolites, such as Gemcitabine and 5-fluoro-
2’deoxyuridine, estrogens as estradiol and bioreductive agents as β-lapachone are not 
stable under the cleavage condition. To overcome this problem, we envisaged a ‘post-
cleavage coupling’ strategy in which the peptide is cleaved from the resin prior to the 
coupling with the therapeutic unit, that is carried out in liquid phase. This preserves the 
conjugate from degradation.   
To achieve this aim, it was exploited a ‘click chemistry’ strategy to properly decorate 
either the peptide and the drug. Among other strategies, we chose to insert a thiol 
group on MAP-NT, through a terminal cysteine residue, that could react with a 
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maleimide group bound on the anticancer agent (Scheme 1.1). This Michael reaction is 
highly selective and does not involve free groups on later chain of the amino acids that 
were deprotected with TFA during the cleavage of the peptide from the resin, allowing 
to lead it in solution phase without formation of side-products. In order to demonstrate 
the feasibility of the method, a MAP-NT-fluorophore (Alexa Fluor ®750) tagged complex 
has been synthesized exploiting thiol-maleimide coupling protocol and tested in 
xenografted mice with HT29 (colon adenocarcinoma). 
 
 
 
Scheme 1.1 - Click chemistry protocol for ‘post-cleavage coupling’ strategy. Step 1) 
simultaneous cleavage from the resin and deprotection of protecting groups on side-
chain of the aminoacid. Step 2) coupling through a Michael reaction. 
The injection of the conjugate in mice, primarily localized in proximity of the tumor 
mass, showed the effective and specific targeting of the conjugate to cancer cells.  
Encouraged by these promising results, it was extended the strategy to drugs. Indeed, 
Paclitaxel, a mitotic inhibitor agent, is the perfect example of successful ‘post-cleavage 
coupling’ strategy.  
 
1.6 Paclitaxel in targeted delivery systems 
 
Taxanes, which include Paclitaxel, docetaxel and other analogues, are a class of potent 
chemotherapeutic drugs that act by binding microtubules and preventing their 
disassembly, thus blocking mitosis and eventually inducing apoptosis. Taxanes are 
highly effective against proliferating cancer and are an established option in the 
standard treatment of ovarian and breast cancer.
25
 
Paclitaxel is one of the more used mitotic inhibitor used in cancer chemotherapy. It is a 
diterpenoid pseudoalkaloid, it has a tetracyclic 17-carbon (heptadecane) skeleton, with 
a total of 11 stereocenters. The active stereoisomer is (-)Paclitaxel. It was discovered in 
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a US National Cancer Institute program at the Research Triangle Institute in 1967 when 
Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, 
Taxus brevifolia and named it taxol (Figure 1.9).
26
 
 
 
 
Figure 1.9 - (-)Paclitaxel (left) and taxus brevifolia (right). 
In 1971 Paclitaxel was found to have cytotoxic effects on solid tumors and leukemic 
cells
27
 and in early 1979 Dr. Horwitz Susan and her group delineated its main 
mechanism of action (since then unknown) involving the stabilization of microtubules.
28 
After numerous in vivo studies, in 1992, Bristol-Myers Squibb marketed the drug as 
TAXOL® with the approval of the FDA where it was used for treatment of breast, ovary 
and AIDS-related Kaposi sarcoma. 
Mechanism of action and current use  
Taxanes are currently known to suppress and inhibit cell growth, differentiation and 
proliferation in indefinitely known cancer cell lines and are the most preferred 
anticancer drugs by physicians. They are commonly known as mitotic inhibitors or 
microtubule inhibitors as they cause a frozen mitosis; hence they are also sometimes 
called as mitotic poisons.
27
 Paclitaxel, in spite of its excellent anti-tumor activity is still 
not cell specific and not all concentrations have similar effects on the microtubules; 
higher concentrations cause microtubule arrangement into bundles, while at lower 
concentrations, there is suppression and stabilization of microtubule dynamics without 
alteration of the polymer mass formed.
29
 Moreover, taxanes have been found to be 
potential angiogenic inhibitors either as single agents, together with chemotherapeutic 
drugs or combination therapies, such as endogenous estrogens (2-methoxyestradiol)
30
 
and bevasizumab
31
 which regulated VEGF (vascular endothelial growth factor) in an 
agonistic manner.  
For the past two decades, Taxol has been undergoing infinite number of clinical studies 
in many cancer patients, in order to know about several factors regarding their 
usefulness as potential anti-neoplastic agents. Paclitaxel has neoplastic activity 
particularly against primary epithelial ovarian carcinoma breast cancer, colon, head, 
non-small cell lung cancer, and AIDS related Kaposi’s sarcoma. This has led, in recent 
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time, to the approval of the drug in many countries for its use as second line treatment 
of ovarian and breast cancers.
32
 Despite of the primary importance of several 
Paclitaxel-based monotherapies, conjoint therapy with platinum derivatives is, 
nowadays, a first line of treatment of ovarian cancer. In particular, Carboplatin-
Paclitaxel combination is an emerging therapeutic protocol for advanced ovarian 
carcinoma, replacing the older and more toxic cisplatin-Paclitaxel one.
33
 The same 
trend that envisages a more effective cancer management with combined therapies is 
found in treatments of breast cancer, for which, binary association with anthracyclines 
and triple with doxorubicin and Gemcitabine prolong patients’ survival rates.
34
 In 
general, thus, in order to achieve disease free survival taxol should be tried with several 
adjuvants to meet up to its expectancy. 
Drawbacks of Paclitaxel therapy and alternative approaches for taxol formulation 
There is no question that Paclitaxel is one of the more effective weapon we have in 
hands to treat a broad range of cancers that are generally considered to be refractory 
to conventional therapy. Unfortunately, its extended use has underlined several 
limitations, mainly related to: 1) availability, 2) solubility, 3) resistance. 
1) Paclitaxel is extracted from the bark of Pacific Yew. Although the extraction 
has increased yields to 0.04% w/w, 4 trees have to be sacrificed to produce 2 g 
of the drug for the chemotherapy of one patient and this is not affordable 
from the environmental point of view.
14
 
 
Paclitaxel is currently formulated in a 
vehicle composed of 1:1 blend of Cremophor EL (polyethoxylated castor oil) 
and ethanol which is diluted with 5-20-fold in normal saline or dextrose 
solution (5%) for administration. Several problems employing this vehicle have 
been reported. For instance, Cremophor vehicle requires to be solubilized, it 
has a toxicity that includes hypersensitivity reactions, nephrotoxicity and 
neurotoxicity.
35
 Moreover, the recommended concentration of the drug in the 
properly diluted clinical formulation is 0.3-1.2 mg ml
−1
 (0.35-14 mM) and has 
only short-term physical stability as some particles slowly tend to precipitate 
out of the aqueous media; 
2) Paclitaxel is poorly soluble in an aqueous medium (approx. 0.6 mM), but can 
be dissolved in organic solvents. Its solutions can be prepared in a mM 
concentration in a variety of alcohols, such as methanol, ethanol, tertiary-
butanol as well as in DMSO. 
3) Acquired resistance to taxanes has become a serious clinical issue with 
increasing prescription. Though there have been a lot of successful outcomes 
with taxanes involved in the treatment of endless number of cancers, drug 
resistance remains a major obstacle which needs to be combated urgently. For 
years, profound researches have been going on just to understand the 
mechanisms related to MDR (multidrug resistance). Few of the mechanisms 
that have been highlighted includes P-glycoprotein which pumps out 
intracellular accumulation of respective drugs.
15
 
 
Considering the above mentioned limitations, the main challenge of actual research is 
to develop alternative and safer strategies for an appropriate deliver of Paclitaxel. 
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Overall, ‘carrier delivery systems’, including liposomes, micelles and particulate drug 
delivery systems, seem to be the best possible approach towards the ideal dosage 
form. 
Paclitaxel has also received extensive chemical studies during its development. Various 
chemical transformations have been carried out, which provided structure-activity 
relationships (SAR). 
 
Kingston et al.
36
 have studied the importance of the various hydroxyl groups of the 
taxane ring system on the activity of taxol (Figure 1.10). In these investigations it was 
shown that both the C-10 and C-7 positions could be deoxygenated without significant 
loss of activity, but that deoxygenation of the C-4 and C-2’ positions did result in a 
significant activity loss. The use of esters as prodrugs has been extensively employed 
for modifying biologically active molecules containing either hydroxyl or carboxyl 
functionalities. For Paclitaxel, the simplicity of synthesis coupled with the facile 
enzymatic hydrolysis dictate esters as a first choice when considering prodrug 
strategies. Studies of 2′-taxol esters as prodrugs demonstrated that esters without α-
substituents hydrolyzed only to the extent of 10% over a 24 h period, while those with 
electron-withdrawing substituents in the α-position showed remarkable enhancement 
in their rates of hydrolysis.
37
 Among the most notable Paclitaxel derivatives synthesized 
so far are those in which the C-2 and C-7 hydroxyl groups of the molecule are engaged 
in a functional group that collapses, upon in vivo activation, releasing Paclitaxel.
38
  
 
Figure 1.10 - Some structure-activity relationships of Paclitaxel. 
In accordance with these considerations, first attempts of our research group were 
aimed to the achievement of a Paclitaxel-MAP-NT conjugate. The so obtained adduct 
should result in a “pro-drug” delivery system. Indeed, while the targeting activity of the 
peptide allows the selective accumulation of the drug in the tumor site, the presence of 
a linkage which can undergo in vivo chemical modification, ensures drug release form 
the adduct. To this purpose, we decided to exploit the more reactive OH function at 
position 2’, to insert an orthogonal group able to react with the cysteine residue on the 
dendrimer. In detail, the thiol-maleimide click reaction was envisaged. Synthetically, 
the OH at position 2’ was esterified with 3-maleimido propionic acid to both achieving 
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the maleimide-functionalization and ensure the presence of the ester bond. Maleimide 
group was, in turn, reacted with the thiol functionalized MAP-NT (Scheme 1.2). 
 
 
Scheme 1.2 – Synthesis of MAP-NT-PTX adduct. 
In vitro cytotoxicity of the so obtained adduct was evaluated by using colon 
adenocarcinoma (HT-29) and pancreas carcinoma (PANC-1) cell lines, compared to that 
of the corresponding free drug (PTX) and to that of an unrelated conjugate (U4-PTX), 
which had been synthesized and conjugated with Paclitaxel by procedures identical to 
those used for synthesis and conjugation of NT4-PTX, though with a different, non-
tumor-selective amino acid sequence. Results obtained with the control U4-PTX 
unrelated peptide conjugate showed that conjugation with a branched peptide that 
does not bind to cancer cells produces a reduction in Paclitaxel activity, thus confirming 
the cytotoxicity on NT4-PTX is due to its peptide-mediated transport into cancer cells.  
NT4-PTX efficacy was tested in vivo in an orthotopic mouse model. Once mice attained 
palpable tumors, they were randomly divided into three groups and treated with NT4-
PTX, free PTX and saline every 4 days by tail vein injection. Tumor growth was 
monitored by measuring volumes every 4 days with a caliber rule. At day 16, the 
average tumor volume of mice treated with NT4-PTX, as measured by caliber and 
imaging, had decreased by about 37% with respect to animals treated with free PTX 
and by 70% with respect to control animals (saline). NT4-Paclitaxel induced tumor 
regression, in the group of animals treated with it, while treatment with unconjugated 
Paclitaxel only produced a reduction in tumor growth with respect to controls, but not 
tumor regression. Mice treated with PTX and NT4-PTX were monitored for at least 2 
weeks after the last drug injection. Among animals treated with NT4-PTX, regression 
was observed in each treated animal and 60% treated animals showed almost complete 
eradication of the disease with no recurrence during 3 weeks without treatment. 
Toxicity of NT4-PTX treatment was evaluated by monitoring animals daily. None of the 
treated animals showed any remarkable change in behavior or significant loss of body 
weight.
25
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2 Gold Nanoparticles 
 
2.1 Metallic functionalized nanoparticles: an improvement of MAP-NT 
strategy 
 
The previously described targeted drug delivery system (see the section 1 for details), 
composed by a targeting moiety (MAP-NT), an amidic (or thiolic) linker and a functional 
unit certainly represents an evolution of traditional targeted drug delivery systems, 
such as mAbs-drug conjugates. As already reported, peptides in such a dendrimeric 
form are particularly suitable for in vivo use, because they acquire a notable resistance 
to degradation by proteolytic enzymes, though maintaining or even increasing their 
natural biological activity. Moreover, neurotensin, synthesized as tetramer, offers 
accessible linking units for coupling of functional moieties. Nevertheless, one of the 
greatest drawbacks of peptide-based targeted therapy is the difficulty in multimeric 
drug binding, whereas, in the case of mAbs, each immunoglobulin is able to carry two 
(IgG) or five (IgM) drug units. This represents a great limit for this strategy, also 
considering, for example, the likelihood of premature hydrolysis of the drug-linker bond 
by means of plasmatic esterases or possible drug release problems, which would even 
decrease the quantity of drug per carrier molecule which would effectively reach the 
tumor cell. In order to maximize the poor drug/carrier molar ratio of MAP-NT-drug 
conjugates, then, our research group has oriented its synthetic efforts on the 
development of more complex drug delivery systems which could match the 
advantages of MAP-NT strategy with higher drug-binding capacity, i.e. the use of a 
nanocarrier. Several nanocarriers could be employed to this purpose, such as inorganic 
non-metallic nanomaterials (e.g. amorphous silica), carbon based nanomaterials (e.g. 
carbon nanotubes), organic macromolecular or polymeric nanomaterials (e.g. 
dendrimers) and metallic nanoparticles. Indeed, due to the highly functionalization of 
their surface, these nanosystems are currently investigated, for drug delivery.
39–43
 
However, most prominent nanomaterials in medical application are metallic 
nanoparticles (MNPs). The small size and the corresponding high surface-to volume 
ratio confers them properties which differ significantly from those of atoms as well as 
of those of the bulk materials. As a matter of fact, their specific and unique optical, 
electrical and magnetic properties make them excellent candidates for biomedical 
applications, such as imaging, hyperthermia, cell labelling, drug and gene delivery, 
especially in cancer therapy and diagnosis. High efficacy and improved safety of 
nanoparticles-based devices for cancer diagnosis and therapy are due firstly to the EPR 
(enhanced permeability and retention) effect, which ensure the targeting activity by a 
passive mechanism. As a matter of fact, nanoscale object, such as liposomes, 
nanoparticles, macromolecules, tend to be accumulated preferentially by tumor tissues 
rather than normal tissues, presumably because of the increased permeability of tumor 
blood vessels in combination with poor lymphatic drainage or transport. Despite this 
advantage, only 10 % of administered NPs reach the tumor because of the uptake by 
the reticuloendothelial system (RES) in which NPs are rapidly shuttled out of circulation 
to the liver or spleen, and nonspecific binding of NPs to non-targeted or non-diseased 
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areas. Concerns about NP toxicity often arise because of this RES accumulation. 
Aggregation can lead to NPs entrapment in the liver, lungs and other tissues due to 
capillary occlusion. 
44
 Thus, it may be profitable to further increase the targeting 
capacity of the MNPs switching from the passive vectorization mechanism to an active 
targeting mechanism.  This can be achieved by conjugating NPs to an appropriate 
ligand, with a specific binding activity to the target cells. In addition, nanoparticles 
provide a platform to attach multiple copies of functional units (i.e. therapeutics or/and 
tracers) increasing the concentration of therapeutics or diagnostics at the pathological 
site. Thus, we focused on the synthesis of a MAP-NT-NPs-drugs conjugates (Figure 2.1) 
as an evolution of the previously synthesized MAP-NT-drug adduct. 
 
 
Figure 2.1 - Schematic representation of the MAP-NT -nanoparticle (NP) - drug 
conjugate. 
Many different metallic nanoparticles have been recently investigated for their 
potential use as therapeutic, diagnostic as well as theranostic devices. 
 
2.2 Paramagnetic metallic nanoparticles 
 
Currently, the only clinically approved metallic nanoparticles are employed in diagnosis 
rather than in therapy. In particular, superparamagnetic iron oxide nanoparticles 
(SPIONs) have replaced gadolinium-based contrast agents in magnetic resonance 
imaging (MRI) for their slower renal clearance and higher relaxation values.
45 
However, 
other paramagnetic NPs have a potential use in MRI. For instance, Cobalt nanoparticles 
(CoNPs) have been recently investigated as efficient contrast agent in this technique, 
due to their higher magnetic moment compare to SPIONs.
41
 Furthermore, being the 
metal with the highest Curie point, cobalt firmly maintains its magnetic properties also 
in stress conditions thus allowing the development of nanosystems with a very 
prolonged shelf-life.
46
 However, metallic nanoparticles have also great therapeutic 
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potential, as it is proved by the wide number of preclinical trials in which they are 
involved.
47  
Thanks to their elevated magnetic moment, SPIONs and most importantly CoNPs, could 
be the ideal candidates for tumor-focused hyperthermia.
 
Indeed, when magnetically 
induced, such MNPs can conduct heat massively and selectively to the tumor cell in 
which they have been accumulated, causing tumor tissue shrinking and necrosis.
48 
When conjugating to a therapeutic agent, SPIONs and CoNPs could be applied for 
magnetic field assisted targeted drug delivery. As a matter of fact, through the 
application of a proper external magnetic field, the NP-drug conjugate can be 
selectively directed towards the tumor thus allowing a selective therapy. 
For all these potential applications, paramagnetic NPs were selected in the past years 
from our research group for the development of selective theranostic devices. At this 
purpose, Combretastatin A4 (CA4) was chosen as therapeutic unit. It is a potent 
antimitotic agent and exhibits strong cytotoxicity against a broad spectrum of cancer 
cell lines, such as murine melanoma, human ovarian and colon cancer cells.
49  
Since 
SPIONs are currently the only clinically approved MNPs, and CoNPs have shown 
interesting properties for a potential application in cancer theranostic, first attempts 
were directed to decorate SPIONs and CoNPs with C-A4. Thus, a proper 
functionalization was inserted on combretastatin A4 skeleton and C-A4-SPIONs and C-
A4-CoNPs conjugates were prepared (Figure 2.2). The synthesis of such drug delivery 
systems presented a certain complexity, also for the difficultly in handing, as well as 
their characterization, since superparamagnetic NPs cannot of course be analyzed by 
NMR analysis. However, so decorated NPs were characterized by IR spectroscopy, 
elemental and thermogravimetric analysis and are being in study for the evaluation of 
their potential application in cancer theranostic. 
 
 
 
Figure 2.2 – CA4-capped SPIONs 
Since difficulties encountered were ascribable to the paramagnetism of these MNPs, 
during my PhD, we decided to focus our research on the development of non-
paramagnetic nanoparticles-based drug delivery system. As for SPIONs and CoNPs, also 
non-paramagnetic MNPs have a potential use for several biomedical applications; 
however they exhibit a more safety profile and ease in handle.  
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2.3 Gold Nanoparticles: Potential applications 
 
Gold nanoparticles (AuNPs) are characterized by a chemical inertness, which render 
them more biocompatible and non-toxic compared to other metallic nanoparticles. 
AuNPs were widely studied for their prominent application in different fields of 
medicine and especially for their potential use in cancer diagnosis (i.e. bioimaging, 
biosensoring) and therapy (i.e. photothermal therapy and hyperthermia, drug delivery 
and targeted drug delivery): most prominent AuNPs applications are below briefly 
discussed.  
Bioimaging: AuNPs have a potential use as contrast agents in X-ray technique; as a 
matter of fact, they could replace iodine-containing contrast agents (ICCA) since they 
showed better contrast with lower X-ray dose and permitting longer imaging times. 
50,51
 
AuNPs have also a potential application for MRI and computed tomography (CT). 
52,53
 
Furthermore, the feasibility to targeted AuNPs renders them more suitable as contrast 
agent compare to those currently available since allowing a selective diagnosis of the 
tumor. 
Thermal therapy: Due to SPR, when AuNP are exposed to a proper energy source, 
electrons collectively coherently oscillate.
54
 Excited electrons lose energy quickly as a 
phonon that heats the environment of the AuNP which in cancer treatments would be 
the cancerous cells. 
55
 Since SPR is strictly related to nanoparticles size and shape, these 
properties can be tuned to obtain AuNPs sensitive to wavelength in the range 700-1000 
nm, because biological tissues are optically transparent at these wavelengths. 
56,57
 
Drug delivery and targeted drug delivery: AuNPs have the ability to firmly bind amines 
and thiols allowing surface modification. A wide variety of biomolecules, e.g. proteins, 
antibodies, genes, as well as smaller molecules, e.g. drugs, antioxidants etc., can be 
attached on the AuNP surface. As above mentioned, AuNPs passively accumulate at 
tumor sites due to the EPR effect, which can thus allow a selective drug deliver into the 
cancer cell. However, due to the uptake by the reticuloendothelial system (RES) and 
accumulation of nanoparticle aggregates mainly at the liver site, only a minor part of 
the administered dose can effectively reach the pathological site. Thus, an 
enhancement of the targeting ability of these nanosystems could enormously improve 
their efficacy in drug delivery. This can be achieved by conjugating the gold core with a 
targeting unit, thus increasing the drug dose at the tumor site.  
 
2.4 Gold nanoparticles Synthetic methodologies 
 
The synthesis of AuNPs with diameter ranging from a few to hundreds of nanometers is 
well-established in aqueous solution as well as in organic solvents. More common 
AuNPs synthetic methodologies envisage the reduction of a gold salt, typically HAuCl4, 
by a reducing agent which leads to the nucleation of Au ions to NPs. Reductive reaction 
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usually occurs in the presence of a stabilizer, which both controls the growth of the 
gold cores, and prevents their agglomeration (Figure 2.3). 
 
 
Figure 2.3 – Section of capped-gold nanoparticle. 
Indeed, molecules with a certain affinity for the Au(0) atoms, spontaneously form a 
protective monolayer on the nanoparticle surface, called self-assembled monolayer 
(SAM). The chemical nature of the stabilizer, as well as the stabilizer-to-gold ratio, 
strongly influences the SAM formation rate, thus determining the gold clusters size. 
Since AuNPs properties strongly depend on their shape and size, the suitable synthetic 
methodology and the proper stabilizer, have to be chosen in order to achieve AuNPs 
with the size required for the specific use.  
Turkevich et al,
58
 in 1951, for the first time synthesized colloidal gold from gold salts by 
using citric acid as reducing agent. The method was refined by G. Frens,
59
 in 1973, and 
Natan,
60
 in 1995, to achieve NPs with better size distribution and size control in the 10-
120 nm range. Currently, this synthetic methodology is used to produce modestly 
monodisperse spherical gold nanoparticles, suspended in water, of around 10–20 nm in 
diameter. Larger particles can be produced by varying the gold-to-citrate ratio, but this 
comes at the cost of mono-dispersity and shape. Synthetically, in the Turkevich method 
a hot aqueous solution of HAuCl4 is reacted with aqueous sodium citrate. The colloidal 
gold will form because the citrate ions act as both a reducing agent, and a capping 
agent (Scheme 2.1). 
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Scheme 2.1 -  Turkevich AuNPs synthesis. 
Considering the advantage in directly synthesizing water-soluble (i.e. biocompatible) 
AuNPs, recently, several research groups have focused their interest on the 
improvement of this synthetic procedure.
61,62
 However, due to the weak gold-to-citrate 
interaction, these NPs are poor stable, since undergo desorption of citrate coating with 
a consequent coalescence and loss of the ability to form colloidal solutions. Thus, the 
citrate layer has to be replaced with a more stable ligand through a place-exchange 
reaction (see section 2.5 for details). 
Both the poor stability and the modest monodispersity of citrate-capped AuNPs were 
overcome when, in 1994, Brust and Schiffrin reported a simple and versatile synthesis 
of alkylthiols-protected AuNPs ranging in diameter between 1-3 nm that has had a 
considerable impact on the overall field of NPs preparation.
63
 They are soluble in 
organic solvents and have a narrow size distribution. A peculiar property of these 
materials is that they behave like large organic compounds; thus, they can be purified 
by precipitation, by repeated centrifugation, using size exclusion chromatography etc., 
without changing their properties.
64
 Synthetically, an acqueous HAuCl4 solution was 
stirred with a tetraoctylammonium bromide (TOAB) toluene solution. The latter acts as 
the phase-transfer reagent, and the AuCl4
-
 is transferred to the organic phase. Then, Au 
(III) was reduced with cold aqueous sodium borohydride, used in large excess, in the 
presence of a proper stabilizer, typically an alkyl thiol. On addition of the reducing 
agent, the organic phase changes color from orange to deep brown within a few 
seconds, indicating the successful of the reaction (Scheme 2.2). 
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Scheme 2.2 – Schematic representation of Brust synthesis procedure. 
 
The procedure, was firstly developed using dodecanethiol as capping agent, but it was 
then adapted to several thiols, such as pentanethiol, 10-mercaptoundecanoic acid etc., 
as well as to molecules fitted out with more than one sulfur atom, such as poly- 
thiols,
65–67
 and disulfides.
68–74
 A greater stability of the monolayer was shown when 
using poly-sulfurated ligands instead of monothiols. As a matter of fact, the polysulfide 
nature allows a polyvalent interaction of the ligand with the gold surface thus 
remarkably reducing the possibility of ligand desorption. 
An evolution of the Brust procedure was achieved when Leff et al., in 1996,
75
 used 
amines instead of thiols. Even if, due to the weaker Au(0)-N interaction compared to 
the Au(0)-S one, amino-capped NPs show a slightly lower stability, they behave very 
similar to their thiol-capped counterpart.  
However, Brust synthesis provide NPs with a very good monodispersity in the range 2-5 
nm. Afterwards, Murray and co-workers extensively investigated the possibility to tune 
the clusters size and their dispersion by changing i) Au : ligand molar ratio; ii) rate of 
reduction; iii) reduction temperature.
76,77
 Briefly, large ligand-to-gold molar ratios 
produce small NPs; fast addition of reductant solution at low temperature leads to 
AuNPs with a narrow size distribution, in the 2-5 nm range.  
 
2.5 Gold nanoparticles Functionalization 
 
One of the most attractive features of monolayer-protected AuNPs is the possibility to 
introduce a wide variety of molecules into the ligand shell, obviously after a proper 
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functionalization i.e. with amine, thiol etc.. In addition, due to the AuNPs 
diamagnetism, NMR analysis can be exploited for the monitoring and characterization 
of the organic shell. 
The three different available approaches for a suitable AuNPs decoration are below 
summarized:  
i) Direct synthesis 
When reducing Au(III) to Au(0) in the presence of a ligand (or a mixture of different 
ligands) with a certain gold affinity (i.e. thiols or amines), the latter is chemosorbed on 
the gold surface. Thus, performing the Au(III) reduction in the presence of a proper 
ligand(s), the desired functionalization of NPs can be achieved. This method can be 
adapted in both aqueous and organic media, depending on the chemical nature of the 
ligand involved. The main limitation is that ligands have to be compatible with reaction 
conditions, i.e. a reductive, basic environment. Furthermore, since the chemical nature 
of the ligand influences gold clusters growth, a good control in NPs size is not ensured 
(Scheme 2.3). 
 
 
 
 
Scheme 2.3- Schematic Direct synthesis of functionalized gold nanoparticles. 
 
ii) Ligand-exchange method 
When capped AuNPs are placed in a solution containing a proper concentration of a 
ligand (or a mixture of different ligands) with a certain Au(0)- affinity, monolayer 
constituents are replaced by free ligands, preserving NPs size and shape. This process 
can be exploited for suitably decorate AuNPs, by choosing the proper incoming 
ligand(s). This represents the most used strategy for NPs functionalization, because, 
besides the great control in gold clusters size, it allows a wide variety of groups to be 
introduced in the monolayer, and to tune the composition of the protecting shell by 
changing the ratio of incoming ligands. The good control of gold nucleation is ensured 
by using classic Brust methodology for the synthesis of alkylthiol-capped NPs, as 
substrate for the place-exchange reaction, thus overcoming the drawback of “direct 
synthesis” protocol (Scheme 2.4). 
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Scheme 2.4 –Place-exchange reaction. 
 
This mild procedure occurs under neutral conditions and is particularly indicated for 
ligands bearing functional moieties that can be easily degradated under “direct 
synthesis” reaction conditions. Murray and co-workers reported several detailed 
studies of the kinetics and the factors determining enhancement or inhibition of this 
process.
78–82
 These studies demonstrated that the place-exchange reaction is an 
equilibrium process between entering and incoming ligands and that steric hindrance 
and stoichiometry of ligands involved can deeply influence the rate and the efficacy of 
the place-exchange reaction. To improve the place-exchange reaction rate the different 
affinity of S and N to Au can be exploited. In particular, using amino-capped AuNPs as 
substrate in an exchange reaction with thiols, the rate of the place-exchange could be 
improved. The efficacy of this process can be further enhanced by using a polydentate 
molecule as entering ligand instead of the thiol one, thus allowing a polyvalent, i.e. 
more stable, interaction with gold surface.  
 
iii) Post synthetic modification 
Pendant functional groups inserted on the organic NPs shell can undergo many 
synthetic transformations. The post-synthetic modification requires reaction 
proceeding under mild conditions, compatible with the structure and the integrity of 
the self-assembled monolayer. The earlier examples reported (Scheme 2.5) are a) the 
esterification of phenolic-decorated AuNPs with propionic anhydride,
83
 b)SN2 reactions 
of bromoalkanethiolate AuNPs with primary amines,
84
 c) amide- or ester-forming 
coupling reactions for the functionalization of carboxylic acid terminated-AuNPs.
85,86
 
Most recently, ‘click chemistry’ was reported as a simple and versatile approach for NPs 
modification. In particular, d) 1,3 dipolar cycloaddition, involving an alkyne and an azide 
to form a triazole ring in the presence of copper salts, 
87
 and e) maleimide-thiol Michael 
addition
88
 were widely described. The latter is particularly attractive for peptide-AuNPs 
conjugation, since a thiol group is typically inserted on the peptide through a cysteine 
residue.  
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Scheme 2.5 - Examples of post-synthetic modifications: a) reaction of p-
mercaptophenol with propionic anhydride; b) SN2 reaction; c) amide and ester coupling 
reaction; d) azide-alkyne click reaction; e) maleimide-thiol click reaction. 
 
2.6 Towards the development of targeted gold nanoparticles- based drug 
delivery systems: 
 
 The great variety of chemical modification to which AuNPs can undergo, together with 
their tunable optical and physical-chemical properties, make them ideal candidates for 
the development of a targeted drug delivery system.  
As detailed in the “introduction”, Paclitaxel is one of the most effective cytotoxic drugs. 
It is active against several types of tumor, such as lung, ovarian and breast cancers. 
However, treatment with Paclitaxel is associated with severe side effects, due to its 
high hydrophobicity and its scarce selectivity towards cancer cells. Thus, it is evident 
how the development of a more safety pharmaceutical form of this therapeutic unit 
could revolutionize the treatment of such types of tumor. In our research group a more 
selective therapeutic form of Paclitaxel was synthesized by conjugating it with the 
targeting peptide, MAP-NT. The limit of this approach is the inability of the peptide to 
bind more than one therapeutic unit. In order to maximize its targeting ability we 
envisaged multi-drug decoration of MAP-NT through the introduction of a highly 
functionalized nanoparticle. 
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Some synthetic issues have to be considered: 
i) A stable anchorage of both peptide and Paclitaxel on gold surface is 
required, thus avoiding undesirable ligand loss in the blood flow after the 
administration of the drug delivery system; 
ii) The high steric hindrance of both peptide and drug moieties has to be 
considered, in order to enable the targeting ability of the peptide for the 
entire stay in the bloodstream and, on the other hand, ensure the 
therapeutic activity of Paclitaxel; 
iii) A limited type of reactive groups can be inserted on the targeting unit. 
The thiol function is one of the available functionalizations, provided 
through the introduction of a cysteine residue. 
 
To overcome these limitations, we envisaged the introduction of a properly designed 
bifunctional linker between the nanoparticle and both the therapeutic and targeting 
units. The suitable linker should possess, a polydentate sulfur moiety, providing a 
strong and stable interaction with the gold surface, 
65–71
 and a functional group able to 
easily react with both the peptide and the Paclitaxel. Considering the cysteine 
functionalization of the peptide and the ease of introduction of a thiol function on 
Paclitaxel, reasonably, we selected a double bond as binding site for functional units. As 
a matter of fact, alkenes can react with thiols in the thiol-ene click reaction, which was 
described as a convenient pathway for nanoparticles decoration.
67
  
The designed tris thiol-alkene bifunctional linker 2.1 is reported in Figure 2.4. 
 
 
 
 
Figure 2.4 – Designed bifunctional linker. 
 
The synthesis of the linker, reported in Scheme 2.6, started by reacting commercially 
available 10-undecenal 2.2 with 1 equiv. of KOH and 7 equiv. of 37% aqueous 
formaldehyde in water : ethanol = 50 : 50 as solvent at room temperature for 24 hours 
and at 50 °C for 4 hours. The tris-alcohol 2.3 was obtained as colorless oil after 
purification by column chromatography, in 60% yield. Afterwards, sulfur atoms were 
introduced by a Mitsunobu reaction with 4.5 equiv. of thiolacetic acid, in the presence 
of 4.5 equiv. of triphenylphosphine and 4.5 equiv. of DIAD (diisopropyl 
azodicarboxylate) in dry THF as solvent, overnight at room temperature and for 2 hours 
at reflux. The product 2.4 was obtained after purification by column chromatography in 
29% yield. Thiolacetyl groups were, in turn, reduced to thiols in the presence of 7.5 
equiv. of LiAlH4 in dry diethyl ether as solvent, for 20 hours, to afford the final linker 2.1, 
in quantitative yield. 
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Scheme 2.6- Synthetic procedure for the achievement of the linker 2.1. 
With the linker in hand, we focused on the alkene-decoration of gold nanoparticles.  
In this respect, two different approaches can be exploited. The selected ligand can be 
used directly as stabilizer in the Au(III) reduction step as well as incoming ligand in a 
place-exchange reaction with alkyl-capped AuNPs. Aimed to ensure a well-control in 
NPs size, penthanethiol-capped AuNPs (AuNPs-C5) were prepared following the Brust 
procedure, and were, in turn, employed in a place-exchange reaction with an excess of 
the linker 2.1.  The mixture was stirred in dry DCM at r.t.. After 3 days, the solution was 
concentrated under vacuum and methanol was added, to promote nanoparticles 
precipitation and thus facilitating removal of unbounded penthanethiol, and the excess 
of the ligand 2.1. Unfortunately, after their precipitation, nanoparticles resulted in an 
agglomerate which cannot be redispersed. Analogous result was obtained when 
conducting the Brust synthesis using linker 2.1 instead of penthanethiol as stabilizer. 
Thus, we moved to consider the likelihood to provide both Paclitaxel and peptide with 
the tridentate moiety before the anchorage on gold, by performing the thiol-ene 
reaction in solution. Aimed to investigate the reactivity of our linker in a thiol-ene click 
coupling, a model reaction between the ester form of 10-mercaptoundecanoic acid and 
the acetylated form of the tris thiol derivative 2.4 was carried out (Scheme 2.7). The 
thiol-ene reaction is a highly stereoselective reaction which proceeds under a variety of 
conditions, including radical pathway and via catalytic processes mediated by 
nucleophiles, acids, bases,
89
 afforded the anti-Markovnikov addition product. A 
summary of the reactions performed is reported in Table 2.1. 
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Scheme 2.7 
 
 
Entry 
Ethyl 10-
mercaptoundecanoate 
Linker 
2.4 
Promoter 
Reaction 
Conditions 
Rif. Yield 
1 1.1 equiv. 1 equiv. UV-lamp 
Dry DCM, 7 
h, r.t. 
67,76
 - 
2 1.1 equiv. 1 equiv. 
BEt3 1M 
solution in 
hexane 
Dry THF, 48 
h, r.t. 
90
 - 
3 1.1 equiv. 1 equiv. 
BEt3 1M 
solution in 
hexane 
Dry THF, 48 
h, 50 °C 
90
 - 
4 1.1 equiv. 1 equiv. 
BEt3 1M 
solution in 
hexane and 
O2 
Dry THF, 48 
h, r.t., O 
91
 - 
5 1 equiv. 1 equiv. / 
H2O, r.t., 24 
h 
92
 - 
6 1.1 equiv. 1 equiv. CeCl3
.
7H2O 
Neat, 24 h, 
r.t. 
93
 - 
 
Table 2.1  
 
Despite several attempts, neither under UV irradiation nor in the presence of chemical 
radical initiators, we achieved the desired product of coupling. We were not able to 
rationalize these unexpected results. However, we considered the replacement of the 
double bond with a functional group able to react in a more promising click reaction. 
The Huisgen reaction between a terminal alkyne and an azide derivative was selected 
as efficient alternative to the thiol-ene reaction; 
94–96
 thus, a new linker bearing a triple 
bond instead of the double one, was designed (Figure 2.5). 
 
 
 
Figure 2.5 – Designed tris-thiol alkyne linker. 
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 Reasonably, it was synthesized following the well-consolidated procedure used for the 
alkene analogous, obviously starting from a proper alkynil derivative (Scheme 2.8). 
 
 
 
Scheme 2.8 – Synthetic procedure for the synthesis of tris-thiol-alkyne linker. 
 Thus, the commercially available 10-undecyn-1-ol 2.6 was oxidized by 1.5 equiv. of 
pyridinium chlorochromate (PCC) in dry DCM for 3 hours, to afford the corresponding 
aldehyde 2.7 which, in turn, underwent procedure described for alkene derivative 2, to 
achieve the tris thioacetylate derivative 2.9. Unfortunately, some synthetic 
complications occurred in the following reduction step, since the desired tris-thiol 2.5 
was achieved just in trace. The 
1
H-NMR analysis of the crude product showed broad 
peaks overlapping to expected signals of tris-thiol 2.5 derivative. This suggested that, 
perhaps, part of the final compound underwent a polymerization reaction, probably 
due to the formation of S-S intermolecular bridges and/or inter- or intra-molecular 
thiol-alkyne coupling reaction.
97
 To circumvent this poor result, we move to consider an 
alternative strategy, aimed to avoid the employment of free thiol functions, which 
seemed to be the main cause of side reactions occurred in the reductive step. After a 
screening in literature, thanks to the high affinity of sulfur-to-gold, the feasibility of 
using disulfide compounds as stable NPs capping agents instead of thiols, has emerged.  
In particular, the use of lipoic acid as stable AuNPs capping agent is described. 
72,73
  
Indeed, the presence of the 1,2-dithiolane ring allows the strong interaction with the 
gold surface. Lipoic acid was thus selected to introduce a polyvalent binding site for 
gold on the new designed linker. On the other hand, keeping the original idea of using a 
click reaction involving thiols for the coupling with the therapeutic and the targeting 
units, maleimide moiety was selected since it can react in the maleimide-thiol click 
reaction, already optimized for the synthesis of the MAP-NT-Paclitaxel adduct. Since 
ester bonds can be easily hydrolyzed in vivo, we considered an amido group for the 
maleimide-lipoic acid conjugation. The designed linker is depicted in Figure 2.6 and the 
synthetic procedure we envisaged was an amidation reaction of activated lipoic acid 
with a proper bis-amine, since introducing both the amide bond and the pendant free 
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amino group required for the introduction of the maleimide residue, through the 
reaction with maleic anhydride. 
 
 
Figure 2.6-lipoc acid-maleimide designed linker 
Thus, 1.0 equiv. of lipoic acid 2.11 was activated through a reaction with 1.0 equiv. of 
N-hydroxysuccinimide and 1.2 equiv. of DCC in dry DCM for 1 hour. Then, the mixture 
was kept at -5 °C overnight and the suspension was filtered to get rid of solid DCU. The 
filtrate was evaporated to achieve 2.12, without further purification, in quantitative 
yield, that was, in turn, reacted with hexamethylenediamine 2.13. Despite several 
attempts, we were unable to settle up suitable conditions for the selective mono-
substitution of the activated acid, since the bis-coupling product was the only one 
recovered. To circumvent this problem, hexamethylene diamine 2.13, was reacted with 
0.15 equiv. of Boc2O (di-tert-butyl-dicarbonate), in dry DCM, at 0 °C for 30 minutes and 
at r.t. overnight. The unreacted diamine was washed away with water and the desired 
final compound 2.14 was isolated in 95 % yield. Then, the activated lipoic acid 2.12 and 
mono N-Boc amine 2.14 were reacted in the presence of 2.0 equiv. of DIPEA as base in 
dry DCM, for 19 hours, at r.t.. The amide 2.15 was obtained, without purification, in 
94% yield. The latter was, in turn, treated with a DCM : TFA 4 : 1 solution for 1 hour, 
giving a crude product whose 
1
H-NMR spectrum showed characteristics signals of the 
expected amine 2.16, overlapping to broader signals.  Anyway, since the presence of 
the amino-functionalized lipoic acid 2.16 was confirmed by ESI-MS analysis, the crude 
product was reacted in the further step with 1 equiv. of maleic anhydride in dry DCM at 
r.t. for 6 hours. The solvent was removed, 1.1 equiv. of sodium acetate were added and 
the mixture was stirred in acetic anhydride at 140 °C for 6 hours.
98
 Unfortunately, the 
1
H-NMR analysis of the crude showed neither product nor starting material’s protons 
characteristic peaks. A slightly better result was obtained reacting 2.16 with 1.0 equiv. 
of maleic anhydride in acetic acid, for 3 hours, at reflux. After purification by flash 
column chromatography, the final linker 2.10 was isolated in 5% yield, over two steps. 
The presence of the final linker 2.10 confirmed the presence of 2.16 in the crude 
product, even if the poor yield indicated that, probably, it was present in a very low 
amount (Scheme 2.9). 
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Scheme 2.9 – Synthetic procedure for the achievement of linker 2.10. 
We thus investigated the introduction of the maleimide residue as 3-maleimido 
propionic acid through an amidation reaction, since this synthetic pathway required 
milder conditions. The required activated form of 3-maleimido propionic acid 2.18 was 
synthesized by reacting 1 equiv. of β-alanine 2.17 with 1 equiv. of maleic anhydride, in 
acetic acid at reflux for 6 hours. The maleimide-acid derivative, obtained in 65 % yield, 
was, in turn, activated as NHS ester with 1.25 equiv. of N-hydroxysuccinimide in the 
presence of 1.5 equiv. of DIC in dry DMF overnight. Derivative 2.18 was achieved in 97 
% yield, without purification. Hence, the amidation between the crude product 2.16 
and the maleimide-derivative 2.18 was performed in the presence of 2.0 equiv. of 
DIPEA in dry DMF at r.t. overnight. The 
1
H-NMR analysis of the crude recovered showed 
intense broad signals, ascribable to the presence of polymers, and characteristic proton 
peaks of the unreacted maleimide derivative 2.18, while the desired final product was 
present just in traces. However, due to the great complexity of the crude, we were not 
able to isolate the compound 2.19 (Scheme 2.10).  
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Scheme 2.10 – Synthetic effort for the synthesis of compound 2.19. 
We thus considered the insertion of lipoic acid residue as the last step of the 
procedure. The maleimide moiety was inserted on the N-Boc hexamethylene diamine 
2.14. Since treatment with maleic anhydride and acetic acid at 140 °C, did not allow the 
isolation of the expected derivative 2.20, 1 equiv. of the mono-protected diamine 2.14 
was reacted with 1 equiv. of maleic anhydride in DCM for 6 hours at r.t.. After the 
evaporation of the solvent, the crude product was suspended in acetic anhydride and 
reacted with 1.1 equiv. of sodium acetate for 6 hours at 110 °C,
 4
 to afford 2.20 after 
purification by flash column chromatography, in 50% yield (Scheme 2.11). 
Unfortunately, either using concentrated or diluted TFA : DCM solution, the desired Boc 
deprotection  was not observed. Indeed, the characteristic signal of maleimide protons 
was not present in the 
1
H-NMR spectrum, thus highlighting the instability of maleimide 
moiety to TFA treatment. 
 
Scheme 2.11 
 
Different amino protecting groups were tested to circumvent this obstacle. 
Unfortunately, neither when using Fmoc nor with Cbz we were able to afford the 
amino-maleimide derivative. Finally, chemical instability of maleimide moiety towards 
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TFA treatment was overcome when using an inorganic acid instead of the organic TFA. 
Indeed, the amino-maleimide derivative 2.22 was achieved, as ammonium chloride, by 
treating derivative 2.21 with a 3M HCl methanol solution for 1 hour at r.t., in 70 % yield. 
Derivative 2.22 was, in turn, conjugated with 1.1 equiv. of NHS ester activated lipoic 
acid 2.12, in the presence of 2 equiv. of DIPEA in dry DMF. After 20 hours at r.t. the 
desired linker 2.19 was isolated in 20 % yield and the structure was confirmed by NMR, 
IR and ESI-MS spectroscopy (Scheme 2.12). 
 
 
 
Scheme 2.12 – Synthesis of the linker 2.19. 
The so prepared linker was designed to serve as binding site for the peptide as well as 
for the drug. While the targeting unit is already provided with the thiol function 
required, due to the presence of the cysteine residue, the thiol functionalization of 
Paclitaxel has to be carried out. Keeping in mind the need of an in vivo hydrolysable 
bond on the drug proximity to ensure the in vivo drug release and thus maintaining the 
cytotoxic activity against the cancer cells, we esterified the OH on the 2’ position of 
Paclitaxel 2.23 with 1.2 equiv. of commercially available 10-mercaptoundecanoic acid 
2.24 in the presence of 0.2 equiv. of DMAP and 1.2 equiv. of DCC. The product 2.25 was 
isolated after 16 hours at r.t., by flash column chromatography, in 73% yield (Scheme 
2.13).  
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Scheme 2.13 – Synthesis of thiol-functionalized Paclitaxel. 
In order to find out suitable click reaction conditions for anchoring thiol-Paclitaxel on 
maleimide-decorated AuNPs, a model reaction between 1 equiv. of Paclitaxel derivative 
2.25 and 1 equiv. of maleimide linker 2.19 in the presence of 1 equiv. of TEA as base in 
dry DMF, was performed. After 3 hours at r.t., the final adduct 2.26 was isolated in 50 % 
yield (Scheme 2.14). 
 
Scheme 2.14 – Synthesis of linker-Paclitaxel adduct via Michael addition. 
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The 
1
H-NMR analysis showed typical peaks of Paclitaxel moiety (blue circle) together 
with characteristic peaks of lipoic acid (yellow square) whose integrals are in 
accordance with derivative 2.26. Morover, the success of the coupling was 
demonstrated by the presence of charachteristic succinimide protons peaks, whose CH2 
showed a multiplet at around 3.8 ppm (red arrow) while the CH proton appears as a 
multiplet at around 3.7 ppm (green arrow) (Figure 2.7). ESI-MS analysis showed 
[M+Na]
+
 peak thus confirming the success of the coupling.  
 
 
Figure 2.7 
 
2.7 Decoration of Gold Nanoparticles 
 
Our first goal was the maleimide decoration of AuNPs by anchoring ligand 2.19 on gold 
surface. To achieve a properly decorated AuNPs with a good gold core size distribution 
in the range 2-5 nm, the place-exchange protocol seemed the most convenient way. 
The process can be facilitated by involving an incoming ligand with a greater affinity for 
gold compared to the leaving one. In detail, amino coated NPs can easily undergo 
place-exchange reaction with sulfurated ligands present in the NPs external 
environment. The greater affinity of Au-to-S compare to Au-to-N, on one hand, 
enhances the place-exchange rate and, on the other hand, avoids incoming ligand 
displacement from amino-ligands, once place-exchange is occurred. 
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Thus, oleylamine-capped AuNPs in a size distribution of 2 - 5 nm, were prepared by 
using the Brust procedure, and were characterized by TEM analysis, to establish the 
average size of gold clusters, and by 
1
H-NMR, to characterize the organic monolayer 
(Figure 2.8). 
a)  
   
b)      
 
Figure 2.8 – a) TEM analysys and b) 
1
H-NMR spectrum of oleylamine-capped AuNPs. 
The broad peak at around 5.0 ppm is characteristic of the vinylic protons of oleylamine 
anchored on gold. 
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 Oleylamine-AuNPs were then placed in a dry DCM solution, containing an excess of the 
maleimide-ligand 2.19, and the mixture was stirred in inert atmosphere. Unfortunately, 
after 16 hours, nanoparticles resulted in a black agglomerate insoluble in many types of 
solvents. The feasibility in exploiting the different affinity of gold to heteroatoms in this 
process was further investigated, by employing TOAB as both phase transferreagent 
and stabilizer.
73
  The ligand 2.19 was added directly in the mixture, after gold clusters 
formation, and the mixture was stirred overnight. Also in this case, gold clusters 
underwent agglomeration.  We thus decided to investigate the use of alkylthiol-capped 
AuNPs as substrate for the place-exchange step. Even if the more stable thiolate 
monolayer might decrease the place-exchange rate, the stronger S-Au bond should 
ensure a better stability of the so coated NPs, thus avoiding agglomeration during this 
crucial step.  
Hence, penthanethiol-capped AuNPs (AuNPs-C5) were synthesized and characterized 
by TEM (Figure 2.9-a) and 
1
H-NMR analysis (Figure 2.9-b). A well monodispersity of NPs 
size in the range 2-5 nm was showed and residual unbounded pentanethiol was not 
present.  
a)  
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b)  
Figure 2.9-a) TEM image b) 
1
H-NMR spectrum of AuNPs-C5. 
The place-exchange reaction, between AuNPs-C5 and ligand 2.19, was carried on in dry 
DCM for 3 days, then the solution was concentrated under vacuum and methanol was 
added in order to promote NPs precipitation and purification. Even if a precipitate was 
observed, the colored supernatant indicated that not all nanoparticles were able to 
precipitate, preventing their efficient purification. Indeed, we were able to collect only 
a minor part of NPs. 
1
H-NMR analysis , besides to several broad peaks in the lower part 
of the spectrum, ascribable to gold-bounded penthanethiol, showed typical peaks of 
the linker (red arrows) together with the maleimide singlet at 6.7 ppm (green arrow) 
(Figure 2.10). 
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Figure 2.10 – 
1
H-NMR collected AuNPs sample which underwent place-exchange with 
the linker. 
Anyway, due to the improper purification, we could not certainly affirm that maleimide 
signal detected by NMR derived only from linker anchored on gold, since some 
unbounded ligand could be present in the mixture. We decided however to perform 
the maleimide-thiol click reaction with thiol-functionalized Paclitaxel 2.25, to verify the 
real success of the ligand-exchange step. Thus, collected AuNPs were solubilized in dry 
DMF and stirred in the presence of an excess of both Paclitaxel derivative 2.25 and TEA 
for 3 hours. Unfortunately, AuNPs purification resulted not trivial and expected signals 
of Paclitaxel moiety were not showed by 
1
H-NMR analysis of recovered NPs. As possible 
cause of these failures, we reasonably hypothesized that the thiol-maleimide click 
reaction between free penthanethiol desorbed from gold in the exchange step and 
maleimide could take place in both the exchange step and in the second step, since, 
due to the ineffective purification, residual free thiols are present in the mixture. In 
order to validate this hypothesis, place-exchange condition were simulated by stirring 
ligand 2.19 in the presence of penthanethiol for 3 days in DCM; then TEA was added, 
thus mimicking click reaction conditions, and the mixture stirred for 3 hours. The 
product of the click reaction was detected in a very few amount after the place-
exchange-like reaction, while it was present as predominant product after TEA addition. 
These results were supported by 
1
H-NMR and ESI-MS analysis. On these evidences and 
considering difficulties emerged in NPs handle, we decided to modify the stoichiometry 
ratio AuNPs : ligand. Hence, the toluene : DCM 4 : 1 solution of AuNPs-C5 and an excess 
of derivative 2.26 was stirred for three days. Also in this case the purification step gave 
some problems. The 
1
H-NMR spectrum of collected NPs showed characteristic proton 
compound 2.26 signals despite some differences, in term of chemical shifts, compared 
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to the unbounded ligand. This result suggested that, perhaps, the place-exchange 
reaction took place. Unfortunately such AuNPs, resulted unstable, since after one day a 
change in the solution color from brown to dark red was displayed, indicating NPs 
coalescence. We reasonably hypothesized that the different final NPs solubility, due to 
the entire replacement of the native monolayer, was the main cause of both difficult 
purification and no lasting stability. To overcome these drawbacks, we investigated the 
feasibility of a partial ligand-exchange, aimed to keep part of the original organic layer, 
thus maintaining the initial AuNPs solubility and stability. Unfortunately, we were not 
able to partially replace penthanethiol with the selected ligand. 
We thus concluded that the replacement of inert capping agent with the only 
maleimide-linker 2.19, as well as the Paclitaxel-linker 2.26, is not the convenient way 
for the development of nanosystems with appropriate properties. In particular, a 
greater stability and a more easy and efficient methodology for removing excess of 
ligands, were required. For this purpose, after a screening in literature,
72,73,99–102
 we 
found out that the introduction of a water soluble stabilizer as a constituent of the 
monolayer, could provide water solubility and, as a consequence, providing access to 
convenient purification techniques, such as dialysis.
103–105
 Several ligands with a 
pendant polar group were described in literature for this purpose, including lipoic 
acid.
72,73
 When using carboxylic acid terminal thiols or disulfides, the water solubility is 
pH-dependent. Thus, a special care in choosing external environment conditions has to 
be taken. For the achievement of pH-indipendent water soluble AuNPs, poly(ethylene 
glycol) (PEG) chain can be used as part of the external shell. The PEG chain can be 
inserted as central part of the ligand as well as pendant unit directly anchored on the 
gold core. Besides the ability to provide pH-indipendent water solubility, the affinity of 
PEG chain for both organic solvent and water render them a very versatile compound.  
Considering that a proper maleimide linker, as well as the Paclitaxel one, had been 
already synthesized and keeping in mind the need in a disulfide function as binding site 
for the gold core, a proper disulfide-PEGylated ligand was prepared through the 
esterification of 1.2 equiv. of lipoic acid 2.11 with 1 equiv. of poly(ethylene glycol) 
methyl ether average MW 750 (mPEG 750) 2.27, in the presence of a catalytic amount 
of DMAP and 1.2 equiv. of DCC. After 16 hours in dry DCM, the expected product 2.28 
was achieved in 97 % yield, without purification (Scheme 2.15). 
 
Scheme 2.15 – Synthesis of PEGylated lipoic acid. 
In order to verify the ability of this PEG chain length of water solubilizing and stabilizing 
NPs, AuNPs-C5 were reacted in a place-exchange reaction with an excess of the 
PEGylated stabilizer 2.28 for 5 days in dry DCM. After removal of the organic solvent, 
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NPs were solubilized in mQ water, centrifugated to get rid of water non-soluble 
compounds, and dialyzed (MWCO membrane 3.5 kDa) against 5 L of mQ water for 3 
days.
1
H- NMR analysis and FT-IR spectrum showed characteristic peaks of PEGylated 
ligand, while UV-vis spectrum did not showed differences compare to the one of 
AuNPs-C5, thus highlighting that gold cores maintained their size during the place-
exchange process. 
Encouraged by this good result, we focused on the introduction of ligand 2.28 as main 
component of the AuNPs organic shell, to provide the nanosystem with the required 
water solubility and stability. Several attempts aimed to find out the suitable PEGylated 
lipoic acid 2.28/maleimide-ligand 2.19/lipoic acid-Paclitaxel 2.26 ratio for the place-
exchange reaction were performed (Table 2.2). 
Entry 
mPEG-lipoic acid 
2.28 
Maleimide-lipoic 
acid linker 2.19 
PTX-lipoic 
acid 2.26 
Water 
solubility  
DCM 
solubility 
1 100%     X X 
2 75% 25% - - X 
3 85% 15% - - X 
4 95% 5% - partial X 
5 95% 2% 3% X X 
 
Table2 
While using 75% and 85% of PEGylated ligand 2.28 (entry 2 and 3 respectively) we were 
not able to obtain water soluble AuNPs, ligands ratio used in entry 4 provided NPs with 
water solubility but no long lasting stability. Indeed, water soluble AuNPs precipitated 
during the dialysis step. However none agglomeration was displayed and the 
precipitate can be re-dispersed simply by shaking the sample, thus confirming the good 
stabilizing ability of the PEGylated ligand. The good result was obtained with ratio 
reported in entry 5. Such AuNPs resulted well soluble and long lasting stable in both 
organic (e.g. DMF, DCM) and aqueous media. AuNPs were dyalized for 4 days against 
mQ water (MWCO membrane 14kDa) and characterized by NMR analysis, FT-IR, TEM 
and UV-vis spectroscopy. The 
1
H-NMR analysis of recovered NPs displayed 
characteristic protons signals of the three ligands thus confirming the success of the 
place-exchange. In detail, in blue circles are highlighted typical proton signals of 
Paclitaxel; the singlet at 6.7 ppm, highlighted in green, is the characteristic peak of 
maleimide protons while the intense peak at 3.6 ppm and the triplet at 3.8 ppm, 
indicated by red arrows, showed the presence of the PEG chain. Integral values of each 
characteristic peak allowed a rough determination of the ligands content ratio. 
PEGylated lipoic acid 2.28/maleimide-ligand 2.19/lipoic acid-Paclitaxel 2.26 resulted in 
a 81%, 1% and 18% respectively (Figure 2.11). 
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Figure 2.11 – H-NMR analysis of AuNPs capped with mPEG-750 ligand, maleimide-
ligand and Paclitaxel ligand.  
FT-IR spectrum clearly showed typical peaks of PEGylated ligand, while signal ascribable 
to other ligands are not very intense.  
Gold cores were characterized by TEM analysis and UV-vis spectroscopy, which 
demonstrated the well preserved size of gold clusters. Indeed, none difference 
between TEM and UV analysis of AuNPs-C5 and the final nanosystem was highlighted 
(Figure 2.12). 
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a)
b) 
c) 
Figure 2.12– a) UV-vis spectrum of AuNPs-C5 compare to b) UV-vis spectrum of AuNPs 
capped with mPEG-lipoic acid : Paclitaxel-lipoic acid : maleimide-lipoic acid in 95 : 3 : 2 
ratio; c) TEM imagine of final nanoparticles.  
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2.8 NT4 conjugation of maleimide-AuNPs-PTX  
 
Decorated AuNPs were conjugated to the NT4 peptide in the Luisa Bracci’s research 
group, at the University of Siena. The general thiol-maleimide procedure, previously 
optimized for the Paclitaxel-NT4 conjugation, was adapted to the gold nanosystems. 
Thus, AuNPs were dissolved in acetonitrile:phosphate buffered saline (PBS) 1:3 and 
then reacted with NT4. The mixture was stirred for 1 hour at r.t., then acetonitrile was 
evaporated and the AuNPs PBS solution was dialyzed for 72 hours, at 4 °C to afford 
purified NT4-AuNPs-PTX. 
 
2.9 In vitro binding activity of NT4-AuNPs-PTX  
 
Binding activity of NT4-AuNPs-PTX was evaluated on human colon adenocarcinoma cell 
lines (HT-29) and monitored by TEM. AuNPs-PTX, not decorated with the peptide, were 
used as reference.  
AuNPs were diluted in the culture medium and incubated with the HT-29 cells at 37 °C. 
The binding activity was evaluated after 30 minutes of incubation. Thus, samples were 
washed and TEM images were recorded (Figure 2.13). 
 
Figure 2.13- Binding assay on a) NT4-AuNPs-PTX and b) AuNPs-PTX, not decorated with 
the peptide. Red arrows highlighted some AuNPs on the cell membrane and 
intracellularly. 
 AuNPs localization on cell membrane was not detected for AuNPs-PTX, not decorated 
with NT4. Otherwise, NT4-AuNPs-PTX showed a preferential accumulation either on cell 
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membrane and intracellularly. This result, even if preliminarily, demonstrated the 
targeting ability of NT4 when bounded to AuNPs, and a tendency of such system to be 
internalized within the cell. This likely depends not only on the good targeting activity 
of the NT4, but also to the suitable size of the nanosystem, which could facilitate the 
process of cellular internalization. However, further investigations will be carried out to 
confirm this outcome. In vitro cytotoxicity will be evaluated and in vivo binding ability 
and cytotoxicity will be performed, compare to AuNPs-PTX not conjugated with the 
peptide.  
In conclusion, after several unsuccessful attempts, we developed a convenient method 
for the preparation of water soluble AuNPs, with an average gold core size in the range 
2-5 nm and with a good monodispersity. Gold cores characteristics were well preserved 
during the surface modification of NPs, as have been demonstrated by TEM and UV 
analysis of both AuNPs-C5 and maleimide-AuNPs-PTX. The final monolayer inserted on 
gold surface contains a certain amount of PEGylated ligand, maleimide and Paclitaxel 
and the nanosystem resulted stable in several different type of solvent (e.g. organic and 
aqueous solvents).  Decorated AuNPs were targeted with the NT4 peptide and a 
preliminary evaluation of the binding activity was in vitro performed. TEM images 
recorded showed a good binding activity besides to the tendency of targeted 
nanosystems to be internalized within the cell. In order to validate this prominent 
outcome, further binding assays, i.e. in vivo binding tests, will be carried out and the 
cytotoxicity will be in vitro and in vivo evaluated.   
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3. Targeted Multi-Paclitaxel Delivery Systems 
 
3.1 Synthesis of multi-valent linkers 
 
The feasibility of providing the targeting peptide NT4 with a great number of drug 
molecules, through the conjugation with a highly drug-functionalized nanoparticle, 
(AuNPs as well as QDs) certainly represents an important evolution of the targeted pro-
drug able to bear only one therapeutic unit since it could allow to maximise the 
targeting potential of the peptide. However, the exactly quantification of drug (i.e. 
Paclitaxel) loaded on the nanoparticle is not trivial. This represents a limit, considering 
the importance of understanding the relationship of drug delivery system cytotoxicity 
with different stoichiometry of vectoring peptide / vectored drug.  
Aimed to face this issue, we decided to develop different targeted systems, able to bear 
a defined number of Paclitaxel molecules to thus evaluate the role of vectored drug 
stoichiometry. In order to avoid differences caused by the chemical nature of the linker, 
a common spacer, obviously provided with a variable (1-3) number of drugs’ binding 
sites, was designed. Additionally, we decided to exploit orthogonal reactions for the 
coupling with the targeting and the therapeutic units. The thiol-maleimide Michael 
reaction, between the thiol group of the cysteine residue on MAP-NT and a maleimide 
moiety, was selected for the coupling of the linker with the targeting unit. Hence, a 
maleimide residue has to be introduced on the linker moiety. At the same time, the 
highly efficient Huisgen click reaction, involving a terminal alkyne and an azide, was 
chosen as suitable process for the coupling (or multi-coupling) of the linker with the 
therapeutic unit(s). The Huisgen reaction, i.e. Copper(I)-catalyzed Azide-Alkyne 
Cycloaddition (CuAAC), is a regioselective 1,3-dipolar cycloaddition requiring a copper(I) 
salt as catalyst. The latter can be generated in situ by reduction of a copper(II) salt with 
a proper reducing agent. The 1,2,3-triazole derivatives formed by click reactions are 
commonly very stable to both metabolic and chemical degradations thus perfectly 
suitable for in vivo applications.
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The choice of a thiol-maleimide reaction together with the CuAAC procedure required 
the synthesis of a maleimide linker bearing 1, 2 or 3 terminal alkyne residues while, 
reasonably, a single azido function had to be installed on the skeleton of Paclitaxel. The 
designed linkers are schematized in Figure 3.1.  
 
 
Figure 3.1 - Designed linkers for MAP-NT delivering of 1, 2 or 3 drug units. 
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A special care in the Paclitaxel functionalization has to be taken, in consideration of the 
need of an in vivo hydrolysable ester bond in the drug proximity. Thus, 1.0 equiv. of 
commercial 6-bromo hexanoic 3.1 acid was reacted with 3 .0 equiv. of NaN3 in dry DMF 
for 6 hours at 85 °C. 
107
 After purification, the corresponding azido derivative 3.2, 
obtained in 47% yield was esterified with the OH on the 2’ position of Paclitaxel 3.3 in 
the presence of 0.2 equiv. of DMAP and 1.2 equiv. of DCC in dry DCM for 24 hours at 
reflux.
108
 The azido functionalized Paclitaxel 3.4 was obtained after purification by 
column chromatography in 85 % yield (Scheme 3.1).  
 
Scheme 3.1 – Azido –functionalization of Paclitaxel. 
The product was characterized by 
1
H-NMR analysis. The success of the coupling was 
demonstrated by i) the deshielding of the doublet relative to the H on the 2’ position, 
from 4.8 to 5.6 ppm (highlighted in red); ii) the integral ratio 1:2 between this proton 
signal and the triplet relative to the methylene in α position to the azide group 
(highlighted in green) (Figure 3.2).   
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Figure 3.2 
With the azido-Paclitaxel in hand, we focused on the development of a general 
procedure for the achievement of the three designed linkers. Attempts of linkers 
synthesis started with the oxidation of commercially available 11-bromo-1-undecanol 
3.5. The reaction was performed with 1.5 equiv. of pyridinium chlorochromate (PCC) in 
dry DCM, under a N2 atmosphere, for 6 hours at r.t., to give the corresponding 
aldehyde 3.6, in 89% yield, used in the next step without purification. The aldehyde 3.6 
was reacted with 7.5 equiv. of 37% aqueous formaldehyde and 1 equiv. of KOH in 50% 
aqueous EtOH, initially for 24 hours at r.t., then for 4 hours at 50 °C. Under these 
conditions, triol 3.7 was obtained, after purification by flash column chromatography, 
in 44% yield (Scheme 3.2).
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Scheme 3.2- Synthesis of the derivative 7. 
Primary bromide of 3.7 was then reacted with 1.1 equiv. of potassium phthalimide in 
dry DMF for 19 hours at 90 °C. The corresponding N-alkylphthalimide 3.8 was obtained 
without purification in 64% yield
110
 (Scheme 3.3).  
 
 56 
 
 
Scheme 3.3- Introduction of phthalimide moiety. 
 
In the next step a selective mono-, bis- and tris- propargylation was attempted under 
different propargyl bromide/base/3.8 ratio and reaction conditions. Initially, we tried to 
isolate the tris-propargyl derivative, but independently upon the amount of propargyl 
bromide, and the base used (sodium carbonate or NaOH), we were able to obtain the 
desired O-alkylation.   
Better results were obtained using 5.0 equiv. of NaH as base and 5.0 equiv. of propargyl 
bromide in dry DMF for 24 hours, at 90 °C. Under these conditions, after purification by 
column chromatography, the bis-propargyl derivative 3.9 was isolated as the major 
product (25% yield) while the tris- substituted derivative 3.10 was obtained in traces 
(Scheme 3.4). 
 
 
Scheme 3.4 
 
These poor results suggested to modify the structure of the linker since to have a more 
nucleophilic hydroxy derivative. Thus we selected commercial ethyl gallate 3.11 as new 
starting material for the preparation of the linker(s). Also in this case, we tried to 
achieve a selective mono-, bis-, or tris- propargylation reaction by simply modulating 
the reaction condition of propargylation (Scheme 3.5). 
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Scheme 3.5 – Possible propargylation products. 
 
According to literature,
111
 3.11 was reacted with propargyl bromide in the presence of 
K2CO3 as base and 18-crown-6. A summary of the reactions performed is reported in 
Table 3.1. 
 
Entry 
Propargyl 
bromide 
(equiv.) 
K2CO3 
(equiv.) 
18-cown-
6 (equiv.) 
Conditions 
3.12 
(yield) 
3.13 
(yield) 
3.14 
(yield) 
1 0.9 0.43 0.002 7h, reflux trace trace 26% 
2 3.1 0.43 0.004 
24h, 
reflux 
- trace 42% 
3 0.9 0.9 0.001 
19h, 
reflux 
trace 3% 19% 
4 6.0 6.0 0.004 
18h, 
reflux 
quant. - - 
 
Table 3.1- Attempts of SN2 reaction on ethyl gallate. 
 
Mono-derivative 3.14 was obtained in acceptable yield when using 0.43 equiv. of K2CO3 
(Entry 2-3). The selective alkylation of the 4-OH group was easily demonstrated by 
1
H-
NMR based on the symmetry of the isolated mono-propargyl derivative. Despite the 
several attempts we were unable to settle up suitable condition for the selective 
preparation of 3.12-3.14 that, moreover, are very difficultly separated by 
chromatography. Thus, we moved to consider three different starting materials 
ensuring a very similar structure for the final linker. In particular, commercial hydroxy 
esters or acid 3.11, 3.15 and 3.16 showed in Figure 3.3 were considered. 
 
 
Figure 3.3- Starting materials selected for achievement of propargyl-linkers. 
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In the first attempt, the synthesis of the tris-propargyl derivative 3.12 was carried out. 
According to the literature,
111
  1.0 equiv. of ethyl gallate 3.11 was reacted with 6.0 
equiv. of propargyl bromide, 6.0 equiv. of K2CO3 and 0.004 equiv. of 18-cown-6 in dry 
acetone at reflux for 18 hours. The desired derivative 3.12 was obtained without 
purification in quantitative yield. 
The same procedure was also applied to bis-phenol 3.15 to give derivative 3.17 in 96% 
yield (Schema 3.6).  
 
 
 
 
Scheme 3.6- Synthesis of bis-propargylate derivative 3.17. 
 
Regarding the synthesis of the mono-propargyl derivative, commercial available 4-
hydroxybenzoic acid 3.16 was esterified under classical Fisher conditions, to give 
quantitative yield of ester 3.18 that, in turn, was reacted under the above reported 
conditions allowing the isolation of propargyl ether 3.19, in quantitative yield (Scheme 
3.7). 
 
 
 
Scheme 3.7- Synthesis of mono-propargyl derivative 3.19. 
 
The further step was the introduction of the maleimide moiety. The synthetic 
methodology was optimized using the tris-propargyl derivative 3.12 as a model. The 
first procedure we envisaged was a nucleophilic substitution using maleimide as 
nucleophile and transforming benzylic position of 3.12 in a suitable electrophile. So, 
ester 3.12 was reduced with 5.0 equiv. of LiAlH4 for 19 hours in dry THF to give the 
corresponding primary alcohol 3.20, in 95% yield. Alcohol 3.20 was transformed in 
primary chloro derivative 3.21 using 1.2 equiv. of PPh3 and 10.0 equiv. of CCl4 in 
refluxing dry THF for 40 hours.
3
 Under these conditions, chloride 3.21 was obtained, 
after purification by flash column chromatography, in 32% yield (Scheme 3.8-method 
a). An excellent improvement in the yield of 3.21 (91 %) was achieved carrying out the 
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chlorination reaction with 2.4 equiv. of SOCl2 and 0.1 equiv. of pyridine in dry Et2O for 3 
hours at reflux (Scheme 3.8-method b). 
 
 
 
 
Scheme 3.8 
 
The nucleophilic substitution between chloride 3.21 and maleimide was performed 
under several different conditions, without any success as summarized in Table 3.2. 
 
Entry 3.21 
(equiv.) 
Maleimide 
(equiv.) 
Base 
(equiv.) 
Solvent Additive 
(equiv.) 
Conditions Results 
1  2.0 1.0 K2CO3 Acetone - 3 days, 
reflux 
- 
2  2.0 1.0 K2CO3 Acetone - 24h, 50 °C - 
3  2.0 1.0 K2CO3 CH3CN - 24h, 50 °C - 
4  3.0 1.0  DMF - r.t. - 
5  3.0 1.0  DMF - 24h, 30 °C - 
6  1.0 1.3 K2CO3 DMF - 80 °C - 
7  1.0 2.0 K2CO3 Dry 
CH3CN 
- 7days, 
reflux 
- 
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8  2.0 3.0 K2CO3 Dry 
CH3CN 
- 4days, 50 
°C 
- 
9  2.0 1.0 K2CO3 Acetone KI 1.2 
equiv. 
18h reflux - 
10  2.0 1.0 K2CO3 CH3CN KI 1.2 
equiv. 
18h 55°C - 
11  1.0 2.0 K2CO3 Acetone KI 2.0 
equiv. 
18h reflux - 
12  1.0 2.0 K2CO3 CH3CN KI 2.0 
equiv. 
18h 55°C - 
 
Table 3.2- summary of attempts for nucleophilic substitution. 
 
Despite these disappointing results, we kept the original idea of using chloride 3.21 as a 
suitable electrophile that was reacted with 1.2 equiv. of potassium phthalimide and 0.1 
equiv. of 18-crown-6 in dry toluene, for 18 hours, at 100 °C.
112
 The good reactivity 
showed by potassium phthalimide under nucleophilic substitution conditions with the 
benzylchloride 3.21, is a peculiar result considering the ineffective of the same reaction 
when using maleimide. The N-alkyl phthalimide derivative 3.22 was isolated in 74% 
yield, after purification by flash column chromatography. In the next step, 3.22 was 
reacted with 2.0 equiv. of N2H4 in EtOH for 2 hours, at 60 °C to liberate primary amine 
3.23 which, in turn, was reacted with 1.0 equiv. of maleic anhydride in AcOH at 140 °C. 
After 6 hours the expected maleimide derivative 3.24 was isolated after purification by 
flash column chromatography, in 12% yield over two steps
110,113
 (Scheme 3.9). 
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Scheme 3.9- Linker synthesis procedure involving Gabriel’s reaction. 
 
Considering the low yield and the number of steps required to get 3.24, we decided to 
consider other synthetic strategies like, for example, the possibility of directly using 
benzyl alcohol 3.20 in a Mitsunobu reaction with maleimide, thus avoiding all the steps 
required for the synthesis of chloride 3.21 and amine 3.23. 
Thus, alcohol 3.20 was reacted under classic Mitsunobu condition: 1.0 equiv. of PPh3 
and 1.0 equiv. of DIAD with 1.0 equiv. of maleimide in dry THF, for 48 hours at reflux, to 
give desired product 3.24 in 12% yield (Scheme 3.10). 
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Scheme 3.10- Mitsunobu step. 
 
Several reaction conditions were tested to improve the Mitsunobu step, without any 
success (Table 3.3). 
  
Table 3.3 – Attempt of Mitsunobu reaction optimization. 
 
A significant further improvement of the procedure was obtained performing the 
Mitsunobu reaction in a microwave reactor, at 110 °C for 1.5 hours. Under these 
conditions linker 3.24 was isolated in comparable yield (22%) but in very shorter 
reaction times. 
The same procedure was applied to the mono- and bis- propargyl derivatives 3.19 and 
3.17, to achieve the corresponding maleimide propargyl compounds 3.25 and 3.26 in 
21% and 29% yield respectively as reported in Scheme 3.11. 
 
 
 
Entry 
3.20 
(equiv.) 
Maleimide 
(equiv.) 
PPH3 
(equiv.) 
DIAD 
(equiv.) 
Conditions 3.24 (yield) 
1 1.1 1.0 1.0 1.0 
dry THF, 72 h, 
r.t. 
6% 
3 1.1 1.0 1.0 1.0 
dry THF, 16 h, 
reflux 
5% 
2 1.0 1.5 1.5 1.5 
dry THF, 19 h 
at r.t., then  
28 h at 50 °C 
3% 
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Scheme 3.11-  i) LiAlH4, dry THF, 19-24h, r.t.: ii) DIAD, PPh3, dry THF, MW 45-80 min., 
120 °C 
3.2 Click reaction: Synthesis of maleimide-Paclitaxel adducts  
 
The final step towards the synthesis of Paclitaxel-maleimide conjugates required the 
Huisgen click reaction between propargyl derivatives 3.24-3.26 and the azido-
functionalized Paclitaxel 3.4. The Huisgen reaction could be performed in different type 
of solvents using commercially available Cu(I) salts as catalyst, but the reaction works 
better using a mixture of a Cu(II) salt together with a reducing agent. 
108,114,115
 We 
decided to use catalytic amount of CuSO4 and sodium ascorbate as the source of Cu(I) 
and a 4:1 mixture of DMF : water as solvent. These conditions were investigated in a 
model reaction between 2.0 equiv. of alkyne 3.19 and 1.0 equiv. of Paclitaxel-2’-6-
azido-hexanoate 3.4 which were reacted at r.t. After 30 hours, the corresponding 1,2,3-
triazole conjugate 3.27 was isolated in 48% yield, after chromatography purification 
(Scheme 3.12). 
  
 
Scheme 3.12- Model click reaction. 
 
With this result in hand, we repeated the click reaction using alkyne linker 3.25 and, 
satisfactorily, the mono-Paclitaxel-maleimide adduct 3.28 was isolated in 42% yield 
(Scheme 3.13).  
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Scheme 3.13- Synthesis of maleimide-Paclitaxel conjugate 3.28. 
 
The structure of the expected product was confirmed by 
1
H-NMR analysis (Figure 3.4-a) 
which showed: i) the characteristic peak of the methylene group in α position to 1,2,3-
triazole ring (around 4.3 ppm; highlighted in red) deshielded compare to the 
methylene-azido protons signal of the starting derivative 3.4 (3.21 ppm), with an 
integral value for two protons; ii) the singlet at 6.7 ppm , relative to maleimide protons, 
with an integral value for two protons  (highlighted in green); iii) The integral ratio 
between aforementioned peaks and other signal’s integrals is coherent with the 
structure of 3.28. ESI-MS analysis supported this data since the peak corresponding to 
[M + Na
+
] 
+
 was showed (Figure 3.4-b). 
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a)   
. 
b)   
Figure 3.4 –a) 
1
H-NMR spectrum and b) ESI-MS of maleimide-mono Paclitaxel derivative 
3.28. 
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Unexpectedly, the reaction failed when repeated identically on alkyne linker 3.26 that 
allowed the isolation of expected bis-Paclitaxel-maleimide adduct 3.29 in roughly 5% 
yield, while the products of the mono-click were isolated as major product (Scheme 
3.14). 
 
 
 
Scheme 3.14- Bis-alkyne-Paclitaxel conjugation. 
 
We considered that, possibly, the remarkable steric hindrance of Paclitaxel-2’-6-azido-
hexanoate 3.4 prevented its double insertion on the linker skeleton. Thus we tested the 
reactivity of derivative 3.26 with the ‘steric non-demanding’ azido derivative 3.2. 
However, despite the different attempts carried out, even under forced reaction 
conditions, also in this case we were unable to detect the formation of any CuAAC 
triazole product (Scheme 3.15), while the unreacted starting materials were recovered. 
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Scheme 3.15- Model bis-click reaction on derivative 3.26. 
 
The lack of reactivity of 1,2,3 tri-substitutes derivative 3.26 under CuAAC conditions is a 
peculiar result with no evident rationals. In the hope to overcome this problem we 
decided to prepare a bis-alkyne with a different substitution pattern on the ring. Thus, 
commercial available ethyl 3,4-dihydroxy-benzoate 3.30 was propargylated under the 
previous reported conditions to give the bis-alkyne 3.31 in quantitative yield. 
Bis-alkyne derivative 3.31 was then used in a model CuAAC test with ethyl 6-azido 
hexanoate 3.32 under the reaction conditions that failed using 3.25. Indeed, bis-triazole 
derivative 3.33, deriving from the coupling of alkyne 3.31 with azide 3.32, was isolated 
in 48% yield (Scheme 3.16).  
 
 
Scheme 3.16. 
 
Encouraged by this result, the bis-linker maleimide derivative 3.34 was synthesized by 
reduction of the ester moiety of 3.31 followed by Mitsunobu reaction with maleimide, 
as reported in Scheme 3.17.  
 
 
Scheme 3.17- i) LiAlH4, dry THF, 19-24h, r.t.: ii) DIAD, PPh3, dry THF, MW 45-80 min., 
120 °C 
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Satisfactorily, 3,4-bispropargyl ether 3.34 reacted with 2.0 equiv. of azido-Paclitaxel 3.4 
under the previous described CuAAC condition and after stirring for 19 hours at 50 °C 
bis-adduct 3.35 was isolated by flash column chromatography in 23% yield (Scheme 
3.18). 
 
 
 
Scheme 3.18-Synthesis of maleimide-bis-Paclitaxel adduct. 
 
The bis-adduct was characterized by 
1
H-NMR and ESI-MS analysis. The NMR spectrum 
showed similar peaks to that observed for the derivative 3.28, with integral values 
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coherent with the bis-functionalization. The result was confirmed by mass spectroscopy 
whose spectrum displayed the peak corresponding to [M + Na
+
]
 +
 and [M + H
+
]
 +
. The 
molecular formula extrapolated from the HR ESI-MS analysis, C123 H135O34N9, is in 
accordance to the theoretical one (Figure 3.5).  
  
 
Figure 3.5- ESI-MS and HR ESI-MS spectra of derivative 3.35. 
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As for mono- and bis- derivatives 3.25 and 3.34, the click reaction was performed for 
tris-alkyne-maleimide linker 3.24. The corresponding tris-Paclitaxel adduct 3.36 was 
isolated, after purification by flash column chromatography, in 16% yield (Scheme 
3.19). 
 
 
Scheme 3.19- Synthesis of tris-Paclitaxel maleimide conjuagate. 
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1
H-NMR analysis confirmed the tris substitution of linker 3.24, since characteristic 
peaks of maleimide-Paclitaxel adducts, whose integrals are in agreement with the tri-
functionalization, were showed. The HR ESI-MS spectroscopy showed peaks 
corresponding to [M + 2H
+
] 
2+
, [M + Na
+
 + H
+
] 
2+
, [M + 2Na
+
] 
2+
, and values of mass 
recorded were consistent with the theoretical molecular formula, C179H197O50N13 (Figure 
3.6). 
 
 
Figure 3.6– HR-ESI-MS analysis of tris Paclitaxel-maleimide adduct. 
 
3.3 NT4-Paclitaxel adducts conjugation 
 
The three Paclitaxel adducts 3.28, 3.35 and 3.36 properly functionalized with the 
maleimide moiety, were conjugated with NT4 to achieve targeted drug delivery 
systems with a different drug / peptide stoichiometry. In Luisa Bracci’s research group, 
at the University of Siena, a general thiol-maleimide procedure has been already 
developed at this purpose. 
25
 In detail, 1.0 equiv. of NT4-Cys and 3.0 equiv. of 
maleimide derivative were reacted in the presence of 1.0 equiv. of DIPEA in DMF 
(Scheme 3.20). The reaction was monitored through analytical HPLC at different times: 
1 h, 3 h, 20 h and 48 h. The final adducts were characterized by MALDI analysis and 
their in vitro cytotoxicity was evaluated. 
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Scheme 3.20- Synthesis of targeted drug delivery systems. 
 
3.4 Cytotoxicity assay 
 
Cytotoxic potency of the targeted pro-drug forms of Paclitaxel was evaluated by 
incubating human breast adenocarcinoma cell lines (MDA-MB 231) with different 
concentrations (range: 10
-9
-10
-5 
M) of the delivery systems NT4-3.28, NT4-3.35 and 
NT4-3.36. EC50 of the previously developed
11
 NT4-PTX adduct 3.37 (Figure 3.7), was 
employed as reference value. Operatively, MDA-MB 231 were plated at a density of 5 × 
103 per well in 96-well microplates. Different concentrations of NT4 conjugates were 
added 24 h after plating. Cells were washed after 1 h incubation and then left 6 days at 
37 °C with the same medium. Growth inhibition was assessed by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). Experiments were 
performed in triplicate. The level of significance is p < 0.05 for two-sided testing. 
 
 
 
Figure 3.7 – Previously developed
25
 NT4-PTX 3.37 
In Figure 3.8 the percentage of surviving cells is plotted against the logarithm of the 
concentration of each tested substance. 
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Figure 3.8 – Cytotoxic activity of the four NT4-xPTX (3.37, NT4-3.28, NT4-3.35 and NT4-
3.36) tested.  
From the analysis of the data reported in Figure 3.8 two important outcomes emerged: 
i) Derivatives NT4-3.28, NT4-3.35 and NT4-3.36 were administered to the 
cell cultures in equimolar amount, in order to compare different Paclitaxel 
doses delivered from the same amount of the targeting peptide. Thus, 
increasing the stoichiometry ratio NT4/Paclitaxel from 1:1 (NT4-3.28) to 
1:3 (NT4-3.36), no significant enhancement in cellular mortality was 
observed. Indeed, cytotoxicity curves relative to NT4-3.28, NT4-3.35 and 
NT4-3.36 administrations appeared almost superimposable. This result 
actually strongly confirmed the targeting ability of the NT4 peptide that is 
able to transfer inside cancer cells a killing dose of PTX even with a 1:1 
stoichiometry. Despite this peculiar cytotoxicity result should be 
confirmed and validate in other experiments and, of course, in vivo, 
nevertheless it opens the way to better designed NT4 multi-drugs adducts 
more than NT4 poly-drugs conjugates; 
 
ii) A slightly different cytotoxicity was shown by equimolar amounts of 
derivatives 3.37 and NT4-3.28, both carrying a single PTX unit. In 
particular, drug delivery system 3.37 showed a better cytotoxicity. Such 
difference can be ascribed to the different chemical nature of the spacer 
inserted on the two conjugates to link the NT4 and the PTX unit. A simple 
alkylic junction is present in adduct 3.37 (Figure 3.7; red arrow), while an 
aromatic spacer was used in NT4-3.28. The correlation between the 
spacer structure and the cytotoxicity probably deserves to be considered 
but not yet been studied in detail. Once the in vivo tests of derivatives 
NT4-3.28, NT4-3.35 and NT4-3.36 will confirm the lack of relationship 
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between stoichiometry and toxicity, the role of the linker chemical 
structure on the whole therapeutic activity will be re-considered since to 
maximize the therapeutic ability of this NT4-PTX adduct. 
 
On the other hands, the cytotoxic evidences previously reported suggested two 
reasonable developments of the research: 
i) In vivo environment can differently influence drug delivery and release in 
comparison to the in vitro conditions. Indeed, some pharmacodynamic 
and pharmacokinetic factors, which differs to that present in the culture 
medium, can influence the in vivo pharmacological activity. For instance, 
the presence of plasmatic esterases could affect the drug delivery towards 
the tumor site, through an early hydrolysis of the drug-carrier bond 
altering the anticancer activity. Moreover, these and other enzymes could 
differently interact with the delivery ability of NT4-drug conjugates due to 
their structure (i.e. 1, 2 or 3 drug moieties). Theoretically, due to the 
trivalent nature, derivative NT4-3.36 should be able to maintain a certain 
therapeutic activity even if one or two Paclitaxel moieties are hydrolyzed 
from the carrier. Analogous behavior is reasonably expected for derivative 
NT4-3.35, while the NT4-3.28 toxicity might show a higher sensitivity to 
these physiological processes. For this reason, a different activity of NT4-
3.28, NT4-3.35 and NT4-3.36 against cancer cells could be expected 
shifting from in vitro to in vivo conditions. Thus, in order to validate our 
data and hypothesis all the drug delivery systems prepared will be used 
for in vivo pharmacological tests; 
ii) Data reported in Figure 3.8 demonstrated the remarkable anticancer 
potency of the prepared drug delivery systems and corroborated the 
targeting ability of NT4 peptide. Keeping in mind the (in vitro) relative 
importance of the NT4:drug stoichiometry, we moved to the design and 
synthesis of multi-drug targeting system where a NT4 peptide is 
conjugated with two or more different anticancer drugs. In other word, 
we imagined to use a NT4 peptide to transfer in the same cancer cell two 
or more different therapeutic agents typically used in the combination 
therapy. In the next chapter are reported the preliminary results obtained 
in the synthesis of one of this system targeted synergetic NT4-
combination conjugates. 
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4. Targeted combination therapy 
4.1 Combination therapy: an evolution of the monotherapy 
 
Chemotherapeutics are the most efficient weapon against cancer developed up to now. 
However, they are associated with some drawbacks. In particular, due to their 
aspecificity, high doses are required for an efficient cancer treatment, leading to side 
effects and drug resistance in the target organism. Different strategies were recently 
developed to overcome these problems. One of the most prominent is the combination 
therapy.  It is defined as a treatment modality that combines two or more different 
therapies, such as chemotherapy, hormone therapy, immunotherapy and radiotherapy, 
to treat a single type of cancer. The co-delivery of different drugs is the most common 
combination therapeutic modality in cancer treatment. The enhanced anticancer 
activity exhibited by this therapeutic approach is due to the synergistic action of drugs. 
This allows a reduction of the administered dose of the single drug, compared to the 
monotherapy, allowing a reduction of side effects, and, most importantly, decreases 
the likelihood of cancer cell mutation that commonly leads to drug resistance.
116,117
 In 
Figure 4.1 advantages related to combination therapy are reported. 
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Figure 4.1-Schematic representation depicting various advantages shown by 
combination drug delivery for cancer therapy. (a) Single drug acts through a particular 
pathway, whereas multiple drugs can show enhanced anticancer activity by acting 
through several pathways. (b) In the case of single drug treatment, MDR proteins such 
as P-gp efflux drug out of the cell, whereas for dual formulations P-gp inhibitor blocks 
the role of MDR proteins and increases the intracellular concentration of other co-
administered drugs resulting in higher efficacy by overcoming the MDR phenotype. (c) 
High dose is needed for single drug treatment and consequently results in toxicity to 
the normal cells, whereas treatment with different drug combinations by synergistic 
action can reduce the dose of each single drug and thereby decrease the toxicity. 
Several combinations of two or more drugs were recently approved by FDA for the 
treatment of many types of cancers, as an efficient alternative to the monotherapy. For 
instance, Paclitaxel in association with cis-platin is the first-line treatment for ovarian 
cancer, Gemcitabine and cis-platin are used against biliary tract tumor,
 
Gemcitabine 
and Nab-Paclitaxel or Gemcitabine, Paclitaxel and carboplatin are effective in 
metastatic breast cancer as well as in pancreatic adenocarcinoma treatment.
118,119
 
However, the effectiveness of these therapies is limited by the inability of such drugs to 
strongly distinguish between healthy and pathological cells. In this respect, the 
approach of conjugating therapeutic unit(s) to a residue with a certain affinity for a 
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target on the cancer cell, e.g. the targeting peptide NT4, could be extended to the 
combination therapy thus achieving a selective multi-drug treatment. 
Among the endless combinations Gemcitabine and Paclitaxel together was the 
therapeutic approach we considered most attractive for the development of a targeted 
combination therapy. 
Gemcitabine 
Gemcitabine (or 2’,2’-difluorodeoxycytidine: dFdC) 4.1 is classified as antimetabolite. 
Structurally, it is a deoxycytidine analog in which hydrogen atoms on the 2' carbon are 
replaced by fluorine atoms. It is marketed as Gemzar® (Figure 4.2). 
 
 
Figure 4.2- Gemcitabine. 
Gemcitabine is used to treat certain types of breast, pancreatic, ovarian, and lung 
cancer and it is being studied in the treatment of other types of cancer. It has a good 
safety profile with a low incidence of toxicities (diarrhea, weakness, hair loss, mouth 
sores, difficulty sleeping, shortness of breath) that occurs in 10-29% of patients. 
Gemcitabine is a pro-drug since it must be activated by cellular enzymes through 
phosphorylation. Di- and tri-phosphorylated form of Gemcitabine, marked as dFdCDP 
and dFdCTP respectively, inhibit processes required for DNA synthesis. Indeed, after 
incorporation of Gemcitabine nucleotide, dFdCTP, on the end of the elongating DNA 
strand, the DNA polymerases are unable to proceed thus causing DNA damage and 
induction of apoptosis. This action ("masked termination") apparently locks the drug 
into DNA as the proofreading enzymes are unable to remove dFdCTP from this 
position.
120
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4.2 Towards the development of a targeted combination therapy 
 
Aimed to develop a targeted combination therapy, we envisaged the anchorage of both 
Paclitaxel and Gemcitabine on the peptide NT4, through a properly designed spacer. 
The first purpose was the conjugation of an equimolar amount of the two drugs and the 
peptide. Thus, we considered a trivalent spacer, depicted in Figure 4.3, provided with 
two binding sites for the drug units and with a maleimide residue, able to react with the 
thiol function installed on the peptide.  
 
 
Figure 4.3 - R = Gemcitabine binding site; R’ = Paclitaxel binding site 
In order to ensure NT4/Gemcitabine/Paclitaxel equimolarity in the final device, and 
contemporary guarantee the in situ therapeutic activity of both drugs, some synthetic 
issues had to be considered: 
i) Orthogonal reactions for the conjugation with Gemcitabine and Paclitaxel 
were reasonably envisaged. As a matter of fact, selective coupling 
reactions ensure drugs equimolarity. On the other hand, proper functions 
had to be inserted on drug units; 
ii) An in vivo hydrolysable linkage has to be inserted on drugs proximity since 
ensuring their release from their pro-drug form in the tumor surrounding. 
As drugs should act synergistically, the same type of hydrolysable bond 
was required on both therapeutic units, thus permitting their 
simultaneously release from the delivery system; 
iii) In vivo hydrolysable bonds cannot be exploited for drugs-spacer 
conjugation since preventing multiple labile sites and a consequent lower 
control in drug release process. 
It is evident that the introduction of an equimolar amount of NT4, Gemcitabine and 
Paclitaxel on the same skeleton, is not a trivial task. We envisaged a Multi 
Component Reaction (MCR) for this purpose, i.e. a chemical reaction where three 
or more components react in a sequential manner to give selectively a single 
product that retains the majority of the starting material atoms. Several types of 
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MCR are reported. Among the several MCR procedures nowadays available we 
focused our attention on the Ugi reaction, a four-component MCR involving a 
carboxylic acid, a primary amine, a carbonyl compound and an isocyanide 
derivative that react one-pot to form a bis-amide (Scheme 4.1). 
 
 
 
Scheme 4.1 - Mechanism of the Ugi reaction 
 
After a screening in literature, we found out that cyclohexyl isocyanide, benzylamine, 
benzaldehyde and alkyl carboxylic acid derivatives exhibited a good reactivity under Ugi 
reaction conditions. Thus, 1.0 equiv. of 6-bromo-hexanoic acid 4.2, 1.0 equiv. of 
cyclohexyl isocyanide 4.3, 0.7 equiv. of benzyl amine 4.4 and 3.3 equiv. of 4-bromo 
benzaldehyde 4.5, all commercially available, were reacted in a model Ugi reaction. 
Reagents were stirred in methanol for 1 hour at r.t. to afford bis-amide 4.6 isolated 
after flash column chromatography, in 58% yield.
121
 (Scheme 4.2) 
 
 
Scheme 4.2 – Model of Ugi reaction. 
Structure of adduct 4.6 was confirmed by 
1
H-NMR and ESI-MS analysis (Figure 4.4-a and 
4.4-b respectively).  
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 a) 
b) 
Figure 4.4- a) 
1
H-NMR and b) ESI-MS spectra of derivative 4.6. 
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Once the good reactivity of selected derivatives was demonstrated, we decided to 
insert benzaldehyde and amine on Paclitaxel and Gemcitabine moieties, respectively, 
while cyclohexyl isocyanide was kept as “inert branch” of the final compound. 
Maleimide residue was inserted as 3-maleimido propionic acid 4.9 which was prepared 
reacting 1.0 equiv. of β-alanine 4.8 with 1.0 equiv. of maleic anhydride 4.7 in acetic acid 
at reflux for 5 hours .
113
 Reactivity of derivative 4.9 under Ugi reaction conditions was 
tested. After 1 hour and 30 minutes at r.t. final adduct 4.10 was isolated in 60% yield 
(Scheme 4.3).  
 
Scheme 4.3 
The latter was characterized by
 1
H-NMR analysis which reasonably showed peaks 
analogous to that described for derivative 4.6 (Figure 4.5-a; highlighted in green, red 
and blue), since the same skeleton is present in both adducts 4.6 and 4.10. The 
characteristic singlet of maleimide moiety, displayed at 6.7 ppm with an integral value 
for two protons in respect to other peaks, indicated that derivative 4.9 is part of the 
final compound. The ESI-MS analysis confirmed this data showing the peak 
corresponding to [M+Na
+
]
+ 
and [2M+Na
+
]
+ 
(Figure 4.5-b). 
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a)  
b)  
Figure 4.5-a) 
1
H-NMR and b) ESI-MS spectra of derivative 4.10. 
 83 
 
Aldehyde functionalization of Paclitaxel 
The efficient Huisgen click reaction involving azido-functionalized Paclitaxel, was 
envisaged for the insertion of a benzaldehyde moiety on the Paclitaxel skeleton. Thus, 
commercial 4-hydroxy benzaldehyde 4.11 was provided with a terminal alkyne through 
the reaction with 4.0 equiv. of propargyl bromide and a catalytic amount of 18-crown-
6. The mixture was stirred in dry acetone for 24 hours at reflux and the alkyne 
derivative 4.12 was isolated in 46% yield. The latter was, in turn, coupled with 1.3 
equiv. of azido Paclitaxel 4.13, in the presence of 0.1 equiv. of CuSO4 and 0.2 equiv. of 
sodium ascorbate in DMF/H2O 4:1 for 24 h, at r.t. The corresponding 1,2,3-triazole 
derivative 4.14 was obtained, after flash chromatography purification, in 20% yield 
(Scheme 4.5). The synthesis of azido-functionalized Paclitaxel is reported in section 3.1. 
 
Scheme 4.5- Insertion of a benzaldehyde residue on the Paclitaxel skeleton. 
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Amino functionalization of Gemcitabine 
The OH on the 3’ position was selected for the selective insertion of a primary amine 
residue on the Gemcitabine skeleton. Thus, the protection of the primary alcohol on 
modified ribose ring and the primary amine on the cytosine ring were performed by 
reacting commercial Gemcitabine 4.1 with 2.2 equiv. of 4,4’-dimethoxytritylchloride in 
the presence of 0.1 equiv. of DMAP and 2.2 equiv. of DIPEA in dry DCM. After 19 hours 
at r.t. derivative 4.15 was isolated in 43% yield. The free hydroxyl group on the 3’ 
position was, in turn, esterified with 1.1 equiv. of 6-azido hexanoic acid 4.16 in the 
presence of 1.0 equiv. of DMAP and 1.1 equiv. of DIC in dry DCM at r.t.. The 
esterification ensured the presence of the in vivo hydrolysable bond needed for the 
drug release. The azido-derivative 4.17 was isolated, after 19 hours, in 46% yield. The 
latter was then reacted with 2.2 equiv. of triphenylphosphine to promote reduction of 
azide group into the corresponding amine
122
 (Scheme 4.6). Due to the difficulties 
encountered in the reduction of the azido to the required primary amino group, we 
decided to use N3 residue in a CuAAC reaction with propargyl derivative 4.19.  
 
Scheme 4.6 
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The latter was prepared by reacting commercial 4-hydroxy benzylamine 4.18 with 1 
equiv. of propargyl bromide, 0.1 equiv. of 18-crown-6 and 1 equiv. of potassium 
tertbutoxide in dry THF at -70 °C for 2 hours and at 0 °C for 2 hours. The low 
temperature led to the selective hydroxyl propargyl-substitution, preventing the 
undesired amino-propargylation. The desired final product 4.19 was obtained in 67% 
yield without purification (Scheme 4.7).
123
 
 
 
Scheme 4.7 
In the further step, alkyne 4.19 will be reacted in a Huisgen reaction with azido-
Gemcitabine 4.17 and the amino-Gemcitabine derivative will be involved in a Ugi 
reaction with aldehyde-paclitaxel, maleimide-acid and cyclohexylisocyanide. Final 
adduct will contain the two drug units and the maleimide residue required for the NT4 
coupling. Indeed, the targeted multi-drugs device will be synthesized and involved in in 
vitro and in vivo tested in order to both verify its anticancer ability and evaluated 
advantages or disadvantages of the targeted combination therapy in comparison to the 
targeted monotherapy.  
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5. Chelating agents: DOTA analogues 
 
Current interest in the clinical use of chelating agents as vehicles for metals in biological 
systems has led to the synthesis and study of a large number of new cyclic polioxa or 
polyaza ligands. One class that has shown great promise for clinical applications is the 
polyazamacrocyclic polycarboxilate ligands.
124
 Particularly, 1,4,7,10-
tetraazacyclodecane-N,N’,N’’,N’’’-tetracetic acid (DOTA) (Figure 5.1) and its analogues 
became a subject of universal interest because they form stable complexes with a wide 
variety of metal ions. Furthermore metal-DOTA complexes have been shown to be 
kinetically inert under physiological conditions.
125
  
 
5.1    
    
Figure 5.1- DOTA and octa-coordination around a metal 
Among metal ions which can be strongly encapsulated by DOTA, radionuclides such as 
111
In(III), 
67
Ga(III) and 
99m
Tc(IV) have suitable physical properties for tumor imaging, 
while 
90
Y(III), 
67
Cu(II), 
186
Re(VII) and 
177
Lu(III) have cytotoxic proprieties which can be 
exploited for therapy. 
Paramagnetic ions, as Gd(III), are instead generally exploited for Magnetic Resonance 
Imaging (MRI), which provides a potent diagnostic alternative to light microscopy and 
radiopharmaceutical methods.
126–129
 The image is based upon the NMR signal of the 
water’s proton, where the signal intensity is a function of the water concentration and 
relaxation times (T1 and T2). Gadolinium contrast mediums enhance and improve the 
quality of the MRI images by increasing the relaxation rate (1/T1) of water protons and 
are widely used in clinical diagnostics.
130
 One of the major problems in conventional 
contrast agents and radiopharmaceuticals is that they are primarily extracellular with 
an aspecific biodistribution. 
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For these reasons, the next generation of contrast agents will include systems able to 
recognize specific targets on the cellular surface that act as early reporters of a given 
pathology. Targeting of over-expressed membrane receptors with specific 
radiopharmaceuticals is already a well-established diagnostic method in nuclear 
medicine for several types of tumors. A somatostatin radioligand, DOTA-[D-Phe1-Tyr3]-
octreotide (DOTATOC), has been the first synthesized for therapeutic purposes, 
because of its stable and easy labelling with 
90
Y. Starting from this successful 
compound, the number of peptide-metal chelate based molecular sensors, diagnostic 
or therapeutic agents is rapidly increasing and is becoming one of the most challenging 
areas of research.
131,132
 
Considering our perspectives in peptide targeted tumor therapy we decided to 
conjugate a chelating agent to our carrier and exploit its efficacy on detecting or killing 
tumors, once complexed with an appropriate metal. For this purpose we selected, as a 
suitable chelating agent, DOTA because of the promising results obtained and the 
opportunity of direct coupling between the peptide’s free amine and its carboxylic 
functionalities. 
In literature is reported that DOTA-peptide conjugates are generally synthesized either 
in solution
133
 or on solid support
134,135
 through a coupling reaction involving the free 
amino group inserted on the peptide residue. DOTA or a derivative can be directly 
attached to the peptide or a spacer may be inserted between the peptide chain and the 
chelator. Based on this, we designed DOTA derivatives 5.2 and 5.3 (Figure 5.2) 
functionalized with a single pending free carboxylic acid moiety, to permit their 
coupling with an amino group of the dendrimeric peptide using standard solid phase 
peptide synthesis. The carboxylic acids not involved in the coupling, were protected as 
t-Bu esters, to avoid side reactions and poli DOTA functionalization. Tert-butyl esters 
are easily deprotected in the final acid cleavage of the modified peptide from the solid 
support with trifluoacetic acid (TFA). 
 
Figure 5.2 
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As a suitable common starting material, 1,4,7,10-tetraazacyclododecane-1,4,7-tris(tert-
butylacetate) 5.5, was prepared, as shown in Scheme 2.46, reacting in 
dimethylacetamide (DMA) tert-butylbromoacetate (3.0 equiv.) with a solution of 
tetraazacyclododecane 5.4 (1 equiv.), commercially available as cyclen, and 
Na(CH3COO) (3.0 equiv.). The tert-butyl ester of DOTA (1,4,7,10-tetraazacyclododecane-
1,4,7-triacetic acid) 5.5 was obtained by precipitation after 20 days under stirring in 
55% yield. (Scheme 5.1) 
 
 
Scheme 5.1 
The derivative 5.6 was obtained by adding 1.2 equiv. of benzylbromoacetate to 
compound 5.5 in DMF in the presence of NaH. 
133
 The reaction mixture was stirred for 
24 hours at r.t., then the product was isolated by flash chromatography, to yield N-
(benzylcarboxymethyl)-1,4,7,10-tetraazacyclododecane-N’,N’’,N’’’-triacetic acid tri-tert-
butyl ester 5.6 in 67% yield. 
A mixture of this compound and 10% Pd/C was hydrogenated in methanol under H2 
atmosphere for 6 hours to yield the modified DOTA macrocycle 5.2 in 50% yield 
(Scheme 5.2). 
 
 
Scheme 5.2 
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Structure of compound 5.2 ensures a selective and efficient coupling with the 
dendrimeric peptide, through the formation of a single amide linkage. However this will 
cause a lower ability of encapsulating metals due to the lack of one carboxylic acid 
group when compared with unmodified DOTA. (Figure 5.3) 
 
  5.2 
Figure 5.3 
Therefore we planned to synthesize the DOTA derivative 5.3, by modification of 
previous methods,
136
 which contemporarily ensures the possibility of an active 
coupling, using the standard solid phase peptide chemistry, and an octa-coordination 
around the selected metal once the t-butyl esters have been hydrolysed. 
Operatively, starting from the commercially available L-glutamic acid-5-benzylester 5.7 
using a method analogous to Holmberg,
134,137
 a suspension with 3.0 equiv. of sodium 
bromide in a cooled 1N solution of bromidric acid was made and 2.0 equiv. of sodium 
nitrite were added portionwise. The yellow solution was stirred for 2 h and finally 560 
µL of 98% sulfuric acid were added, followed by diethylether. The product 5.8 was 
obtained in 82% yield. 
The protection of the free carboxylic group was obtained adding dropwise a solution of 
2.0 equiv. of tert-butyltrichloroacetimidate (TBTA) in cyclohexane to a solution of 1.0 
equiv. of 5.8 in CHCl3. During the addition a white precipitate formed, which was 
dissolved by the addition of DMA before adding a catalytic amount of boron 
trifluoridiethyl etherate. The reaction mixture was stirred for three days at r.t. and 
bromoester 5.9 was isolated, after purification, in 50% yield. 
The following coupling with the macrocyclic ring was performed as usual, in mild basic 
conditions. A mixture of 1.0 equiv. of 5.5 and 3.0 equiv. of K2CO3 was stirred in dry 
acetonitrile at 60°C for 10 min before adding dropwise, over a period of 40 min, a 
solution of 2.0 equiv. of 5.9 in dry acetonitrile. After 42 h under stirring at 60°C, benzyl 
ester 5.10 was isolated in 59% yield. Finally 5.10 was dissolved in absolute ethanol and 
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hydrogenated over 10% Pd/C under a H2 atmosphere for 48 hours to give the desired 
product 5.3 in 79% yield without purification. (Scheme 5.3) 
 
 
 
Scheme 5.3 
 
As it is shown in Scheme 5.3 this derivative can be conjugated to the dendrimeric 
peptide without affecting its complexation ability, because, like for DOTA, an octa-
coordination around the metal, resulting in a compact square-antiprism involving four 
nitrogen atoms in one plane and the four oxygen atoms in a second plane, is perfectly 
available. 
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Thus, Luisa Bracci’s research group at University of Siena, will deal with the coupling of 
such derivatives with the targeting peptide NT4, properly provided with an amino 
terminal non-peptidic PEGylated branch. The amidation coupling can be performed 
directly on solid support, since the chelating derivative can be treated as an amino acid. 
The cleavage step, involving concentrated TFA, besides the release of the peptide from 
the solid support, allow the tertbutylated acids deprotection on DOTA derivative, thus 
rendering acid groups available for chelating the selected metal ion. Indeed, it will be 
octa-coordinated within the DOTA structure as the last step of the procedure, before in 
vivo testing of the new targeting imaging tool. 
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6. Quantum Dots  
 
QDs manipulations and in vitro and in vivo tests were performed by Prof. Luisa Bracci’s 
research group at the University of Siena. 
 
6.1 Characteristics of QDs 
 
Quantum Dots (QDs) are semiconductor nanocrystals with a core-shell structure and a 
diameter that typically ranges from 2 to 10 nm.
138
 Recently, they have been explored 
for a wide range of applications, such as solar cells, transistors, LEDs as well as medical 
application with best regard  for both in-vitro and in-vivo imaging and cancer therapy 
and theranostic.  QDs exhibit a wide range of unique and excellent optical properties, 
such as a broad absorption spectra coupled with a narrow emission spectrum bands. 
Furthermore, QDs display long-lasting and more stable photoluminescence compared 
to conventional organic fluorophore (e.g. rhodamine), which render them particularly 
attractive for the in-vivo imaging application. The frequency of the light emitted by a 
specific quantum dot is related directly to its size; smaller particles tend to emit higher-
energy radiation. (Figure 6.1) Thus QDs size is strongly related to their application. 
 
 
 
  c)   
 
Figure 6.1 – a) absorption spectra and b) fluorescence spectra of CdSe QDs in different 
size. c) QDs colours related to their size. 
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6.2 Structure of QDs 
 
QDs are usually composed by a core of a semiconducting material enclosed within a 
shell of another semiconductor. The core of QDs is usually composed of compounds 
from groups II–VI such as CdSe, CdS or CdTe, groups III–V such as InP or InAs, or groups 
IV–VI such as PbSe. The shell is usually composed of ZnS
139,140
 (CdSe/ZnS QDs are the 
most widely used for biomedical research).  
The ZnS shell protects the core from oxidation, increases photostability and improves 
its quantum yield up to 80% when compared with that of the core alone, which is 
usually less than 10%.
141,142
 On the other hand, since in-vivo oxidative environment lead 
to a release of heavy metal ions from the QD, the protective shell increases QDs human 
safety. The inorganic core-shell is, in turn, coated by an organic layer responsible for 
QDs physical-chemical properties, e.g. solubility (Figure 6.2). In addition, several 
different molecules, ranging from small molecules to peptides or polymers, can be 
conjugated with QDs making them a very versatile tools for different research areas.
143
 
(see below for details). 
 
 
 
Figure 6.2 - Schematic structure of QDs. 
6.3 QDs synthesis and functionalization  
 
As for AuNPs, several synthetic methodologies, in both organic and aqueous solvents, 
were developed for the synthesis of well monodisperse QDs with well-tuned optical 
properties by varying the NPs size.
142,144
  The most used synthetic procedure involves 
organometallic precursors, which are reacted, in the presence of a stabilizer, at high 
temperature (300 °C). QDs with different selected sizes can be prepared by setting the 
reaction time. Analogously to AuNPs, the high affinity of thiols towards the ZnS shell 
can be exploited for a suitable decoration of the QDs surface.  
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In particular, the thiolate ligand can be introduced directly during the synthetic step 
(Figure 6.3-a) as well as capped QDs can undergo place-exchange reaction with ligand 
properly provided with a thiol function (Figure 6.3-b).   
a)  
b)  
Figure 6.3- a) Direct synthesis of coated CdSe/ZnS quantum dots; b) place-exchange 
reaction. 
However, the more widely used approach is the “post synthetic modification”.   
Commonly, the well-defined amidation reaction, involving carboxylated QDs, is used. 
Synthetically, external carboxyl groups are activated by N-(3-dimethylaminopropyl)-
ethylcarbodiimide (EDC) or sulfo-N-hydroxysuccinimide (s-NHS) and, in turn, reacted 
with an amino-functionalized unit. This strategy was then adapted to amino coated 
QDs, achieving the carboxylated-ligands conjugation.
145
  
When the amidation reaction cannot be used for the direct coupling, it however can be 
exploited to insert on the QDs surface, through a bifunctional linker, a suitable reactive 
group, such as maleimide moiety or a terminal alkyne or an azide etc., in order to adapt 
the synthetic procedure to this limit. The properly functionalized QDs and biomolecules 
can thus be linked through a click chemistry reaction.
145
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So, the great versatility of the post-synthetic functionalization approach, allows the 
anchorage of a wide variety of molecules and biomolecules on QDs surface.  
In Figure 6.4, an overview of different bioconjugation (left side, BOI = biomolecule of 
interest) and surface coating (right side) strategies for QDs is reported. Two surface coating 
strategies are presented: encapsulation with amphiphilic polymers (i, ii) and cap exchange 
with hydrophilic ligands exploiting the thiol-affinity of the ZnS shell of the QD (iii–v).
146
 
 
 
 
Figure 6.4 – Different strategies for QDs decoration. 
 
6.4 QDs for targeted theranostic 
 
As above said, QDs are being intensively studied with a focus on their application as 
contrast agents. As all metallic NPs, also QDs passively accumulate in the tumour site, 
due to the EPR effect. Nevertheless, it would be convenient increasing their targeting 
ability by conjugating their surface with a molecule with a certain affinity for a target 
unit on the tumour, thus enhancing the effectiveness for imaging application. However, 
the ability of NPs to bind a great number of molecules on their surface has to be 
considered. Indeed, the likelihood to decorate the QDs surface with several therapeutic 
units, allows extending the QDs potential application from diagnostic to theranostic. As 
a matter of fact, the peculiar features of the inorganic core render the nanosystem 
suitable as tumour tracer, while the multi-functionalization with both targeting and 
therapeutic units allows a selective therapy. Thus, the development of targeted multi 
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drugs-QDs could represent a breakthrough in medical research. On these 
considerations, our work was focused on the NT4-QDs-drugs conjugation as an 
evolution of the previously described NT4-AuNPs-drugs devices. 
 
6.5 Construction of NT4-QDs  
 
Qdot® 705 ITK™ amino (PEG) quantum dots (maxima emission at 705 nm) were 
selected as substrate for the development of targeted QDs. The organic monolayer of 
these nanoparticles is composed of an amino-derivatized PEG, which prevents non-
specific interactions and provides a convenient handle for conjugation. In particular, 
amino-QDs efficiently react with activated acid. Thus, the latter ones were reacted with 
an activated acid-maleimide bifunctional linker, sulfo-SMCC 6.1, for 1 hour in 
phosphate buffer saline (PBS) at pH = 4. 
Maleimide moieties so inserted were, in turn, reacted with the targeting peptide in the 
well-tuned maleimide-thiol reaction (Scheme 6.1). The bifunctional linker was used in 
defect, ensuring the presence of free amino groups in the successive step, in view of 
their drug-decoration (see section 6.6 for details). 
  
 
 
Scheme 6.1 - Schematic illustration of the preparative procedures of NT4-QDs 705. 
NT4-QDs were purified using superdex 200 by size exclusion chromatography. The 
concentration of purified NT4-QDs in the eluate was calculated to be 250 nM, according 
to the extinction coefficient at 532 nm of 2.1 × 10
6
 (mol/L)−1 cm−1 provided by the 
manual.  
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6.5.1 Stability assays of NT4-QDs: 
 
NT4-QDs were characterized by TEM analysis, which showed a well-dispersity of the 
system without any aggregation, thus demonstrating that the NT4-conjugation did not 
affect NPs morphology and stability and hence their potential use for our purpose 
(Figure 6.5-a). 
A previous evaluation of cytotoxicity of QDs has to be carried out in view of their 
application in cellular and in vivo study. Thus, human adenocarcinoma cell lines (HT-29) 
were incubated for 24 hours with NT4-QDs and unconjugated QDs in concentrations 
ranging from 0.5 to 20 nM. No significant cytotoxic activity was showed in each sample 
(Figure 6.5-b).  
 
 
 
Figure 6.5- Characterization of NT4-QDs. A) TEM image of monodispersed NT4-
functionalized NIR QDs. The average size of the particles is around 10 nm. B) 
Cytotoxicity of NT4-QDs and free QDs in HT-29 human colon adenocarcinoma cell line 
after 24 hours incubation. 
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6.5.2 In vitro binding and internalization of NT4-QDs 
 
Binding ability of targeted QDs was evaluated in comparison of unconjugated QDs, by 
immunofluorescence assay on human adenocarcinoma cell line (HT-29).  
Nuclei were stained with DAPI (blue), plasma membrane was stained with Wheat Germ 
Agglutinin-Alexa Fluor 488 (green) while the red signal indicated QDs accumulation.  
NT4-QDs binding on cancer cell membrane was revealed after 30 minutes of incubation 
(T0). After 1 hour of incubation, NT4-QDs were localized into the cell membrane while, 
at following incubation times, NT4-QDs were clearly visualized intracellularly. On the 
other hand, no signal was detected either on the cell membrane or intracellularly, with 
undecorated QDs (Figure 6.6), thus demonstrating that the binding ability is related to 
the NT4 peptide conjugation.  
   
 
Figure 6.6- Binding and internalization (T 1h, 2h, and 4h) of NT4-QDs (red) on HT-29 by 
immunofluorescence.  
 
Once the stability and the targeting ability of NT4-QDs was demonstrated, we focused 
on providing such system with a proper number of drug units, in order to combine the 
demonstrated targeted diagnostic activity with the therapeutic potential of Paclitaxel.  
 
6.6 Construction of NT4-QDs-PTX  
Aimed to exploit the well-defined amidation protocol involving NHS ester derivative 
(see section 6.5 for details) for the achievement of PTX-QDs conjugation, a proper 
function has to be inserted on the drug unit. Keeping in mind the need of an ester bond 
for ensuring the in vivo drug release, Paclitaxel was reacted with 1.6 equiv. of succinic 
anhydride in the presence of 0.3 equiv. of DMAP, in dry pyridine, for 24 hours at r.t., to 
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afford the corresponding derivative 6.3 selectively esterified on the 2’ OH, in 
quantitative yield (Scheme 6.2).  
Scheme 6.2 – Acid functionalization of Paclitaxel. 
 
To activate the acid moiety as NHS ester, N-succinimydil diphenylphosphonate (SDPP) 
6.6 was required. It was prepared by reacting N-hydroxysuccinimide 6.5 with an 
equimolar amount of diphenyl phosphoryl chloride 6.4 in the presence of 1.4 equiv. of 
TEA in dry DCM for 6 hours at r.t.. SDPP 6.6 was used without purification in the further 
reaction with Paclitaxel derivative 6.3, in the presence of 1.4 equiv. of TEA as base. 
After 6 hours in acetonitrile at r.t. the NSH ester form of Paclitaxel 6.7 was isolated in 
51% yield (Scheme 6.3).  
 
Scheme 6.3- Synthesis of NHS ester Paclitaxel. 
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Maleimide residues were inserted on QDs surface by reacting the bifunctional linker 
6.1, sulfo-SMCC, with amino QDs in an amidation reaction. The linker 6.1 was used in 
substechiometric amount thus ensuring the presence of unreacted amino groups which 
were, in turn, reacted under the same amidation conditions with NHS ester Paclitaxel 
6.7. After 1 hour in acetonitrile at r.t. in the dark, the mixture was purified by NAP5 
Sephadex G-25 column, eluting with PBS. Collected QDs were incubated with a PBS 
solution of MAP-NT and, after 1 hour, 2-mercapto ethanol was added in order to 
saturate unreacted maleimide residues. The synthetic protocol is reported in Scheme 
6.4. 
 
 
Scheme 6.4 – Synthesis of NT4-QDs-PTX. 
 
The quantization was performed through spectrophotometric analysis at 532 nm in 
which ε = 2.1x10
6
 (mol/L)
-1
cm
-1
. 
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6.6.1 Binding and cytotoxicity experiments of NT4-QDs-PTX 
 
Human colon adenocarcinoma cell lines (HT-29) were incubated with a 20 nM solution 
of NT4-QDs-PTX. QDs-PTX, not decorated with the peptide, were used in the same 
concentration as reference. After 30 minutes, the binding ability of the two systems 
was evaluated. In the figure, nuclei were stained with DAPI (blue signal), while the red 
signal indicated the NT4-QDs-PTX accumulation.  
Analyzing immunofluorescence images, a localization of NT4-QDs-PTX on cell 
membrane was showed (red line), while no QDs signal was detected in the cell 
surrounding when QDs-PTX are not decorated with the targeting peptide. This data 
confirmed the well-demonstrated targeting ability of the peptide and its capacity to 
efficiently deliver the QDs-PTX conjugate on the tumor site.  
 
 
 
Figure 6.7 - Binding assay for NT4-QDs-PTX and QDs-PTX on HT-29 cell line. 
 
6.6.2 Cytotoxicity assays 
 
Cytotoxicity of both NT4-QDs-PTX and QDs-PTX was evaluated through test on human 
colon adenocarcinoma cell lines (HT29), by using different concentrations of QDs (40 
nM, 20 nM, and 10 nM). Each sample was incubated for 1 h at 37 °C, then, cells were 
washed with medium and were allowed to grow for 6 days, at 37 °C. Cells viability was 
evaluated with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
(Figure 6.8).  A greater cytotoxicity of the targeted QDs-PTX was highlighted, in 
particular when using a 20 nM concentration of the nanosystem.  
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 Indeed, while almost no toxic effect was shown for QDs-PTX, the targeted system was 
able to kill the 80% of involved cells.  
 
Figure 6.8- Cytotoxicity of NT4-QDs-PTX and QDs-PTX in different concentrations. 
 
In conclusion, an efficient protocol for NT4 decoration of commercial amino-QDs was 
developed as well as for their decoration with both NT4 and Paclitaxel. Once the 
stability and the efficient targeting ability of peptide-decorated QDs was established, 
we developed a targeted theranostic system whose targeting potential together with 
its therapeutic activity was demonstrated. In the next steps, we will focus on the in vivo 
binding and cytotoxicity evaluation of the theranostic QDs-based drug delivery system. 
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7. Conclusions and future prospective 
 
As already said in “Preface”, I was admitted to PhD as a supernumerary student. In the 
last three years I received three research grants on two different topics. In the first year 
of my PhD I worked on the development of model compounds for the study of 
Hydrogen Atom Transfer (HAT) mechanisms in energy-related processes, whose 
preliminary results are not reported in this thesis. The work herein reported was 
carried out in my second and third PhD years, thanks to a research grant financed by 
Istituto Toscana Tumori (ITT) and in collaboration with Luisa Bracci’s research group 
from the Department of Medical Biotechnologies at the University of Siena. 
My PhD project was focused on the development of targeted multivalent drug delivery 
systems, as an evolution of the targeted drug delivery system (NT4-PTX) previously 
developed in our research group. Targeted delivery systems bearing a variable and 
defined number of Paclitaxel units (1-3) were synthesized. Their in vitro cytotoxicity 
assays demonstrated their great activity as anticancer agents and clirified, even if 
preliminarly, the role of vectored drug on their toxic potency.  
Targeted devices bearing a higher number of therapeutic units were developed by 
conjugating the targeting unit to a highly functionalized nanoparticles (QDs or AuNPs), 
with the aim to maximize the targeting ability of NT4. Preliminary in vitro assays 
demonstrated a good binding and anticancer activity of QDs-based delivery systems, 
while AuNPs-based targeted carriers are currently being studied. Besides that, we 
designed a polyvalent NT4-based device able to carry into the tumor synergistically 
acting drugs, for the development of a targeted combination therapy.  
Conclusions and ongoing investigation are reported in detail for each chapter.  
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Experimental section 
 
Materials and methods 
All the reactions were monitored by TLC on commercially available precoated plates  
silica gel 60 F 254) and the products were visualized with acidic vanillin solution. Silica 
gel 60, 230–400 mesh, was used for column chromatography. 
1
H and 
13
C NMR spectra 
were recorded with Varian Gemini 200 or Varian Mercury Plus 400 using as solvent: 
- CDCl3 using the reference at 7.26 ppm of the residue of chloroform in 
1
H NMR spectra 
and at 77.0 ppm in the 
13
C NMR spectra. Melting points were measured on a Stuart 
SMP50 Automatic Melting Point. FT-IR spectra were recorded in CDCl3 solutions with 
FT Infrared Spectromer 1600 Perkin-Elmer. GC – MS spectra were recorded with a QMD 
100 Carlo Erba. ESI - MS spectra were measured with JEOL MStation JMS700. 
Commercial available reagents, catalysts and ligands were used as obtained, unless 
otherwise stated, from freshly opened container without further purifications. Dry 
dichloromethane, diethyl ether, tetrahydrofuran and dimethylformamide were 
obtained by Pure Solv Micro device. Acetone was distilled over calcium chloride. 
 
Synthesis of 2’-maleimido-paclitaxel (1.2) 
 
 
To a solution of Paclitaxel (0.050g, 0.06 mmol) in 8 mL of dry DCM, DMAP (0.0007 g, 
0.006 mmol) was added, under a N2 atmosphere. The colourless solution was cooled at 
0°C, then 3-maleimidopropionic acid (0.01 g, 0.06 mmol) was added, followed by DIC (9 
µL, 0.06 mmol). The reaction mixture was stirred for 18 h at r.t. to give a reddish 
solution, then poured onto 20 mL of DCM and washed with a saturated solution of 
NH4Cl (3x40 mL), then a saturated solution of NaHCO3 (2x40 mL) followed by a 
saturated solution of NH4Cl (5x40 mL). The recollected organic layer was dried over 
Na2SO4, filtered and evaporated to obtain a reddish oil (48 mg). The crude was purified 
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by flash chromatography using EtP : AcoEt 2 : 3 as eluent to obtain the final pure 
product (54) as white powder in 52% yield.  
1
H NMR (400MHz, CDCl3) reported in literature.
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13
C-NMR (100 MHz, CDCl3) δ 9.59; 14.77; 20.80; 22.14; 22.67; 26.77; 32.47; 33.29; 
35.48; 43.13; 45.54; 52.36; 58.49; 71.74; 72.09; 74.47; 75.12; 75.60; 79.14; 81.02; 84.45 
(24C, Caliph.) 126.52; 127.43; 128.27; 128.50; 128.72; 129.01; 129.22; 130.26; 131.87; 
132.67; 133.64; 134.03; 136.87; 142.86 (22C); 167.04; 167.24; 167.68; 169.36; 169.88; 
171.24 (7C, C=O); 203.83 (1C).  
FT-IR (CDCl3) 3607.75, 3517.24 (m, OH stretch. free and bonded); 3387.93 (m, NH 
stretch. bonded); 3060.96 (w, CHarom stretch.); 2948.27, 2896.55 (w, CHaliph. stretch.); 
1737.63 (s, C=Oester stretch.); 1711.82 (s, C=Oketone stretch.); 1664.51 (s, C=Oamide 
stretch.) cm
-1
. 
ESI -MS: m/z = 1027.33 [M+Na]
+
; 1039.67 [M+Cl]
-
. 
 
Synthesis of 2-(hydroxymethyl)-2-(non-8-en-1-iy)propan-1,3-diol (2.3) 
 
 
 
To a solution of 10-undecenal (454 mg; 2.69 mmol) and CH2O (1.6 mL 37% aqueous 
solution) in H2O/EtOH 50/50 (7 mL) a solution of KOH (151 mg; 2.69 mmol) in H2O/EtOH 
50/50 (7mL) was added at 0 °C. the mixture was stirred for 20 hours at room 
temperature and at 50 °C for 4 hours. Then, EtOH was evaporated under reduce 
pressure and the aqueous phase was extracted with diethyl eter (3x). The organic phase 
was dried over Na2SO4, filtered and evaporated under reduce pressure. The crude was 
purified by flash column chromatography using DCM : MeOH 9: 1 as eluent to obtain 
the product as colourless oil (410 mg) in 66% yield. Spectroscopic data were previously 
reported.
148
 
1
H NMR (200MHz, CDCl3) δ 5.90-5.70 (m, 1H); 5.03-4.90 (m, 2H); 3.67 (s, 6H); 3.46 (bs, 
3H, OH); 2.07-1.97 (m, 2H); 1.26 (bs, 8H); 1.17(bs, 4H), ppm. 
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Synthesis of S, S’-(2-((acetylthio)methyl)-2-(non-8-en-1-yl)propan-1,3-
dyil)diethanthiolate (2.4) 
 
 
 
To a solution of PPh3 (2762 mg; 10.53 mmol) in dry THF (35 mL) DIAD (2129 mg; 10.53 
mmol) was added dropwise at 0 °C under nitrogen atmosphere. The mixture was 
heated at room temperature and a solution of 2-(hydroxymethyl)-2-(non-8-en-1-
iy)propan-1,3-diol 2.3 (540 mg; 2.34 mmol) and thioacetic acid (802 mg; 10.53 mmol) in 
dry THF (12 mL) was added. The mixture was stirred under nitrogen overnight at room 
temperature and at reflux for 1 hour, then EtOH (12 mL) was added and the mixture 
was stirred at reflux 1 hour more. Volatile components were evaporated under reduce 
pressure then the residue was extracted with hexane (20 mL) to obtain a yellow oil that 
was purified by flash column chromatography using DCM as eluent to obtain the pure 
product as yellow oil (270 mg) in 29 %. 
Spectroscopic data were previously reported
149
. 
1
H NMR (200 MHz, CDCl3) δ 5.90-5.70 (m, 1H), 5.03-4.85 (m, 2H), 2.97 (s, 6H), 2.33 (m, 
9H), 2.07-1.93 (m, 2H), 1.30-1.10 (m, 12H) ppm. 
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Synthesis of 2-(mercaptomethyl)-2-(non-8-en-1-yl)propane-1,3-dithiol (2.1) 
 
 
To a suspension of LiAlH4 (21 mg; 0.55 mmol) in dry THF (1.5 mL) a solution of S, S’-(2-
((acetylthio)methyl)-2-(non-8-en-1-yl)propan-1,3-dyil)diethanthiolate 2.4 (30 mg; 0.074 
mmol) in dry THF (1.5 mL) was added portionwise at 0 °C in inert atmosphere. The 
mixture was stirred at room temperature overnight then added to a mixture of 3M HCl 
and ice. The aqueous phase was extracted with DCM. The organic phase was dried over 
Na2SO4 , filtered and evaporated under reduce pressure to obtain a yellow oil (30 mg) 
in quantitative yield. 
Spectroscopic data were previously reported
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1
H NMR (200 MHz, CDCl3) δ 5.91-5.71 (m, 1H), 5.04-4.88 (m, 2H), 2.58 (d, J = 10 Hz, 6H), 
2.05-1.99 (m, 2H), 1.42-1.10 (m, 15H) ppm. 
FT-IR (CDCl3) cm
-1
: 2583 (SHstretch.).  
ESI - MS: m/z = 277 [M-H]
-
. 
 
Synthesis of undec-10-ynal (2.7) 
 
 
 
To a solution of PCC (320 mg, 1.49 mmol) in 2 mL of dry DCM, 10-undecyn-1-ol ( 167 
mg, 0.99 mmol)  was added dropwise under nitrogen. After 3 hours the mixture was 
quenched with water (10 mL) and washed with a saturated aqueous solution of NaCl 
(3x10 mL). The organic phase was dried over Na2SO4, filtered and evaporated under 
reduce pressure to afford a brownish oil (150 mg) in 91 % yield. The crude product was 
used without purification. Spectroscopic data were previously reported
150
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Synthesis of 2-(hydroxymethyl)-2-(non-8-yn-1-yl)propane-1,3-diol (2.8) 
 
 
To a solution of undec-10-ynal 2.7 (480 mg, 2.86 mmol) and CH2O (13 mL 37% aqueous 
solution) in 8 mL of H2O/EtOH 50/50 a solution of KOH (151mg; 2.69 mmol) in 7 mL of 
H2O/EtOH 50/50 was added at 0 °C. The mixture was stirred for 20 hours at room 
temperature and at 50 °C for 4 hours. Then, EtOH was evaporated under reduce 
pressure and the aqueous phase was extracted with diethyl eter (3x20 mL). The organic 
phase was dried over Na2SO4, filtered and evaporated under reduce pressure. The 
crude was purified by flash column chromatography using DCM : MeOH 10: 1 as eluent 
to obtain a colourless oil (320 mg) in 49% yield. 
1
H NMR (400MHz, CDCl3) δ 3.72 (bs, 3H, OH), 3.65 (s, 6H), 2.16 (td, J = 6.8 Hz, J = 2.6 Hz, 
2H), 1.94 (t, J = 2.6 Hz, 1 H), 1.5 (quint., J = 6.8 Hz, 2H), 1.37-1.16 (m, 10H) ppm. 
13
C NMR (400MHz, CDCl3) δ 127.7, 84.7, 68.2, 66.1, 42.8, 30.4, 29.0, 28.6, 28.4, 22.9, 
18.3 ppm. 11 found of 13 real.  
 
Synthesis of S,S'-(2-((acetylthio)methyl)-2-(non-8-yn-1-yl)propane-1,3-diyl) 
diethanethioate (2.9) 
 
To a solution of PPh3 (932 mg; 3.55 mmol) in 12 mL of dry THF,  DIAD (718 mg; 3.55 
mmol) was added dropwise at 0 °C under nitrogen atmosphere. The mixture was 
heated at room temperature and a solution of 2-(hydroxymethyl)-2-(non-8-yn-1-
yl)propane-1,3-diol 2.8 (180 mg; 0.789 mmol) and thioacetic acid (270 mg; 3.55 mmol) 
in 4 mL of  dry THF was added. The mixture was stirred under nitrogen overnight at 
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room temperature and at reflux for 1 hour, then EtOH (4 mL) was added and the 
mixture was stirred at reflux 1 hour more. Volatile components were evaporated under 
reduce pressure then the residue was extracted with hexane (9 mL) to obtain a yellow 
oil that was purified by flash column chromatography using DCM as eluent to obtain 
the pure product as yellow oil (180 mg) in 57% yield 
1
H NMR (400MHz, CDCl3) δ 2.97 (s, 1H), 2.33 (s, 9H), 2.17 (td, J = 6.8 Hz, J = 2.4 Hz, 2H), 
1.93 (t, J = 2.4 Hz, 1H), 1.51 (quint., J = 6.8 Hz, 2H), 1.40-1.22 (m, 10H) ppm. 
 
13
C NMR (400MHz, CDCl3) δ 194.7, 68.4, 67.8, 41.0, 36.0, 35.2, 30.9, 30.4, 29.8, 28.8, 
28.6, 28.4, 32.3 ppm. 13 found of 19 real. 
FT-IR (CDCl3)  3307, 2934, 2116, 1691 cm
-1
. 
 
Synthesis of 2,5-dioxopyrrolidin-1-yl 5-(1,2-dithiolan-3-yl)pentanoate (2.12) 
 
 
To a solution of commercial lipoic acid (200 mg, 0.97 mmol) and N-hydroxysuccinimide 
(112 mg, 0.97 mmol) in dry DCM (2 mL) a solution of dicyclohexylcarbodiimide (DCC) 
(250 mg, 1.21 mmol) in dry DCM (1.5 mL) was added dropwise at 0 °C. The mixture was 
stirring at 0 °C for 10 minutes and then at r.t. for 1 h. Then, the white suspension was 
kept at -20 °C overnight to fully precipitate DCU. The suspension was filtered under 
vacuum to get rid of the precipitate and the filtered solution was evaporated to afford 
2,5-dioxopyrrolidin-1-yl 5-(1,2-dithiolan-3-yl)pentanoate as a yellow solid in a 
quantitative yield without further purification. Spectroscopic data were previously 
reported. 
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1
H NMR (400 MHz, CDCl3) δ 3.61-3.54 (m, 1H), 3.21-3.08 (m, 2H), 2.83 (s, 4H), 2.62 (t, J 
= 7.3 Hz, 2H) 2.50-2.42 (m, 1H), 1.96-1.88 (m, 1H), 1.82-1.75 (m, 2H), 1.74 (m, 2H), 1.60-
1.51 (m, 2H) ppm. 
13
C NMR (100 MHz, CDCl3) δ 169.1, 168.4, 56.1, 40.1, 38.5, 34.4, 30.7, 28.3, 25.6, 24.4 
ppm. 
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Synthesis of tert-butyl(6-aminohexyl)carbamate (2.14) 
 
 
To a solution of hexamethylen diamine (1300 mg, 11.18 mmol) in 49 mL of dry DCM, a 
solution of di-tert-butyl-dicarbonate (488 mg, 2.24 mmol) in 6.5 mL of dry DCM was 
added dropwise in 20 minutes at -10 °C. The mixture was left in the ice-bath and was 
left to warm at room temperature. The reaction mixture was stirred overnight. Then, 
the white precipitate was filtered out and the filtrate was evaporated. The so obtain 
white solid was dissolved in 50 mL of AcOEt and the organic layer was washed with 
brine (3 x 50 mL). The organic layer was dried over Na2SO4, filtered and evaporated 
under vacuum to obtain a white solid (460 mg) in 95% yield.  The product was used 
without further purification. Spectroscopic data were previously reported.
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1
H NMR (CDCl3, 400 MHz) δ 4.54 (br. s, 1H), 3.08-3.10 (m, 2H), 2.68 (t, J = 7.0 Hz, 2H), 
1.89 (s, 2H), 1.43-1.50 (m, 13H), 1.31-1.34 (m, 4H) ppm. 
 
 
Synthesis of tert-butyl-(6-(5-(1,2-dithiolan-3-yl)pentanamido)hexyl)carbamate (2.15) 
 
 
 
To a solution of tert-butyl(6-aminohexyl)carbamate 2.14 (197 mg, 0.912 mmol) and 
DIPEA (147 mg, 1.14 mmol) in dry DCM (5 mL), a solution of 2,5-dioxopyrrolidin-1-yl 5-
(1,2-dithiolan-3-yl)pentanoate 2.12 (231 mg, 0.76 mmol) in dry DCM (5mL) was added 
under nitrogen atmosphere. The mixture was stirred overnight, than diluted with DCM 
(30 mL). The organic layer was washed with a saturated aqueous solution of NaHCO3 
(30 mL) and with water (4x30 mL). The organic layer was dried over Na2SO4 , filtered and 
evaporated under vacuum  to obtain the amide as white solid (290 mg) in 94% yield. 
The product was used without further purification. 
1
H NMR (400 MHz, CDCl3) δ 5.67 (bs, 1H, NH), 4.54 (s, 1H, NH), 3.63-3.49 (m, 1H), 3.27-
3.05 (m, 6H), 2.53-2.37 (m, 1H), 2.17 (t, J = 7Hz, 1H), 1.98-1.28 (m, 25 H) ppm. 
13
C NMR (100MHz, CDCl3) δ 172.6, 156.1, 56.4, 40.2, 39.1, 38.4, 36.5, 34.9, 34.6, 30.0, 
29.5, 28.9, 28.4, 25.4 ppm. 14 found of 19 real.  
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Synthesis of N-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexyl)-5-(1,2-dithiolan-3-
yl)pentanamide (2.10) 
 
 
 
To a solution of tert-butyl-(6-(5-(1,2-dithiolan-3-yl)pentanamido)hexyl)carbamate 2.15 
(130 mg, 0.32 mmol) in DCM (5 mL) trifluoroacetic acid (1 mL) was added dropwise at 0 
°C. The mixture was stirred at r.t. for 4 hours, then a saturated aqueous solution of 
Na2CO3 was added until pH = 7-8. The aqueous phase was extracted with DCM (3x 10 
mL). The organic layer was dried over Na2SO4, filtered and evaporated under vacuum  to 
obtain a yellowish oil. The crude product was suspended in acetic acid (1.2 mL) and 
maleic anhydride (42 mg, 0.43 mmol) was added. The mixture was stirred at 140 °C for 
3 hours. The solution was then evaporated under vacuum and residual acetic acid was 
removed by azeotroping with toluene (2 x 5 mL). ). The yellowish oil was purified by 
flash column chromatography to affors the final product as white solid (7 mg) in 5% 
yield. 
1
H NMR (400 MHz, CDCl3) δ 6.69 (s, 2H), 5.51 (br. s, NH, 1H), 3.66-3.47 (m, 3H), 3.27-
3.04 (m, 4H), 2.55-2.38 (m, 1H) 2.38-1.82 (m, 3H), 1.82-1.76 (m, 14 H) ppm. 
ESI - MS: m/z = 407.42 [M+Na]
+
. 
 
Syntesis of 2,5-dioxopyrrolidin-1-yl 3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-
yl)propanoate (2.18) 
 
To a solution of N-hydroxysuccinimide (98 mg, 0.85 mmol) and 3-(2,5-dioxo-2,5-
dihydro-1H-pyrrol-1-yl)propanoic acid (115 mg, 0.68 mmol) in dry DMF (4 mL), DIC (172 
mg, 1.36 mmol) was added dropwise at 0 °C. After 15 min. the solution was left to 
warm at room temperature and the mixture was stirred under nitrogen overnight. The 
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mixture was diluted with DCM (40 mL) and washed with water (7 x 30 mL). The organic 
layer was dried over Na2SO4, filtered and evaporated under vacuum to obtain a white 
solid (110 mg) in 61% yield. The product was used without further purification.
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1
H NMR (CDCl3, 400 MHz) δ 6.71 (s, 2H), 3.94 (t, J=7.0 Hz, 2H), 3.02 (t, J=7.0 Hz, 2H), 
2.82 (s, 4H) ppm. 
 
Synthesis of tert-butyl(6-(3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-
yl)propanamido)hexyl)carbamate (2.20) 
 
 
 
To a solution of 2,5-dioxopyrrolidin-1-yl 3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-
yl)propanoate 2.18 (200 mg, 0.75 mmol) in 7 mL of dry DMF a solution of tert-butyl(6-
aminohexyl)carbamate 2.14 (175 mg, 0.80) in 7 mL of dry DMF was added slowly under 
nitrogen atmosphere. The reaction mixture was stirred for 22 hours, than diluted with 
AcOEt and washed with a saturated aqueous solution of NaHCO3 (30 mL) and with 
water (6 x 30 mL). The organic layer was dried over Na2SO4 , filtered and evaporated 
under vacuum  to obtain a white solid (200 mg) in 73% yield, which was used without 
purification in the next step. 
1
H NMR (400 MHz, CDCl3) δ 6.69 (s, 2H), 5.91 (br.s, 1H, NH), 4.58 (br.s, 1H, NH), 3.82 (t, 
J = 7.2, 2H), 3.21-3.16 (m, 2H), 3.11-3.06 (m, 2H), 2.50 (t,  , J = 7.2, 2H), 1.41 (s, 9H), 
1.33-1.28(m, 8H) ppm. 
13
C NMR (100MHz, CDCl3) δ 170.5, 169.5, 110.5, 34.7, 34.3, 29.9, 29.2, 28.4, 26.3, 
26.09, 26.07, 26.0, 25.5 13 found of 18 real. 
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Synthesis of 6-(3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanamido)hexan-1-
aminium chloride (2.22) 
 
 
A solution of tert-butyl(6-(3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-
yl)propanamido)hexyl)carbamate 2.20 (179 mg, 0.49 mmol) in 1 mL a 3 M solution of 
HCl in methanol was stirred at room temperature for 1 hour; then the mixture was 
dried under vacuum to give a colorless oil (154 mg) in  70% yield. The product was used 
without purification. 
1
H NMR (400 MHz, CDCl3) δ 6.82 (s, 2H),3.77 (t, J = 6.8 Hz, 2H), 3.30 (quint., J = 1.6 Hz, 
2H),  3.13 (t, J = 6.8 Hz, 2H), 2.47 (t,  J = 6.8 Hz, 2H), 1.70-1.63 (m 4 H), 1.53-1.35 (m, 8H) 
ppm. 
ESI - MS: m/z = 268 [M+1]
+
, 290.33 [M+Na]
+ 
, 557.17 [2M+Na]
+ 
 
Synthesis of N-(6-(3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanamido)hexyl)-5-(1,2-
dithiolan-3-yl)pentanamide (2.19) 
 
 
 
To a solution of 6-(3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanamido)hexan-1-
aminium chloride 2.22 (335 mg, 0.953 mmol) in 7 mL of dry DMF, DIPEA (224 mg, 1.73 
mmol) and a solution of 2,5-dioxopyrrolidin-1-yl 5-(1,2-dithiolan-3-yl)pentanoate 2.12 ( 
263 mg, 0.87 mmol) in 7 mL of dry DMF were added. The solution was stirred under 
nitrogen for 20 hours. The mixture was then diluted with ethyl acetate ( 30 mL) and 
washed with a saturated aqueous solution of NaHCO3 (30 mL) and with water (6 x 30 
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mL). The organic layer was dried over Na2SO4, filtered and evaporated under vacuum. 
The crude was purified on silica gel to obtain a white solid (62 mg) in 20% yield. 
1
H NMR (400 MHz, CDCl3) δ 6.70 (s, 2H), 5.80 (bs, 1H, NH), 5.59 (bs, 1H, NH), 3.83 (t, J= 
7.2 Hz, 2H), 3.60-3.53 (m, 1H), 3.26-3.07 (m, 6H), 2.51 (t, J = 7.2 Hz, 2H), 2.49-2.13 (m, 
1H), 1.94-1.86 (m, 1H), 1.73-1.61(m, 6H), 1.51-1.43 (m, 6H), 1.34-1.29 (m, 4H) ppm.  
13
C NMR (100MHz, CDCl3) δ 172.8, 170.5, 169.5,134.2, 56.5, 40.2, 39.0, 38.7, 38.5, 36.5, 
34.7, 34.6, 34.3, 29.4, 29.2, 28.9, 25.8, 25.4 ppm. 18 found of 19 real. 
ESI - MS: m/z = 478.42 [M+Na]
+
. 
 
Synthesis of (2aR,4S,4aS,6R,11S,12S,12bS)-9-((3-benzamido-2-((11-
mercaptoundecanoyl)oxy)-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4,11-dihydroxy-
4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-
methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b-diyl diacetate (2.25) 
 
 
 
In a schlenk tube, to a solution of Taxol (145 mg, 0.17 mmol) and DMAP (4.4 mg, 0.036 
mmol) in 7 mL of dry DCM, the solution of 11-mercaptoundecanoic acid (44.5 mg, 0.2 
mmol) and DCC (41 mg, 0.2 mmol) in 7 mL of dry DCM were slowly added at 0 °C under 
nitrogen. The mixture was warmed at r.t. and stirred overnight. Then, the solution was 
diluted with DCM (30 mL) and washed with an aqueous saturated solution of NH4Cl 
(2x30 mL), a saturated aqueous solution of NaHCO3 (3x30 mL) and with an aqueous 
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saturated solution of NH4Cl (2x30 mL). The organic layer was dried over Na2SO4 , filtered 
and evaporated under vacuum. The crude was purified by column chromatography on 
silica gel to afford the final product as a white solid (130 mg, 0.123 mmol) in a 73 % 
yield. 
1
H NMR (400 MHz, CDCl3) δ 8.12 (d, J = 7.2 Hz, 2H), 7.73 ( d, J = 6.8Hz, 2H), 7.58 ( t, J = 8 
Hz, 1H), 7.53-7.48 (m, 3H), 7.43-7.31 (m, 7H), 6.91 (d, J = 8.8 Hz, 1H), 6.29 (s, 1H), 6.25 
(t, J =8.8 Hz, 1H), 5.94 (dd, J = 3.2 Hz, J =8.8 Hz, 1H), 5.67 (d, J = 6.8 Hz, 1H), 5.50 (d, J = 
3.6 Hz, 1H), 4.96 (d, J = 9.6 Hz, 1H), 4.47-4.41 (m, 1H), 4.30 (d, J = 8.4 Hz, 1H), 4.19 (d, J 
= 8.4 Hz, 1H), 3.80 (d, J = 6.8 Hz, 1H), 2.58-2.32 ( m, 11H), 2.21-2.12 ( m, 4H), 1.94-1.84 
(m, 7H), 1.63-1.53 (m, 5H), 1.37-1.22 (m, 18H) ppm.   
13
C NMR (100MHz, CDCl3) δ 203.7, 172.7, 171.2, 169.7, 168.0, 167.0, 142.7, 136.9, 
133.6, 132.7, 131.9, 130.1, 29.1, 128.9, 128.7, 128.6, 128.4, 84.4, 80.9, 79.1, 76.3, 75.5, 
75.0, 73.7, 72.1, 71.6, 58.4, 52.8, 45.5, 43.1, 35.5, 35.4, 33.9, 33.7, 29.3, 29.2, 29.1, 
28.9, 28.8, 28.3, 26.7, 24.6, 24.5, 22.6, 22.1, 20.8, 14.8, 9.5 ppm 
ESI - MS: m/z = 1075.83 [M+Na]
+
. 
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Synthesis of (2aR,4aS, 6R, 11S, 12S, 12bS)-9-((2-((11-((1-(3-((6-(5-(1,2-dithiolan-3-yl)-3-
oxopropul)2,5-dioxopyrrolidin-3-yl)thio)undecanoyl)oxy)-3-benzamido-3-
phenylpropanoyl)-12-(benzoyloxy)-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-2a, 
3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-1H-7, 11-
methanocyclodeca[3,4]benzo[1,2-b]oxete-6, 12b-diyl diacetate (2.26) 
 
In a schlenk tube to a solution of 2.25 (118 mg, 0.112 mmol) in dry DMF (10 mL) a 
solution of 2.19 (51 mg, 0.112 mmol) in dry DMF (20 mL) and triethylamine (11 mg, 
0.112 mmol) were added at room temperature under nitrogen atmosphere. The 
solution was stirred for 5 hours then quenched with water. The aqueous phase was 
extracted with DCM (3x30 mL). the organic phase was washed with water (6x30 mL) 
and a satured solution of NH4Cl (2x30 mL). The organic layer was dried over Na2SO4 , 
filtered and evaporated under vacuum  to obtain a white solid (170 mg) which was 
purified by flash column chromatography (eluent: ethyl acetate then DCM:methanol 
15:1) to obtain the product as a white solid (85 mg, 50% yield). 
1
H NMR (400 MHz, CDCl3) δ 8.11 (d, J = 7.2 Hz, 2H), 7.73 (d, J = 7.2 Hz, 2H), 7.57 (t, J =.6 
Hz, 1H), 7.52-7.47 (m, 3H), 7.41-7.30 (m, 7H), 7.00 (d, J =9.2 Hz, 1H), 6.28 (s, 1H), 6.23 
(t, J =8.8 Hz, 1H), 6.05-6.02 (m, 1H), 5.91 (dd, J1 = 9.2 Hz, J2 = 3.6 Hz, 1H), 5.79-5.76 (m, 
1H), 5.66 (d, J = 7.2 Hz, 1H), 5.47 (d, J = 3.6 Hz, 1H), 4.95 (d, J = 9.6 Hz, 1H), 4.45-4.39 
(m, 1H), 4.29 (d, J = 8.8 Hz, 1H), 4.18 (d, J = 8.4 Hz, 1H), 3.80-3.75 ( m, 3H), 3.70-3.66 (m, 
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1H), 3.57-3.50 (m, 1H), 3.23-3.06 (m, 7H), 2.88-2.80 (m, 1H), 2.75-2.68 (m, 1H), 2.60-
2.30 (m, 12H), 2.14 (t, J = 7.2 Hz, 3H), 2.03-1.98 (m, 4H), 1.92-1.82 (m, 5H), 1.69- 1.11 
(m, 39H) ppm. 
13
C NMR (100MHz, CDCl3) δ 203.8, 176.5, 174.7, 172.9, 172.8, 171.2, 169.8, 169.5, 
168.2, 167.1, 166.9, 142.7, 137.0, 133.7, 133.6, 132.7, 132.0, 130.2, 129.2, 129.0, 128.7, 
128.4, 127.1, 126.6, 110.5, 108.5, 84.4, 81.0, 79.0, 75.6, 75.1, 73.8, 72.1, 71.7, 58.4, 
56.5, 52.9, 45.6, 43.1, 40.2, 39.03, 39.02, 38.9, 38.4, 36.5, 36.1, 35.5, 35.4, 34.6, 33.71, 
33.67, 31.7, 29.4, 29.3, 29.2, 29.1, 29.0, 28.92, 28.87, 28.8, 28.7, 26.8, 25.90, 25.88, 
25.4, 24.7, 22.7, 22.1, 20.8, 14.8, 9.6 ppm. (71 found of real 79)  
ESI - MS: m/z = 1531.50 [M+Na]
+
. 
 
Synthesis of Thioctic acid-mPEG750 (2.28) 
 
 
In a schlenk tube to a solution of mPEG 750 (1.21 mmol) and DMAP in dry DCM (4 mL) a 
suspension of DCC and thioctic acid in dry DCM (6 mL) was added dropwise at 0 °C. the 
mixture was left warmed at rt and stirred under nitrogen overnight. Then the white 
precipitate was filtered off and the filtrate was evaporated. The crude was dissolved in 
ethyl acetate ( 40 mL) and washed with water (2x15mL). The organic phase was dried 
over Na2SO4, filtered and evaporated under vacuum  to obtain the final product (1.1 g; 
1.17 mmol), without further purification, in a 97% yield. 
1
H NMR (400 MHz, CDCl3) δ 4.2 (t, J = 8 Hz, 2H), 3.69-3.51 (m, 66H), 3.36 (s, 3H), 3.19-
3.06 (m, 2H), 2.45-2.38 (m, 1H), 2.33 (t, J = 8 Hz, 2H), 1.93-1.85 (m, 2H), 1.71-1.60 (m, 
5H), 1.52-1.39 (m, 2H) ppm. 
 
Brust synthesis for gold nanoparticles 
HAuCl4 x 3 H2O (40 mg, 0.10 mmol) in 20 mL H2O were transferred in 10 mL of toluene 
using TOAB (137 mg, 0.25 mmol) as phase transfer. A solution of pentanethiol (10.4 mg, 
0.10 mmol) or oleylamine (294 mg, 1.10 mmol) in 5 mL of toluene was added under 
stirring, then a cold solution of NaBH4 (54 mg, 1.43 mmol) in 3 mL of H2O was added 
under vigorous stirring. The solution became dark brown in 20 seconds. The solution 
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was stirred at room temperature for 3 hours, then water was removed and the organic 
phase was concentrate under reduce pressure until 2 mL. Methanol was added and the 
suspension was centrifugated for 15 minutes at 6000 rpm/min. The procedure was 
repeated for three times. Capped gold nanoparticles were stored in a toluene solution. 
 
Synthesis of 6-Azido-hexanoic acid (3.2 and 4.16) 
 
 
To a solution of 6-Bromo-hexanoic acid (600 mg, 3.08 mmol) in DMF (3 mL), NaN3 (601 
mg, 9.25 mmol) was added. The mixture was stirred at 85 °C for 24 h, then DCM (15 mL) 
was added, and the mixture was washed with HCl 0.1 M (15 mL) followed by water 
(6x50 mL). The organic phase was dried over Na2SO4, filtered and evaporated to give 
210 mg the azido derivative, as a yellow oil, in 43% yield. 
1
H NMR (400 MHz, CDCl3) δ 1.35-1.51 (m, 2H), 1.56-1.75 (m, 4H), 2.38 (t, J = 7.4 Hz, 2H), 
3.28 (t, J = 6.6 Hz, 2H) ppm.  
 
Synthesis of Taxol-2’-6-azide-hexanoate (3.4 and 4.13) 
 
 
To a solution of Paclitaxel (200 mg, 0.23 mmol) in dry DCM (8 mL), DMAP (6 mg, 0.05 
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mmol) was added, in a N2 atmosphere. The colourless solution was cooled at 0 °C, then 
6-azido-hexanoic acid 3.2 (44 mg, 0.28 mmol) was added, followed by DCC (58 mg, 0.28 
mmol). The reaction mixture was stirred for 24 h, at reflux, under a N2 atmosphere, 
then poured onto DCM (15 mL) and washed with a saturated solution of NH4Cl (3x40 
mL), then a saturated solution of NaHCO3 (3x40 mL) followed by a saturated solution of 
NH4Cl (3x40 mL). The recollected organic layer was dried over Na2SO4, filtered and 
evaporated to obtain a white solid (270 mg). The crude was purified by flash column 
chromatography (EP/AcOEt 1:1) to obtain 195 mg of 3.4 (4.13), as white powder, in 
85% yield. 
1
H NMR (400MHz, CDCl3) δ 1.14 (s, 3H), 1.23 (s, 3H), 1.31-1.38 (m, 4H), 1.52-1.63 (m, 
3H), 1.68 (s, 3H), 1.94 (s, 3H), 2.17 (s, 1H), 2.23 (s, 3H), 2.33-2.42 (m, 2H), 2.46 (s, 3H), 
2.48-2.60 (m, 2H), 3.21 (t, J = 6.8 Hz, 2H), 3.82 (d, J = 7.2 Hz, 1H), 4.20 (d, J = 8.8 Hz, 1H), 
4.31 (d, J = 8.8 Hz, 1H), 4.42-4.47 (m, 1H), 4.97 (d, J = 9.6 Hz, 1H), 5.51 (d, J = 3.6 Hz, 
1H), 5.68 (d, J = 7.2 Hz, 1H), 5.96 (dd, J = 12.0 Hz, J = 2.8 Hz, 1H), 6.25 (t, J = 10.0 Hz, 1H), 
6.29 (s, 1H), 6.88 (d, J = 9.2 Hz, 1H), 7.34-7.63 (m, 11H), 7.74 (d, J = 8.4 Hz, 2H), 8.13 (d, J 
= 8.4 Hz, 2H) ppm. 
 
Synthesis of 11-bromo undecenal (3.6) 
 
 
To a suspension of PCC (1280 mg; 5.98 mmol) in dry DCM (4 mL) a solution of 11-bromo 
undecanol (1000mg; 3.98 mmol) in dry DCM (4 mL) was added under nitrogen 
atmosphere. After 4 hours the solution was diluted with H2O (20 mL) and the aqueous 
phase was extracted with diethyl eter (3x20 mL). The organic phase was washed with 
H2O (20 mL) and a saturated solution of NaCl (3x20 mL). The organic phase was dried 
over Na2SO4, filtered and evaporated under reduce pressure to obtain a brown solid 
(810 mg) in 89% yield. The product was used without further purification. Spectroscopic 
data are previously reported.
154
 
1
H-NMR (200MHz, CDCl3) δ 9.75 (t, J = 1.8 Hz, 1H; CHO); 3.39 (t, J = 6.8 Hz, 2H); 2.41 (td, 
J = 7.4 Hz, J = 1.8 Hz, 2H); 1.84 (quint., 2H); 1.54-1.41 (m, 2H); 1.27 (bs, 12H) ppm. 
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Synthesis of 2-(9-bromononyl)-2-(hydroxymethyl) propane-1,3-diol (3.7) 
 
 
To a solution of 11-bromoundecanal 3.6 (160 mg; 0.642 mmol) and CH2O (0.385 mL 
37% aqueous solution) in H2O/EtOH 50/50 (2 mL) a solution of KOH (36mg; 0.642 
mmol) in H2O/EtOH 50/50 (2mL) was added at 0 °C. The mixture was stirred at room 
temperature for 20 hours and at 50 °C for 4 hours. Then, EtOH was evaporated under 
reduce pressure and the aqueous phase was extracted with diethyl eter (3x). The 
organic phase was dried over Na2SO4, filtered and evaporated under reduce pressure. 
The crude was purified by flash column chromatography using DCM : MeOH 9: 1 as 
eluent to obtain a colorless oil (100 mg) in 50%.  
1
H NMR (400MHz, CDCl3) δ 3.66 (s, 6H); 3.58 (bs; 3H, OH); 3.39 (t, J = 6.8 Hz, 2H); 1.83 
c(quint., 2H); 1.42-1.36 (m, 2H); 1.26- 1.15 (m, 12H) ppm. 
13
C NMR (400MHz, CDCl3) δ 66.4; 42.8; 34.1; 30.7; 30.5; 29.4 (2C); 28.7; 28.1; 22.9 ppm. 
ESI - MS: m/z = 333.05 [M+Na]
+
. 
 
Synthesis of 2-(11-Hydroxy-10,10-bis-hydroxymethyl-undecyl)-isoindole-1,3-dione 
(3.8) 
 
 
To a solution of 11-Bromo-2,2-bis-hydroxymethyl-undecan-1-o  3.7 (730 mg, 2.35 
mmol) in DMF dry (15 mL), potassium phthalimide (479 mg, 2.58 mmol) was added. The 
yellow reaction mixture was stirred at 90 °C for 19 h, under a N2 atmosphere. The 
reaction mixture was quenched with water (25 mL) and it was extracted with DCM 
(3x35 mL). The organic phase was washed with water (7x25 mL), dried over Na2SO4, 
filtered and evaporated to give 570 mg of compound 8, as a white solid, in 64% yield. 
Melting point: 94 °C. 
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1
H NMR (400 MHz, CDCl3) δ 1.16-1.30 (m, 14H), 1.64 (t, J = 7.2 Hz, 2H), 3.13 (s, 3H), 3.65 
(t, J = 7.2 Hz, 2H), 3.71 (s, 6H), 7.69-7.71 (m, 2H), 7.82-7.84 (m, 2H) ppm. 
13
C NMR (100 MHz, CDCl3) δ 1.0, 22.8, 26.7, 28.5, 29.0, 29.3, 30.4, 30.7, 38.0, 42.8, 66.9, 
123.1, 132.1, 133.9, 168.5 ppm. 
FT-IR (CDCl3)  3630, 3551, 2931, 2857, 1711 cm
-1
.  
 
Synthesis of 2-(11-Prop-2-ynyloxy-10,10-bis-prop-2-ynyloxymethyl-undecyl)-
isoindole-1,3-dione (3.10) 
 
 
A solution of 2-(11-Hydroxy-10,10-bis-hydroxymethyl-undecyl)-isoindole-1,3-dione 3.8 
(50 mg, 0.13 mmol) in DMF dry (1 mL) was cooled at 0 °C, under a N2 atmosphere, and 
NaH (60% in oil, 16 mg, 0.65 mmol) was added. After 15 min, propargyl bromide (72 µL, 
0.65 mmol) was added at 0 °C, dropwise. The yellow-brown solution was stirred at 0 °C 
for 45 min, then it was stirred at r.t. and then at 90 °C, under a N2 atmosphere, for 48 h. 
The reaction mixture was cooled at 0 °C, it was acidified with HCl 0.1 M (10 mL) and it 
was extracted with DCM (3x20 mL). The organic layers were collected together, washed 
with water (6x40 mL), dried over Na2SO4, filtered and evaporated to give compound 
3.10, as a yellow oil, in trace. The bis-substituted derivative 3.9 (2-(10-Hydroxymethyl-
11-prop-2-ynyloxy-10-prop-2-ynyloxymethyl-undecyl)-isoindole-1,3-dione) was isolated 
in 25% yield and characterized. 
Characterization of 3.9: 
1
H NMR (400 MHz, CDCl3) δ 1.25-1.31 (m, 12H), 1.63-1.67 (m, 4H), 2.43 (t, J = 2.4 Hz, 
2H), 2.47 (t, J = 6.0 Hz, 1H), 3.48 (d, J = 9.0 Hz, 2H), 3.52 (d, J = 9.0 Hz, 2H), 3.57 (d, J = 
6.0 Hz, 2H), 3.66 (t, J = 7.2 Hz, 2H), 4.13 (at, J = 2.0 Hz, 4H), 7.69-7.71 (m, 2H), 7.82-7.84 
(m, 2H) ppm. 
13
C NMR (100 MHz, CDCl3) δ 22.8, 26.8, 28.6, 29.1, 29.4, 30.3, 30.5, 38.1, 42.7, 58.7, 
66.9, 72.4, 74.4, 79.7, 123.1, 132.1, 133.8, 168.5 ppm. 
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FT-IR (CDCl3)  3692, 3308, 2931, 2857, 1711 cm
-1
.  
Characterization of 3.10: 
1
H NMR (400 MHz, CDCl3) δ 1.25-1.35 (m, 14H), 1.62-1.70 (m, 2H), 2.39-2.41 (m, 2H), 
3.40 (s, 6H), 3.48 (d, J = 9.0 Hz, 2H), 3.67 (t, J = 7.2 Hz, 2H), 4.11 (d, J = 2.0 Hz, 6H), 7.69-
7.72 (m, 2H), 7.83-7.85 (m, 2H) ppm. 
13
C NMR (100 MHz, CDCl3) δ 22.8, 26.9, 28.6, 29.2, 29.5, 30.4, 38.1, 42.7, 58.6, 70.1, 
70.8, 74.0, 80.2, 123.1, 132.1, 133.8, 168.5 ppm. 
FT-IR (CDCl3)  3322, 2933, 2856, 1712 cm
-1
.  
 
Synthesis of 3,4,5-Tris-prop-2-ynyloxy-benzoic acid ethyl ester (3.12) 
 
 
 
To a solution of ethyl gallate (500 mg, 2.52 mmol) in acetone dry (5 mL), K2CO3 (1.57 g, 
11.36 mmol), 18-crown-6 (3 mg, 0.01 mmol) and propargyl bromide (1.26 mL, 11.34 
mmol) were added, under a N2 atmosphere. The suspension was stirred at reflux for 72 
h. Acetone was evaporated, water (40 mL) was added and the mixture was extracted 
with DCM (3x30 mL). The organic phase was dried over Na2SO4, filtered and evaporated 
to give 830 mg of compound 3.12 in quantitative yield.  
1
H NMR (400 MHz, CD3OD) δ 1.38 (t, J = 7.2 Hz, 3H), 2.86 (t, J = 2.4 Hz, 1H), 3.00 (t, J = 
2.4 Hz, 2H), 4.36 (q, J = 7.2 Hz, 2H), 4.78 (d, J = 2.4 Hz, 2H), 4.83 (d, J = 2.4 Hz, 4H), 7.47 
(s, 2H) ppm. 
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Synthesis of 3,5-Dihydroxy-4-prop-2-ynyloxy-ethyl benzoate (3.13) 
 
 
 
To a solution of ethyl gallate (100 mg, 0.5 mmol) in acetone dry (1 mL), K2CO3 (30 mg, 
0.21 mmol), 18-crown-6 (1 mg, 0.004 mmol) and propargyl bromide (173 µL, 1.55 
mmol) were added, under a N2 atmosphere. The suspension was stirred at reflux for 24 
h. Acetone was evaporated, water (15 mL) was added and the mixture was extracted 
with DCM (3x20 mL). The organic phase was dried over Na2SO4, filtered and evaporated 
to give 100 mg of crude. This was purified by flash column chromatography 
(CHCl3/AcOEt 2:1) to give 50 mg of 3.13, as a colorless solid, in 42% yield. 
Melting point: 139 °C. 
1
H NMR (400 MHz, CD3OD) δ 1.35 (t, J = 7.2 Hz, 3H), 2.82 (t, J = 2.4 Hz, 1H), 4.29 (q, J = 
7.2 Hz, 2H), 4.84 (d, J = 2.4Hz, 2H), 4.90 (s, 2H), 7.02 (s, 2H) ppm. 
 
13
C NMR (100 MHz, CDCl3) δ 14.6, 60.0, 62.0, 76.7, 80.1, 109.9, 127.4, 138.3, 152.1, 
168.0 ppm. 
FT-IR (CDCl3)  1713, 2985, 3305, 3542, 3743 cm
-1
. 
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Synthesis of 3,5-Bis-prop-2-ynyloxy-benzoic acid methyl ester (3.17) 
 
 
 
To a solution of 3,5-Dihydroxy-benzoic acid methyl ester (412 mg, 2.38 mmol) in 
acetone dry (4 mL), K2CO3 (1.316 g, 9.52 mmol), 18-crown-6 (3 mg, 0.009 mmol) and 
propargyl bromide (1.06 mL, 9.52 mmol) were added, under a N2 atmosphere. The 
suspension was stirred at reflux for 24 h. Acetone was evaporated, water (15 mL) was 
added and the mixture was extracted with DCM (3x30 mL). The organic phase was 
dried over Na2SO4, filtered and evaporated to give 470 mg of pure product 3.17, as a 
pale yellow powder, in 81% yield. 
1
H NMR (400 MHz, CDCl3) δ 2.55 (t, J = 2.4 Hz, 2H), 3.90 (s, 3H), 4.71 (d, J = 2.4 Hz, 4H), 
6.80 (t, J = 2.4 Hz, 1H), 7.29 (d, J = 2.4 Hz, 2H) ppm. 
 
Synthesis of 4-Hydroxy-benzoic acid ethyl ester (3.18) 
 
 
 
To a solution of 4-hydroxy-benzoic acid (1.5 g, 10.86 mmol) in EtOH (10 mL), 
concentrated H2SO4 (1 mL) was added. The reaction mixture was stirred for 24 h at r.t., 
and then was stirred at reflux for 2 h. The solution was quenched with water (25 mL) 
and was extracted with Et2O (3x30 mL). The organic phase was dried over Na2SO4, 
filtered and evaporated to obtain 1.75 g of pure product 3.18, in quantitative yield. 
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1
H NMR (200 MHz, CDCl3) δ 1.38 (t, J = 7.0 Hz, 3H), 4.36 (q, J = 7.0 Hz, 2H), 6.35 (s, 1H), 
6.84-6.91 (m, 2H), 7.92-8.00 (m, 2H) ppm. 
 
Synthesis of 4-Prop-2-ynyloxy-ethyl benzoate (3.19) 
 
 
 
To a solution of 4-Hydroxy-benzoic acid ethyl ester 3.18 (500 mg, 3.01 mmol) in 
acetone dry (6 mL), K2CO3 (832 mg, 6.02 mmol), 18-crown-6 (3 mg, 0.01 mmol) and 
propargyl bromide (671 µL, 6.02 mmol) were added, under a N2 atmosphere. The 
suspension was stirred at reflux for 24 h. Acetone was evaporated, water (30 mL) was 
added and the mixture was extracted with DCM (3x30 mL).  
The organic phase was dried over Na2SO4, filtered and evaporated to give 600 mg of 
compound 3.19, as a brown oil, in quantitative yield. 
1
H NMR (200 MHz, CDCl3) δ 1.38 (t, J = 7.6 Hz, 3H), 2.55 (t, J = 2.4Hz, 1H), 4.35 (q, J = 7.6 
Hz, 2H), 4.75 (d, J = 2.4Hz, 2H), 6.99 (m, 2H), 8.02 (m, 2H) ppm. 
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Synthesis of (3,4,5-Tris-prop-2-ynyloxy-phenyl)-methanol (3.20) 
 
 
A suspension of LiAlH4 (581 mg, 22.4 mmol) in THF dry (7.5 mL) was cooled at 0 °C and a 
solution of 3,4,5-Tris-prop-2-ynyloxy-benzoic acid ethyl ester (1.4 g, 4.48 mmol) in THF 
dry (7.5 mL) was added, dropwise. The reaction mixture was stirred at r.t. overnight, 
under a N2 atmosphere. Then the mixture was cooled at 0 °C and a saturated solution 
of NH4Cl (30 mL) was added. Then it was acidified to pH=2 with HCl 10%. The mixture 
was extracted with DCM (3x40 mL), dried over Na2SO4, filtered and evaporated to give 
1.15 g of compound 3.20 in 95% yield. 
1
H NMR (200 MHz, CDCl3) δ 2.45 (t, J = 2.4 Hz, 1H), 2.51 (t, J = 2.4 Hz, 2H), 4.64 (s, 1H, 
OH), 4.72 (d, J = 2.4 Hz, 2H), 4.76 (d, J = 2.4 Hz, 4H), 6.77 (s, 2H) ppm. 
 
Synthesis of 5-Chloromethyl-1,2,3-tris-prop-2-ynyloxy-benzene (3.21) 
 
 
 
To a suspension of (3,4,5-Tris-prop-2-ynyloxy-phenyl)-methanol 3.20 (400 mg, 1.48 
mmol) in Et2O dry (1 mL), a solution of pyridine (5 µL, 0.07 mmol) and SOCl2 (129 µL, 
1.78 mmol) in Et2O dry (0.5 mL) was added, dropwise. The reaction mixture was stirred 
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at reflux for 1 h, and then a solution of pyridine (5 µL, 0.07 mmol) and SOCl2 (129 µL, 
1.78 mmol) in Et2O dry (0.5 mL) was added, dropwise. The reaction mixture was stirred 
at reflux for 3 h and then it was poured onto water (15 mL) and was extracted with Et2O 
(3x25 mL). The organic phase was washed with water (20 mL), dried over Na2SO4, 
filtered and evaporated to gain 390 mg of 3.21, as a brown oil in 91% yield.  
1
H NMR (200 MHz, CDCl3) δ 2.47 (t, J = 2.4 Hz, 1H), 2.53 (t, J = 2.4 Hz, 2H), 4.54 (s, 2H), 
4.73 (d, J = 2.4 Hz, 2H), 4.77 (d, J = 2.4 Hz, 4H), 6.80 (s, 2H) ppm. 
 
Synthesis of 1-(3,4,5-Tris-prop-2-ynyloxy-benzyl)-pyrrole-2,5-dione (3.24) 
 
 
A solution of PPh3 (89 mg, 0.34 mmol) in THF dry (2 mL) was cooled at 0 °C and DIAD 
(67 µL 0.34 mmol) was added dropwise. After 5 minutes a solution of (3,4,5-Tris-prop-
2-ynyloxy-phenyl)-methanol 3.20 (100 mg, 0.37 mmol) in THF dry (1 mL) was added, 
followed by the addition of a solution of maleimide (33 mg, 0.34 mmol) in THF dry (2 
mL), after 10 minutes. The flask was placed in microwave reactor. Microwave 
irradiation was performed at 80 °C for 30 min and then at 100 °C for 1 h. THF was 
evaporated obtaining 330 mg of a brown oil. The crude was purified by flash column 
chromatography (DCM/AcOEt 30:1) to obtain 27 mg of 3.24, a colorless solid as pure 
product, in 22% yield.  
Melting point: 120 °C. 
1
H NMR (400 MHz, CDCl3) δ 2.45 (t, J = 2.4 Hz, 1H), 2.51 (t, J = 2.4 Hz, 2H), 4.60 (s, 2H), 
4.68 (d, J = 2.4 Hz, 2H), 4.73 (d, J = 2.4 Hz, 4H), 6.72 (s, 2H), 6.75 (s, 2H) ppm.  
13
C NMR (100 MHz, CDCl3) δ 41.4, 57.0, 60.3, 75.2, 76.0, 78.2, 79.1, 108.8, 132.3, 134.2, 
136.7, 151.5, 170.2 ppm. 
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FT-IR (CDCl3)  1711, 3308 cm
-1
. 
ESI - MS: m/z = 372.17 [M+Na]
+
. 
 
Synthesis of 1-(4-Prop-2-ynyloxy-benzyl)-pyrrole-2,5-dione (3.25) 
 
 
 
A suspension of LiAlH4 (344 mg, 9.05 mmol) in THF dry (2 mL) was cooled at 0 °C and a 
solution of 4-Prop-2-ynyloxy- ethyl benzoate 3.19 (369 mg, 1.81 mmol) in THF dry (2 
mL) was added, dropwise. The reaction mixture was stirred at r.t. overnight, under a N2 
atmosphere. Then the mixture was cooled at 0 °C and a saturated solution of NH4Cl 
(15mL) was added. Then it was acidified to pH=2 with HCl 10% and was extracted with 
DCM (3x20 mL), dried over Na2SO4, filtered and evaporated to give 280 mg of the 
corresponding alcohol derivative ((4-Prop-2-ynyloxy-phenyl)-methanol) in 95% yield. 
1
H NMR (200 MHz, CDCl3) δ 2.52 (t, J = 2.4 Hz, 1H), 4.64 (s, 1H), 4.70 (d, J = 2.4 Hz, 2H), 
6.95-7.02 (m, 2H), 7.30-7.35 (m, 2H) ppm. 
A solution of PPh3 (267 mg, 1.02 mmol) in THF dry (2 mL) was cooled at 0 °C and DIAD 
(200 µL, 1.02 mmol) was added, dropwise. After 5 min a solution of (4-Prop-2-ynyloxy-
phenyl)-methanol (153 mg, 0.94 mmol) in THF dry (1 mL) was added, followed by the 
addition of a solution of maleimide (82 mg, 0.85 mmol) in THF dry (2 mL) after 10 min. 
The flask was placed in microwave reactor. Microwave irradiation was performed at 
100 °C for 1 h and then at 120 °C for 45 min. THF was evaporated obtaining 730 mg of a 
brown oil. The crude was purified by flash column chromatography (DCM) to obtain 43 
mg of 3.25, a colorless solid as pure product in 21% yield.  
Melting point: 109 °C. 
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1
H NMR (400 MHz, CDCl3) δ 2.50 (t, J = 2.0 Hz, 1H), 4.61 (s, 2H), 4.66 (d, J = 2.0 Hz, 2H), 
6.69 (s, 2H), 6.91 (d, J = 8.8 Hz, 2H), 7.30 (d, J = 8.8 Hz, 2H) ppm. 
13
C NMR (100 MHz, CDCl3) δ 40.7, 55.7, 75.6, 78.4, 114.9, 129.3, 129.8, 134.1, 157.1, 
170.4 ppm.  
FT-IR (CDCl3)  1711, 1732, 2258, 3308 cm
-1
. 
 
Synthesis of 1-(3,5-Bis-prop-2-ynyloxy-benzyl)-pyrrole-2,5-dione (3.26) 
 
 
 
A suspension of LiAlH4 (250 mg, 6.55 mmol) in THF dry (2 mL) was cooled at 0 °C and a 
solution of 3,5-Bis-prop-2-ynyloxy-benzoic acid methyl ester 3.17 (320 mg, 1.31 mmol) 
in THF dry (3 mL) was added, dropwise. The reaction mixture was stirred at r.t. 
overnight, under a N2 atmosphere. Then the mixture was cooled at 0 °C and a saturated 
solution of NH4Cl (15 mL) was added. Then it was acidified to pH=2 with HCl 10%. The 
mixture was extracted with DCM (3x20 mL), dried over Na2SO4, filtered and evaporated 
to give 280 mg of crude. This was purified by flash column chromatography (DCM/Et2O 
10:1) to give 250 mg of the corresponding alcohol (1-(3,5-Bis-prop-2-ynyloxy-benzyl)-
pyrrole-2,5-dione) in 88% yield.  
1
H NMR (200 MHz, CDCl3) δ 2.53 (t, J = 2.4 Hz, 2H), 4.63 (s, 2H), 4.67 (d, J = 2.4 Hz, 4H), 
6.53 (t, J = 2.4 Hz, 1H), 6.62 (d, J = 2.4 Hz, 2H) ppm. 
A solution of PPh3 (115 mg, 0.55 mmol) in THF dry (2 mL) was cooled at 0 °C and DIAD 
(108 µL, 0.55 mmol) was added, dropwise. After 5 min a solution of (3,5-Bis-prop-2-
ynyloxy-phenyl)-methanol (110 mg, 0.51 mmol) in THF dry (1 mL) was added, followed 
by the addition of the solution of maleimide (45 mg, 0.46 mmol) in THF dry (2 mL) after 
10 min. The flask was placed in microwave reactor. Microwave irradiation was 
performed at 120 °C for 1h and then at 120 °C for 20 min. THF was evaporated 
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obtaining 420 mg of crude. This was purified by flash column chromatography (DCM) to 
obtain 39 mg of 3.26 as pure product in 29% yield.  
Melting point: 127 °C. 
1
H NMR (400 MHz, CDCl3) δ 2.52 (t, J = 2.4 Hz, 2H), 4.61 (s, 2H), 4.65 (d, J = 2.4 Hz, 4H), 
6.52 (t, J = 2.0 Hz, 1H), 6.58 (d, J = 2.0 Hz, 2H), 6.71 (s, 2H) ppm. 
13
C NMR (100 MHz, CDCl3) δ 41.2, 55.9, 75.8, 78.1, 101.4, 107.8, 134.2, 138.4, 158.7, 
170.2 ppm. 
FT-IR (CDCl3)  1713, 2254, 3155, 3308 cm
-1
. 
ESI - MS: m/z = 318.25 [M+Na]
+
. 
 
Synthesis of Taxol-ethyl benzoate-adduct (3.27) 
 
 
 
To a solution of 4-Prop-2-ynyloxy-ethyl benzoate 3.19 (134 mg, 0.07 mmol) in DMF (1 
mL), CuSO4 (0.5 mg, 0.003 mmol) and sodium ascorbate (1 mg, 0.006 mmol) were 
added. After 5 min, a solution of taxol-2’-6-azide-hexanoate 3.4 (33 mg, 0.03 mmol) in 
DMF dry (1 mL) was added. The solution was stirred for 24 h. Then water (0.5 mL), 
CuSO4 (0.5 mg, 0.003 mmol) and sodium ascorbate (1 mg, 0.006 mmol) were added. 
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After 7 h, the reaction mixture was poured onto water (25 mL) and was extracted with 
DCM (3x30 mL). The organic phase was washed with water (7x25 mL), dried over 
Na2SO4, filtered and evaporated to give 30 mg of crude. The crude was purified by flash 
column chromatography (AcOEt/EP 1:1) to obtain 20 mg of pure product 3.27 as a 
white solid in 48% yield.  
Melting point: 201 °C.  
1
H NMR (400 MHz, CDCl3) δ 1.13 (s, 3H), 1.23 (s, 3H), 1.25-1.31 (m, 2H), 1.36 (t, J = 6.8 
Hz, 2H), 1.57-1.64 (m, 2H), 1.68 (s, 3H), 1.82-1.89 (m, 2H), 1.93 (s, 3H), 2.08-2.14 (m, 
3H), 2.22 (s, 3H), 2.29-2.41 (m, 3H), 2.44 (s, 3H), 2.51-2.59 (m, 3H), 3.80 (d, J = 6.8 Hz, 
1H), 4.19-4.21 (m, 1H), 4.25-4.35 (m, 4H), 4.41-4.47 (m, 1H), 4.96 (d, J = 8.8 Hz, 1H), 
5.24 (s, 2H), 5.49 (d, J = 4.0 Hz, 1H), 5.68 (d, J = 7.2 Hz, 1H), 5.96 (dd,  J = 9.6 Hz, J = 4.0 
Hz, 1H), 6.22 (t, J = 8.0 Hz, 1H), 6.29 (s, 1H), 6.99 (d, J = 8.8 Hz, 2H), 7.05 (d, J = 9.2 Hz, 
1H), 7.31-7.62 (m, 10H), 7.72 (d, J = 7.2 Hz, 2H), 7.98 (d, J = 8.8 Hz, 2H), 8.13 (d, J = 6.8 
Hz, 2H) ppm. 
13
C NMR (100 MHz, CDCl3) δ 9.6, 14.3, 14.7, 20.8, 22.1, 22.6, 23.8, 25.5, 26.7, 29.6, 33.3, 
35.5, 43.1, 45.5, 49.9, 52.8, 58.4, 60.7, 62.0, 71.8, 72.0, 74.0, 75.0, 75.5, 76.4, 79.1, 
81.0, 84.4, 114.3, 122.6, 123.5, 126.5, 127.0, 128.4, 128.6, 129.0, 129.2, 130.2, 131.5, 
131.9, 132.8, 133.6, 136.9, 142.6, 143.5, 161.7, 166.2, 166.9, 167.1, 168.1, 169.8, 171.1, 
172.2, 203.7 ppm.  
FT-IR (CDCl3)  1715, 2947, 3447 cm
-1
.  
ESI - MS: m/z = 1219.42 [M+Na]
+
. 
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Synthesis of Mono-Taxol-Maleimide adduct (29) 
 
 
To a solution of 1-(4-Prop-2-ynyloxy-benzyl)-pyrrole-2,5-dione 3.25 (10 mg, 0.04 mmol) 
in DMF (2 mL) CuSO4 (1 mg, 0.006 mmol) and sodium ascorbate (2 mg, 0.01 mmol) were 
added. After 5 min, a solution of taxol-2’-6-azide-hexanoate 3.4 (49 mg, 0.05 mmol) in 
DMF (2 mL) and water (1.5 mL) were added. The solution was stirred at r.t. for 24 h. 
The reaction mixture was poured onto water (25 mL) and was extracted with DCM 
(3x30 mL). The organic phase was washed with water (7x25 mL), dried over Na2SO4, 
filtered and evaporated to give 50 mg of crude. The crude was purified by flash column 
chromatography (AcOEt/EP 5:1) to obtain 21 mg of pure product (3.28) as a white solid 
in 42% yield. 
1
H NMR (400 MHz, CDCl3) δ 1.13 (s, 3H), 1.23 (s, 3H), 1.25-1.31 (m, 3H), 1.57-1.64 (m, 
2H), 1.68 (s, 3H), 1.82-1.89 (m, 3H), 1.93 (s, 3H), 2.08-2.14 (m, 1H), 2.22 (s, 3H), 2.29-
2.41 (m, 3H), 2.44 (s, 3H), 2.51-2.59 (m, 2H), 3.80 (d, J = 6.8 Hz, 1H), 4.18-4.32 (m, 4H), 
4.41-4.47 (m, 1H), 4.60 (s, 2H), 4.96 (d, J = 8.8 Hz, 1H), 5.16 (s, 2H), 5.49 (d, J = 4.0 Hz, 
1H), 5.68 (d, J = 7.2 Hz, 1H), 5.96 (dd,  J = 9.6 Hz, J = 4.0 Hz, 1H), 6.22 (t, J = 8.0 Hz, 1H), 
6.29 (s, 1H), 6.67 (s, 2H), 6.90 (d, J = 8.8 Hz, 2H), 7.07 (d, J = 9.2 Hz, 1H), 7.28-7.63 (m, 
12H), 7.72 (d, J = 7.2 Hz, 2H), 8.13 (d, J = 7.2 Hz, 2H) ppm. 
13
C NMR (100 MHz, CDCl3) δ 9.5, 14.7, 20.8, 22.1, 22.6, 23.8, 25.5, 26.7, 29.6, 33.3, 
35.50, 35.52, 40.7, 43.1, 45.5, 49.8, 52.8, 58.4, 62.0, 71.7, 72.0, 74.0, 75.0, 75.5, 76.4, 
79.0, 81.0, 84.4, 114.8, 122.5, 126.5, 127.0, 128.4, 128.6, 129.04, 129.08, 129.1, 129.8, 
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130.1, 131.9, 132.7, 133.64, 133.67, 134.1, 136.8, 142.6, 144.1, 157.7, 166.9, 167.1, 
168.1, 169.8, 170.4, 171.1, 172.2, 203.7 ppm.  
ESI - MS: m/z = 1256.42 [M+Na]
+
. 
 
Synthesis of 3,4-Bis-prop-2-ynyloxy-benzoic acid ethyl ester (3.31) 
 
 
To a solution of 3,4-Dihydroxy-benzoic acid ethyl ester (258 mg, 1.42 mmol) in acetone 
dry (4 mL), K2CO3 (782 mg, 5.66 mmol), 18-crown-6 (2 mg, 0.007 mmol) and propargyl 
bromide (630 µL, 5.66 mmol) were added, under a N2 atmosphere. The suspension was 
stirred at reflux for 24 h. Acetone was evaporated, water (15 mL) was added and the 
mixture was extracted with DCM (3x30 mL). The organic phase was dried over Na2SO4, 
filtered and evaporated to give 380 mg of crude. This was purified by flash column 
chromatography (ACOEt/EP 1:1) to gain 297 mg of pure product (3.31) in 81% yield. 
1
H NMR (400 MHz, CDCl3) δ 1.37 (t, J = 7.2 Hz, 3H), 2.53 (t, J = 2.4 Hz, 2H), 4.35 (q, J = 
7.2 Hz, 2H), 4.80 (d, J = 2.4 Hz, 2H), 4.81 (d, J = 2.4 Hz, 2H), 7.06 (d, J = 9.2 Hz, 1H), 7.71-
7.73 (m, 2H) ppm.  
13
C NMR (100 MHz, CDCl3) δ 14.3, 56.6, 56.9, 60.9, 76.2, 76.4, 77.7, 77.9, 113.1, 115.4, 
124.0, 124.2, 146.8, 151.2, 166.0 ppm. 
FT-IR (CDCl3)  1718, 2857, 2935, 3437 cm
-1
. 
ESI - MS: m/z = 208.08 [M+Na]
+
. 
 
 
 
 134 
 
Synthesis of 6-Azido-hexanoic acid ethyl ester (3.32) 
 
 
To a solution of 6-Azido-hexanoic acid (93 mg, 0.59 mmol) in EtOH (2 mL), concentrated 
H2SO4 (2 drops) was added. The reaction mixture was stirred for 24 h at r.t. The solution 
was quenched with water (15 mL) and was extracted with DCM (2x25 mL). The organic 
phase was dried over Na2SO4, filtered and evaporated to obtain 81 mg of pure product 
(33), as a colorless oil in 75% yield. 
1
H NMR (400 MHz, CDCl3) δ 1.25 (t, J = 7.2 Hz, 3H), 1.36-1.44 (m, 2H), 1.57-1.69 (m, 4H), 
2.30 (t, J = 7.6 Hz, 2H), 3.26 (t, J = 7.2 Hz, 2H), 4.12 (q, J = 7.2 Hz, 2H) ppm. 
13
C NMR (100 MHz, CDCl3) δ 14.2, 24.4, 26.2, 28.5, 34.1, 51.2, 60.2, 173.4 ppm. 
FT-IR (CDCl3)  1727, 2100, 2868, 2942, 2983 cm
-1
. 
 
Synthesis of 3,4-Bis-[1-(5-ethoxycarbonyl-pentyl)-1H-[1,2,3]triazol-4-ylmethoxy]-
benzoic acid ethyl ester (3.33) 
 
 
To a solution of 3,4-Bis-prop-2-ynyloxy-benzoic acid ethyl ester 3.31 (30 mg, 0.12 
mmol) in DMF (3 mL) CuSO4 (4 mg, 0.024 mmol) and sodium ascorbate (9 mg, 0.05 
mmol) were added. After 5 min, a solution of 6-Azido-hexanoic acid ethyl ester 3.32 (56 
mg, 0.30 mmol) in DMF (3 mL) and water (1 mL) were added. The solution was stirred 
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at r.t. for 24 h. The reaction mixture was poured onto water (15 mL) and was extracted 
with DCM (3x25 mL). The organic phase was washed with water (7x25 mL), dried over 
Na2SO4, filtered and evaporated to give 47 mg of crude. The crude was purified by flash 
column chromatography (AcOEt/EP 2:1) to obtain 36 mg of pure product (3.33), as a 
white solid, in 48% yield. 
1
H NMR (400 MHz, CDCl3) δ 1.22 (2t, J = 7.2 Hz, 6H), 1.30-1.35 (m, 4H), 1.36 (t, J = 7.2 
Hz, 3H), 1.60-1.69 (m, 4H), 1.84-1.95 (m, 4H), 2.27 (2d, J = 7.2 Hz, 4H), 4.09 (2q, J = 7.2 
Hz, 4H), 4.30-4.36 (m, 6H), 5.26 (s, 2H), 5.30 (s, 2H), 7.06 (d, J = 8.4 Hz, 1H), 7.66-7.69 
(m, 4H) ppm. 
13
C NMR (100 MHz, CDCl3) δ 14.2, 14.3, 24.2, 25.9, 29.90, 29.94, 33.9, 50.09, 50.14, 
60.3, 60.9, 63.2, 63.6, 113.7, 116.2, 122.9, 123.0, 123.9, 124.5, 143.5, 143.6, 147.8, 
152.4, 166.0, 173.3 ppm.  
FT-IR (CDCl3)  1724, 2248, 2871, 2942, 2983 cm
-1
. 
ESI - MS: m/z = 651.33 [M+Na]
+
. 
 
Synthesis of 1-(3,4-Bis-prop-2-ynyloxy-benzyl)-pyrrole-2,5-dione (3.34) 
 
 
 
A suspension of LiAlH4 (160 mg, 4.21 mmol) in THF dry (4 mL) was cooled at 0 °C and a 
solution of 3,4-Bis-prop-2-ynyloxy-benzoic acid ethyl ester (140 mg, 0.54 mmol) in THF 
dry (4 mL) was added, dropwise. The reaction mixture was stirred at r.t. overnight, 
under a N2 atmosphere. Then the mixture was cooled at 0 °C and a saturated solution 
of NH4Cl (15 mL) was added. Then it was acidified to pH=2 with HCl 10%. The mixture 
was extracted with DCM (3x20 mL), dried over Na2SO4, filtered and evaporated to give 
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130 mg of crude. The crude was purified by flash column chromatography (DCM/MeOH 
20:1) to gain 70 mg of the corresponding alcohol ((3,4-Bis-prop-2-ynyloxy-phenyl)-
methanol), as a white solid, in 42% yield. 
1
H NMR (200 MHz, CDCl3) δ 2.49-2.52 (m, 2H), 4.63 (d, J = 5.0 Hz, 2H), 4.76 (at, J = 2.2 
Hz, 4H), 6.97-7.09 (m, 3H) ppm. 
A solution of PPh3 (92 mg, 0.35 mmol) in THF dry (1 mL) was cooled at 0 °C and DIAD 
(70 µL, 0.35 mmol) was added dropwise. After 5 min, a solution of (3,5-Bis-prop-2-
ynyloxy-phenyl)-methanol (70 mg, 0.32 mmol) in THF dry (2 mL) was added, followed 
by the addition of the solution of maleimide (29 mg, 0.29 mmol) in THF dry (2 mL) after 
10 min. The flask was placed in microwave reactor. Microwave irradiation was 
performed at 120 °C for 1 h and then at 120 °C for 20 min. THF was evaporated 
obtaining 280 mg of crude. This was purified by flash column chromatography 
(DCM/Et2O 10:1) to obtain 28 mg of a yellow solid as pure product (3.34) in 33% yield. 
1
H NMR (400 MHz, CDCl3) δ 2.49 (t, J = 2.4 Hz, 1H), 2.51 (t, J = 2.4 Hz, 1H), 4.61 (s, 2H), 
4.72 (d, J = 2.4 Hz, 2H), 4.73 (d, J = 2.4 Hz, 2H), 6.69 (s, 2H), 6.96-6.97 (m ,2H), 7.06 (d, J 
= 1.2 Hz, 1H) ppm. 
13
C NMR (100 MHz, CDCl3) δ 41.0, 56.8, 56.9, 75.9, 76.0, 78.2, 78.4, 114.7, 115.3, 122.2, 
130.1, 134.2, 147.1, 147.4, 170.3 ppm. 
FT-IR (CDCl3)  1711, 1732, 3307 cm
-1
. 
ESI - MS: m/z = 318.17 [M+Na]
+
. 
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Synthesis of Bis-Taxol-Maleimide adduct (3.35) 
 
 
 
To a solution of 1-(3,4-Bis-prop-2-ynyloxy-benzyl)-pyrrole-2,5-dione 3.34 (15 mg, 0.05 
mmol) in DMF (1.5 mL), CuSO4 (1 mg, 0.007 mmol) and sodium ascorbate (4 mg, 0.02 
mmol) were added. After 5 min, a solution of taxol-2’-6-azide-hexanoate 3.4 (97 mg, 
0.10 mmol) in DMF (1.5 mL) and water (1 mL) were added. The solution was stirred at 
r.t. for 24 h. The reaction mixture was poured onto water (20 mL) and was extracted 
with DCM (3x20 mL). The organic phase was washed with water (7x25 mL), dried over 
Na2SO4, filtered and evaporated to give 90 mg of crude. The crude was purified by flash 
column chromatography (AcOEt/EP 5:1  AcOEt), to obtain 27 mg of pure product 
(3.35) as a brown solid in 23% yield. 
1
H NMR (400 MHz, CDCl3) δ 1.12-1.25 (m, 18H), 1.56-1.75 (m, 10H), 1.75 -1.92 (m, 16H), 
2.04-2.10 (m, 4H), 2.20 (s, 6H), 2.26- 2.37 (m, 6H), 2.43 (s, 6H), 2.49-2.62 (m, 4H), 3.79 
(d, J = 7.2 Hz, 2H), 4.18 (d, J = 7.6 Hz, 2H), 4.29 (d, J = 8.4 Hz, 2H), 4.41-4.46 (m, 2H), 
4.55 (s, 2H), 4.95 (d, J = 9.6 Hz, 2H), 5.17 (s, 1H), 5.19 (s, 1H), 5.50 (d, J = 4.0 Hz, 2H), 
5.66 (d, J = 6.8 Hz, 2H), 5.94 (dd, J = 4.0 Hz, J = 9.2 Hz, 2H), 6.20 (t, J = 8.0 Hz, 2H), 6.29 
(s, 2H), 6.66 (s, 2H), 6.93-6.95 (m, 1H), 7.15-7.18 (m, 2H), 7.29-7.63 (m, 24H), 7.71 (d, J = 
7.6 Hz, 4H), 8.12 (d, J = 7.2 Hz, 4H) ppm. 
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13
C NMR (100 MHz, CDCl3) δ 9.6, 14.8, 20.8, 22.1, 22.7, 23.8, 25.5, 26.8, 29.6, 33.3, 35.4, 
35.6, 43.1, 45.6, 49.8, 53.0, 58.4, 71.7, 72.0, 74.1, 75.0, 75.6, 79.1, 81.0, 84.4, 126.7, 
127.1, 128.5, 128.6, 128.7, 129.0, 129.2, 130.2, 131.9, 132.8, 133.6, 133.7, 134.2, 137.0, 
142.7, 167.0, 167.1, 168.2, 169.8, 170.4, 171.1, 172.3, 203.7 ppm. 
Ft-IR (CDCl3)  1713, 2248, 2258, 2944, 3447, 3524, 3567 cm
-1
. 
ESI - MS: m/z = 2303.88 [M+Na]
+
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 139 
 
Synthesis of Tri-Taxol-Maleimide adduct (3.36) 
 
 
To a solution of 1-(3,4,5-Tris-prop-2-ynyloxy-benzyl)-pyrrole-2,5-dione 3.24 (8 mg, 0.02 
mmol) in DMF (3 mL), CuSO4 (1 mg, 0.007 mmol) and sodium ascorbate (3 mg, 0.01 
mmol) were added. After 5 min, a solution of taxol-2’-6-azide-hexanoate 3.4 (90 mg, 
0.09 mmol) in DMF (3 mL) and water (1.5 mL) were added. The solution was stirred at 
r.t. for 48 h. The reaction mixture was poured onto water (25 mL) and was extracted 
with DCM (3x30 mL). The organic phase was washed with water (7x25 mL), dried over 
Na2SO4, filtered and evaporated to give 40 mg of crude. The crude was purified by flash 
column chromatography (DCM/MeOH 10:1), to obtain 12 mg of pure product as a 
white solid in 16% yield. 
1
H NMR (400 MHz, CDCl3) δ 1.12 (s, 9H), 1.25 (s, 9H), 1.25-1.40 (m, 6H), 1.54-1.62 (m, 
6H), 1.66-1.96 (m, 12H), 1.79-1.87 (m, 4H), 1.91 (s, 9H), 2.05-2.11 (m, 3H), 2.20 (s, 9H), 
2.25-2.36 (m, 9H), 2.42 (s, 9H), 2.49-2.66 (m, 6H), 3.42-3.50 (m, 3H), 3.78 (d, J = 7.2 Hz, 
3H), 4.09-4.31 (m, 15H), 4.40-4.53 (m, 3H), 4.95 (d, J = 9.6 Hz, 3H), 5.07-5.15 (m, 4H), 
5.48 (d, J = 4.0 Hz, 3H), 5.66 (d, J = 6.8 Hz, 3H), 5.93 (dd, J = 6.8 Hz, J = 4.4 Hz, 3H), 6.17-
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6.23 (m, 3H), 6.29 (s, 3H), 6.66 (s, 2H), 6.69 (s, 2H), 7.31-7.53 (m, 27H), 7.59-7.73 (m, 
12H), 8.12 (d, J = 8.4 Hz, 6H) ppm.  
13
C (100 MHz, CDCl3) δ 9.6, 14.8, 20.8, 22.05, 22.08, 22.7, 23.8, 24.9, 25.5, 26.7, 29.60, 
29.64, 29.68, 33.2, 33.9, 43.1, 49.1, 49.8, 58.4, 75.5, 79.0, 80.9, 84.3, 84.4, 126.7, 127.1, 
128.64, 128.69, 129.0, 129.1, 130.1, 133.6, 136.9, 166.9, 167.1, 168.2, 169.8, 170.3, 
171.1, 172.3, 203.7 
Ft-IR (CDCl3)  1713, 2801, 2860, 3308, 3435 cm
-1
.  
ESI - MS: m/z = 1665.17 [(M+2H)/2]
+
. 
 
Synthesis of 6-Bromo-hexanoic acid benzyl-[(4-bromo-phenyl)-cyclohexylcarbamoyl-
methyl]-amide (4.6) 
 
To a solution of cyclohexyl isocyanide (20 mg, 0.18 mmol), 4-Bromo-benzaldehyde (113 
mg, 0.61 mmol), 6-Bromo-hexanoic acid (37 mg, 0.19 mmol) in MeOH (1 mL), 
benzylamine (13 µL, 0.12 mmol) was added, dropwise. The reaction mixture was stirred 
at r.t. for 1h. MeOH was evaporated to obtain 150 mg of crude. The crude was purified 
by flash column chromatography (EP/AcOEt 3:1  2:1) to gain 40 mg of 4.6, as a pink 
solid, in 58% yield. 
Melting point: 127 °C. 
1
H NMR (400 MHz, CDCl3) δ 1.01-1.15 (m, 3H), 1.24-1.40 (m, 4H), 1.56-1.86 (m, 9H), 
2.32-2.40 (m, 1H), 2.21-2.29 (m, 1H), 3.34 (t, J = 6.8 Hz, 2H), 3.72-3.79 (m, 1H), 4.51 (d, J 
= 17.6 Hz, 1H), 4.72 (d, J = 17.6 Hz, 1H), 5.78 (d, J = 7.6 Hz, 1H), 5.85 (s, 1H), 6.98 (d, J = 
8 Hz, 2H), 7.18-7.22 (m, 5H), 7.36 (d, J = 8 Hz, 2H) ppm. 
13
C NMR (100 MHz, CDCl3) δ 24.2, 24.65, 24.71, 25.4, 27.7, 32.4, 32.68, 32.74, 33.6, 
33.7, 48.6, 50.1, 62.2, 108.5, 110.4, 122.6, 126.0, 127.1, 128.4, 131.2, 131.7, 134.2, 
137.3, 168.2, 174.6 ppm. 
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ESI - MS: m/z = 577.42 [M-H]
-
. 
 
Synthesis of N-Benzyl-N-[(4-bromo-phenyl)-cyclohexylcarbamoyl-methyl]-3-(2,5-
dioxo-2,5-dihydro-pyrrol-1-yl)-propionamide (4.10) 
 
 
 
To a solution of cyclohexyl isocyanide (20 mg, 0.18 mmol), 4-Bromo-benzaldehyde (113 
mg, 0.61 mmol), 3-(2,5-Dioxo-2,5-dihydro-pyrrol-1-yl)-propionic acid 4.9 (32 mg, 0.19 
mmol) in MeOH (1 mL), benzylamine (13 µL, 0.12 mmol) was added, dropwise. The 
reaction mixture was stirred at r.t. for 1h. MeOH was evaporated to obtain 170 mg of 
crude. The crude was purified by flash column chromatography (EP/AcOEt 1:1) to gain 
40 mg of 4.10, as a white solid, in 60% yield. 
Melting point: 190 °C 
1
H NMR (400 MHz, CDCl3) δ 1.01-1.16 (m, 3H), 1.27-1.37 (m, 2H), 1.56-1.69 (m, 4H), 
1.85-1.88 (m, 2H), 2.51-2.59 (m, 1H), 2.67-2.75 (m, 1H), 3.70-3.77 (m, 1H), 3.81 (t, J = 
7.2 Hz, 1H), 4.50 (d, J = 17.6 Hz, 1H), 4.68 (d, J = 17.6 Hz, 1H), 5.70 (d, J = 8 Hz, 1H), 5.88 
(s, 1H), 6.64 (s, 2H), 6.93 (d, J = 6.8 Hz, 2H), 7.16-7.21 (m, 5H), 7.35 (d, J = 8.4 Hz, 2H) 
ppm. 
13
C NMR (100 MHz, CDCl3) δ 24.7, 24.8, 25.4, 32.1, 32.69, 32.72, 34.1, 28.7, 49.9, 61.7, 
122.7, 125.9, 127.1, 128.5, 131.3, 131.7, 134.0, 134.1, 136.8, 167.9, 170.4, 171.9 ppm. 
FT-IR (CDCl3)  1711, 2248, 2857, 2936, 3424 cm
-1
. 
ESI - MS: m/z = 1126.75 [2M+Na]
+
. 
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Synthesis of 3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanoic acid (4.9) 
 
 
A suspension of maleic anhydride (1.50 g, 16.84 mmol) and β-alanine (1.65 g, 16.84 
mmol) in 45 mL of acetic acid was heated at reflux (bath temperature: 140 °C) for 90 
min., then stirred at r.t. for 16 h. The solution was refluxed again for 4h. The solution 
was then evaporated under vacuum and residual AcOH was removed by azeotroping 
with toluene (2 x 50 mL). The yellowish oil was dissolved in 50 mL of water and 
extracted with AcOEt (4 x 50 mL). The combined organic layers were dried over Na2SO4, 
filtered and evaporated to obtain a yellow powder. The crude residue was crystallized 
(AcOEt, 50 mL, 7° C) and washed with cold AcOEt (2 x 5 mL) to give desired compound 
as white solid in 50 % yield, without purification. 
1
H and 
13
C NMR spectra are reported in literature
155
 
1
H NMR (500 MHz, CDCl3) δ 6.72 (s, 2 H), 3.83 (t, J =7.2 Hz, 2 H), 2.70 (t, J = 7.2 Hz, 2 H) 
ppm. 
 
Synthesis of 4-Prop-2-ynyloxy-benzaldehyde (4.12) 
 
 
 
To a solution of 4-Hydroxy-benzaldehyde (250 mg, 2.05 mmol) in acetone dry (20 mL), 
K2CO3 (1.133 g, 8.2 mmol), 18-crown-6 (2 mg, 0.008 mmol) and propargyl bromide (913 
µL, 8.2 mmol) were added, under a N2 atmosphere. The suspension was stirred at reflux 
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for 24h. Acetone was evaporated, water (40 mL) was added and the mixture was 
extracted with DCM (3x30 mL). The organic phase was dried over Na2SO4, filtered and 
evaporated to give 340 mg of crude. This was purified by flash column chromatography 
(DCM) to gain 150 mg of 48 as a white solid in 46% yield. 
1
H NMR (200 MHz, CDCl3) δ 2.57 (t, J = 2.2 Hz, 1H), 4.78 (d, J = 2.2 Hz, 2H), 7.06-7.11 (m, 
2H), 7.83-7.87 (m, 2H), 9.90 (s, 1H) ppm. 
 
Synthesis of Taxol-Benzaldehyde adduct (4.14) 
 
 
 
To a solution of 4-Prop-2-ynyloxy-benzaldehyde 4.12 (7 mg, 0.04 mmol) in DMF (1 mL), 
CuSO4 (1 mg, 0.007 mmol) and sodium ascorbate (3 mg, 0.01 mmol) were added. After 
5 min, a solution of taxol-2’-6-azide-hexanoate 4.13 (60 mg, 0.06 mmol) in DMF (1 mL) 
and water (1 mL) were added. The solution was stirred at r.t. for 48 h. The reaction 
mixture was poured onto water (15 mL) and was extracted with DCM (3x15 mL). The 
organic phase was washed with water (7x25 mL), dried over Na2SO4, filtered and 
evaporated to give 70mg of crude. The crude was purified by flash column 
chromatography (DCM/MeOH 20:1), to obtain 10 mg of pure product (4.14) as a white 
solid in 20% yield. 
1
H NMR (400MHz, CDCl3) δ 1.04-1.40 (m, 11H), 1.58-1.76 (m, 7H), 1.82 -1.95 (m, 5H), 
2.22 (s, 3H), 2.29- 2.41 (m, 3H), 2.45 (s, 3H),3.43-3.52 (m, 2H), 3.81 (d, J = 7.2 Hz, 1H), 
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4.20 (d, J = 7.6 Hz, 1H), 4.27 (d, J = 7.6 Hz, 1H), 4.42-4.47 (m, 1H), 4.97 (d, J = 9.2 Hz, 
1H), 5.29 (s, 2H), 5.50 (d, J = 3.6 Hz, 1H), 5.68 (d, J = 7.2 Hz, 1H), 5.97 (dd, J = 3.6 Hz, J = 
9.2 Hz, 1H), 6.23 (t, J = 9.2 Hz, 1H), 6.29 (s, 1H), 7.09 (d, J = 8.8 Hz, 2H), 7.31-7.63 (m, 
12H), 7.74 (d, J = 7.6 Hz, 2H), 7.83 (d, J = 8.8 Hz , 2H), 8.14 (d, J = 7.2 Hz, 2H), 9.86 (s, 1H) 
ppm. 
13
C NMR (100MHz, CDCl3) δ 9.6, 14.8, 20.8, 22.1, 22.7, 23.8, 24.9, 25.6, 26.8, 29.7, 33.3, 
33.9, 35.5, 43.2, 45.6, 49.1, 50.0, 52.8, 58.5, 62.1, 71.8, 72.1, 74.0, 75.0, 75.6, 77.0, 
79.1, 81.0, 84.4, 108.5, 110.5, 115.1, 122.8, 126.6, 127.1, 128.5, 128.7, 129.0, 130.2, 
130.3, 132.0, 132.8, 133.7, 136.9, 142.7, 143.3, 156.7, 163.0, 167.0, 168.1, 169.8, 171.2, 
172.3, 190.8, 203.8 ppm. 
FT-IR (CDCl3)  1718, 2857, 2935, 3437 cm
-1
. 
ESI - MS: m/z = 1174.83 [M+Na]
+
. 
 
Synthesis of (4-(prop-2-yn-1-yloxy)phenyl)methanamine 4.19 
 
 
 
To a suspension of 4 hydroxybenzylamine (400mg, 3.23 mmol), potassium tert-butoxide 
(362 mg, 3.23 mmol) and 18-crown-6 (87 mg, 0.33 mmol) in dry THF (14 mL) propargyl 
bromide (384 mg, 3.23 mmol) was added at -70°C under N2. The reaction mixture was 
stirred at -65°C for 1 hour and for 2,5 hours at 0°C. Then, the mixture was quenched 
with 100 mL of water and the organic phase was extracted with AcOEt (2X100ml). The 
combined organic layers were washed with H2O (100ml) and a saturated solution of 
NaCl (2x80ml), dried over Na2SO4, filtered and concentrated under vacuum to afford the 
final product in 65% yield wwithout purification. 
1
H NMR (400 MHz; CDCl3): δ 1.69 (br s, 2H), 2.51 (t, 
4
JCH,CH2 = 2.4 Hz, 1H), 3.81 (s, 2H), 
4.67 (d, 
4
JCH2,CH = 2.4 Hz, 2H), 6.94 and 7.24 (AA’BB’, 4H) ppm. 
13
C NMR (100 MHz; CDCl3): δ 45.8,  55.8, 75.4, 78.6, 114.9, 128.2, 136.4, 156.4.
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Synthesis of DMTr-Gemcitabine (4.15) 
 
 
 
Gemcitabine (50 mg, 0.19 mmol) was dissolved in dry DCM (1 mL) and DIPEA (54 mg, 
0.42 mmol) and DMAP (2 mg, 0.02 mmol) were added, under a N2 atmosphere. DMTrCl 
(141 mg, 0.42 mmol) was dissolved in dry DCM (0.5 mL) and it was added to the above 
described solution, at 0°C, dropwise. The solution turns yellow. The solution was stirred 
at r.t., for 20 h and then DCM (20 mL) was added and it was extracted with water (3x20 
mL). The organic layer was dried over Na2SO4, filtered and evaporated to give 150 mg of 
crude. It was purified by flash column chromatography (DCM/MeOH 30:1) to gain 70 
mg of product 4.15 in 43% yield. 
1
H NMR (200 MHz, CDCl3) δ 3.38-3.52 (m, 2H,), 3.69-3.73 (m, 12 H), 4.02-4.06 (m, 1 H), 
4.40-4.45 (m, 1 H), 4.88 (d, 1 H, J = 6.8), 6.30-6.42 (m, 1 H), 6.70-6.81 (m, 8 H), 7.01-7.32 
(m, 20 H), 7.57 (d, 1 H, J = 6.8) ppm. 
13
C NMR (100 MHz, CDCl3) δ 55.3, 61.2, 70.4, 80.4, 84.5, 86.7, 95.5, 113.2, 113.6, 127.4, 
127.8, 128.3, 128.4, 129.9, 130.2, 135.0, 135.1, 135.7, 136.1, 141.0, 144.2, 144.8, 155.1, 
158.4, 158.5, 165.3 ppm.  
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Synthesis of DMTr-Gemcitabine-2’-6-azide-hexanoate (4.17) 
 
 
 
To a solution of bis-DMTr-Gemcitabine 4.15 (56 mg, 0.06 mmol) in dry DCM (1 mL), 
DMAP (8 mg, 0.06 mmol) was added. The solution was cooled at 0 °C, then DIC (9 mg, 
0.07 mmol) and 6-azido-hexanoic acid (11 mg, 0.07 mmol) were added, under a N2 
atmosphere. The yellow solution was stirred at r.t. overnight, then poured onto Et2O 
(15 mL) and washed with a saturated solution of NH4Cl (2x20 mL), then a saturated 
solution of NaHCO3 (2x20 mL) followed by a saturated solution of NH4Cl (2x20 mL). The 
recollected organic layer was dried over Na2SO4, filtered and evaporated to obtain 50 
mg of crude. This was purified by flash column chromatography (DCM/MeOH 30:1) to 
obtain 30 mg of 4.17 in 46% yield. 
1
H NMR (400 MHz, CDCl3) δ 1.37-1.43 (m, 2H), 1.56-1.69 (m, 4H), 2.32-2.45 (m, 2H), 
3.26 (t, J = 6.8 Hz, 2H), 3.29-3.31 (m, 1H), 3.38-3.42 (m, 1H), 3.74-3.76 (m, 12H), 4.06-
4.09 (m, 1H), 4.94 (d, J = 7.2 Hz, 1H), 5.42-5.48 (m, 1H), 6.42 (t, J = 8.4 Hz, 1H), 6.73-6.82 
(m, 8H), 7.08-7.21 (m, 14H), 7.26-7.28 (m, 4H), 7.38 (d, J = 7.2 Hz, 1H) ppm. 
13
C NMR (100 MHz, CDCl3) δ 24.1, 26.0, 28.4, 33.4, 51.0, 55.0, 55.1, 61.2, 70.1, 86.7, 
95.2, 108.4, 109.9, 113.1, 113.5, 126.8, 127.4, 127.7, 127.8, 128.3, 128.4, 129.7, 129.8, 
130.0, 134.9, 134.9, 135.8, 136.0, 144.2, 144.3, 158.5, 158.58, 158.64, 165.4, 171.5 
ppm. 
FT-IR (CDCl3)  1755, 2110, 2245, 2839, 2936, 3393 cm
-1
. 
ESI - MS: m/z = 1029.33 [M+Na]
+
. 
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Synthesis of 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (5.5) 
 
     
 
 
 
 
To a solution of tetraazacyclododecane (1.50 g, 8.72 mmol) and Na(CH3COO) (2.14 g, 
26.13 mmol) in dimethylacetamide (31 mL), tert-butylbromoacetate (5.10 g, 26.13 
mmol) was added. The white suspension was stirred for 20 days, then the precipitate 
was filtered and dried to give 4 as a white solid in 55% yield.  
1
H NMR (200 MHz, CDCl3) δ 1.44 (s, 9H, tBu); 1.45 (s, 18H, tBu); 2.82-2.96 (m, 12H, 
CH2); 3.03-3.12 (m, 4H, CH2); 3.28 (s, 2H, CH2); 3.36 (s, 4H, CH2); 10.00 (s, 1H, NH) ppm 
13
C NMR (50 MHz, CDCl3) δ 28.1 (6C, CH3); 28.2 (3C, CH3); 47.5, 49.2, 51.3, 58.2 ( 2C, 
CH2); 81.6 (1C, N-CH2); 81.8 ( 2C, N-CH2); 169.6 ( 1C, CO); 170.5 ( 2C, CO) ppm. 
 
Synthesisi of N-(benzylcarboxymethyl)-1,4,7,10-tetraazacyclododecane-N’,N’’,N’’’-
triacetic acid tri-tert-butyl ester (5.6) 
 
 
Compound 5.5 (2.38 g, 7.44 mmol) was added to a suspension of 60% NaH in DMF, 
after 2 hours stirring, benzylbromoacetate (2 g, 8.7 mmol) was added dropwise below 
0 °C. The reaction mixture was stirred for 27 h at room temperature (r.t.), then a 
solution of 5% citric acid was added and the mixture extracted with chloroform. The 
product obtained was purified by flash chromatography with 8/1= CH2Cl2/MeOH as 
eluent to give 5 in 67% yield. 
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1
H NMR (200 MHz , DMSO-d6) δ 1.40 (bs, 18H), 1.44 (s, 9H), 2.43-1.94 (bs, 6H), 3.29-
2.71 (bs, 7H), 3.31 (s, 2H), 3.46–3.39 (m, 2H), 5.13 (s, 2H), 7.35 (s, 5H).  
13
C NMR (50 MHz, DMSO-d6) δ 31.2, 50.5, 52.3, 52.6, 53.8, 57.1, 58.3, 75.3, 85.7, 
85.7, 128.7, 129.8, 144.7, 172.9, 174.3. 
 
Synthesis of 2-(4,7,10-tris(2-tert-butoxy-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-
yl)acetic acid (5.2) 
 
 
 
A mixture of 5.6 (0.83 g, 1.25 mmol) and 10% Pd/C (0.11 g) was hydrogenated in 
methanol under a positive H2 atmosphere for 6 h. The catalyst was removed by 
filtration, and the filtrate was evaporated to yield the modified DOTA macrocycle 1 in 
50% yield without further purification.  
1
H NMR (200 MHz, CDCl3) δ 1.40 (s, 9H), 1.41 (s, 18H), 2.64 (bs, 4H), 2.72 (bs, 4H), 2.87 
(bs, 4H), 3.33 (bs, 4H), 3.36 (s, 6H), 3.46 (m, 2H) ppm. 
 
13
C NMR (50 MHz, DMSO) δ 36.83, 36.88, 56.09, 58.59, 60.78, 61.88, 64.61, 65.63, 
89.53, 179.30 ppm.  
MALDI-MS (m/z): 572.6. [M+H]
+
 
ESI-MS (m/z): 573.4. [M+H]
+
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Synthesis of 5-(benzyloxy)-2-bromo-5-oxopentanoic acid (5.8) 
 
 
 
To a suspension of L-glutamic acid-5-benzylester (1.50 g, 6.48 mmol) and sodium 
bromide (2.27 g, 22.08 mmol) in a 1N solution of bromidric acid, cooled at 0°C, 
sodium nitrite (0.79 g, 11.45 mmol) was added portionwise. The yellow solution was 
stirred at this temperature for 2 h and finally 560 μL of 98% sulfuric acid was added, 
followed by diethylether. The water phase was extracted several times with Et2O and 
the combined organic layers washed with brine. The crude product was purified by 
flash chromatography with 1/1=EtOAc/EtP, to obtain bromo-derivative 5.8 in 82% 
yield. 
 
1
H NMR (200 MHz, (CD3)2SO) δ 2.00-2.40 (m, 4H, CH2), 4.38-4.50 (m, 1H, CH-Br),  5.08 
(s, 2H, CH2), 5.74 (s, 1H, OH), 7.35 (m, 5H, Harom). 
13
C NMR (50 MHz, CDCl3) δ 29.3 (1C, CH2), 31.4 (1C, CH2), 44.3 (1C, C-Br), 66.6 (1C, 
CH2), 128.0 (1C, Carom),128.2, 128.4 (2C, CHarom), 135.3 (1C, Carom), 172.0, 173.3 (1C, 
CO). 
 
Synthesis of 5-benzyl 1-tert-butyl 2-bromopentanedioate (5.9) 
 
 
 
A solution of tert-butyltrichloroacetimidate (TBTA) (2.20 mL, 12.05 mmol) in 8 mL of 
cyclohexane was added dropwise to another solution of 5.8 (1.70 g, 5.63 mmol) in 7 mL 
of CHCl3. During the addition a white precipitate formed, which was dissolved by the 
addition of DMA followed by boron trifluoridiethyl etherate (120 μL, 0.56 mmol) as a 
catalyst. The reaction mixture was stirred for three days at r.t. then concentrated and 
the remaining DMA phase was extracted with hexane (3x10mL). The hexane phase was 
evaporated and the crude product product was purified by flash chromatography with 
20/1=EtOAc/EtP followed by 10/1, to give But ester 5.9 in 50% yield.  
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1
H NMR (200 MHz, (CD3)2SO) δ 1.47 (s, 9H, CH3); 2.20-2.50 (m, 2H, CH2); 2.52-2.60 (m, 
2H, CH2); 4.24 (dd, 1H, J1 = 6.0 Hz, J2 = 8.2 Hz, CH-Br); 5.13 (s, 2H, CH2); 7.36 (m, 5H, 
Harom). 
 
Synthesis of 5-benzyl 1-tert-butyl 2-(4,7,10-tris(2-tert-butoxy-2-oxoethyl)-1,4,7,10-
tetraaza cyclododecan-1-yl)pentanedioate (5.10) 
 
 
 
To a solution of 5.5 (918 mg, 1.79 mmol) in 31 mL of dry CH3CN, K2CO3 (740 mg, 5.36 
mmol) was added. The reaction mixture was stirred at 60 °C for 10 min before adding 
dropwise, over a period of 40 min, a solution of 5.9 (1.14 g, 3.58 mmol) in 15 mL of dry 
CH3CN. After 42 h under stirring at 60° C the yellow solution was filtered throw celite 
and concentrated. The residue was purified by flash column chromatography using 
20/1=CH2Cl2/MeOH followed by 8/1 as eluent, to obtain 5.10 in 59% yield. Melting 
point: 145°C.  
1
H NMR (200 MHz, CDCl3) δ 1.45 (s, 36H, CH3); 1.90-3.60 (m, 27H); 5.07 (s, 2H, CH2); 
7.33 (m, 5H). 
 
Synthesis of 5-tert-butoxy-5-oxo-4-(4,7,10-tris(2-tert-butoxy-2-oxoethyl)-1,4,7,10-
tetraazacyclododecan-1-yl)pentanoic acid (5.3) 
 
 
 
5-benzyl 1-tert-butyl 2-(4,7,10-tris(2-tert-butoxy-2-oxoethyl)-1,4,7,10-tetraaza 
cyclododecan-1-yl)pentanedioate 5.10 (100 mg, 0.127 mmol) was dissolved in 2.8 mL of 
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absolute ethanol and to this solution 37 mg of 10% Pd (C) were added. The reaction 
mixture was hydrogenated for two days, filtered over cotton wool pad and the filtrate 
concentrated to give 5.3 in 79% yield without purification. 
1
H NMR (400 MHz, CD3OD) δ 1.49 (s, 9H, CH3); 1.50 (s, 18H, CH3); 1.53 (s, 9H, CH3); 
1.98-2.30 (m, 8H); 2.46-2.88 (m, 11H); 2.90-3.20 (m, 4H); 3.42-3.6 (m, 4H).  
13
C NMR (100 MHz, CD3OD) δ 28.3 (6C, CH3); 28.1 (6C, CH3); 33.3 (1C, CH2); 45.2, 53.9, 
54.0, 56.6, 56.9 (12C, CH2); 61.3 (1C, CH); 82.9 (2C, C(CH3)3), 83.0, 83.6 (1C, C(CH3)3); 
174.6, 174.7, 176.5, 176.7 (1C, CO).  
FT-IR : 3422, 2974, 2929, 2840, 1726, 1362, 1223, 1166 cm
-1
. 
ESI-MS M+=701, 723 (100%); CI, 56(100%), 157, 600. 
 
 
Synthesis of Synthesis of Taxol-2
’
-hemisuccinate (6.3) 
 
 
 
To a solution of taxol (0.1 g, 0.12 mmol) in 4 mL of dry pyridine, succinic anhydride 
(0.014 g, 0.14 mmol) and DMAP (0.003 g, 0.02 mmol) WEre added. The obtained 
solution was stirred for 3 h, at r.t, under a N2 atmosphere, and then the solvent was 
evaporated under vacuum to obtain a colorless oil. The crude was dissolved in 20 mL of 
DCM and washed with a saturated solution of NH4Cl (3 x 40 mL), followed by water (3 x 
40 mL), to get rid of residual pyridine. The organic layer was dried over Na2SO4, filtered 
and evaporated to obtain a white solid as pure final compound (6.3) in 38% yield.
 1
H 
NMR
 
and 
13
C NMR spectra are described in literature.
38
 
ESI-MS: m/z = 852.17 [M-succ]
-
, 952.17 [M-H]
-
, 1906.00 [2M-H]
-
; 976.17 [M+Na]
+
. 
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Synthesis of N-succinimidyl diphenylphosphate (SDPP) (6.6) 
 
 
 
To a solution of N-hydroxysuccinimide (115 mg, 1 mmol) in dry DCM (4 mL) diphenyl 
chlorophosphate(268.6 mg, 1 mmol) and trimethylamine (101.19, 1 mmol) were added 
and the mixture was stirred at r.t. for 2 hours. The solvent was evaporated under 
vacuum and the crude product was dissolved in 10 mL of ethyl acetate and washed 
with a saturated aqueous solution of NaCl (3x10 mL). The organic layer was dried over 
Na2SO4, filtered and evaporated to obtain a white solid (350 mg) in quantitative yield. 
The product was used without purification and was stored in a freezer under nitrogen. 
1
H-NMR (400 MHz, CDCl3) δ 7.50-7.22 (m, 10H), 2.81 (s, 4H) ppm. 
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Synthesis of 1-benzamido-3-(((2aR,4S,4aS,6R,11S,12S,12bS)-6,12b-diacetoxy-12-
(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-
2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-
methanocyclodeca[3,4]benzo[1,2-b]oxet-9-yl)oxy)-3-oxo-1-phenylpropan-2-yl (2,5-
dioxo-2,5-dihydro-1H-pyrrol-1-yl) succinate (6.7)  
 
To a solution of taxol-2’-hemisuccinate 6.3 (40 mg, 0.035 mmol) in acetonitrile ( 1.2 mL) 
SDPP 6.6 (18 mg, 0.053 mmol) and trimethylamine (14 mg, 0.14 mmol)were added. The 
mixture was stirred under nitrogen for 6 hours, and then the solvent was evaporated 
under vacuum. The crude product was purified by flash column chromatography to 
afford the final product as a white solid in a 51% yield over two steps.  
Spectroscopic data were previously reported. 
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1
HNMR (300 MHz, CDCl3) δ 8.14 (d, J = 6.9, 2H), 7.71 (d, J = 6.9, 2H), 7.61 (t, J = 7.5 Hz, 
1H), 7.54-7.33 (m, 10H), 6.30 (s, 1H), 6.28 (t, J = 8.4, 1H), 5.98 (dd, J = 9.3, 3.0, 1H), 5.69 
(d, J = 7.5, 1H), 5.48 (d, J = 3.0, 1H), 4.99 (d, J = 8.4, 1H), 4.45 (dd, J = 10.7, 6.2 1H), 4.32 
(d, J = 7.8, 1H), 4.21 (d, J = 8.7, 1H), 3.82 (d, J = 7.2, 1H), 2.91-2.51 (m, 8H), 2.49 (s, 3H), 
2.38 (t, J = 7.5 Hz, 2H), 2.23 (s, 3H), 2.21-2.02 (m, 3H), 1.95 (s, 3H), 1.86 (m, 1H), 1.68(s, 
3H), 1.24 (s, 3H), 1.14 (s, 3H) ppm. 
ESI - MS: m/z = 1073.25 [M+Na]
+
. 
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